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ABSTRACT

mRNAs containing nonsense codons encode truncated polypeptides that can
interfere with the function of their corresponding full-length polypeptides. However,
levels of most nonsense mRNAs are reduced in eukaryotic and prokaryotic cells
when compared to that of corresponding functional mRNAs. Genes that encode
proteins responsible to selectively reduce levels of nonsense mRNA have been
identified only in lower eukaryotes.

Here, I describe the cloning of a putative

human group I RNA helicase whose amino acid sequence is 60% identical to that
of UPF1, a bona fide yeast group I RNA helicase required for rapid degradation of
nonsense mRNA. Besides the seven RNA helicase consensus motifs, UPF1 and
its human homologue share two similar zinc finger-like domains, which are absent
in other group I RNA helicases. Blocking of protein expression by antisense RNA
derived from the human gene increased levels of nonsense immunoglobulin heavy
chain mRNA in a mouse hybridoma line.

I, thus, have identified the first

mammalian protein that regulates levels of nonsense mRNA, and I have named it
NORF1 (Il.Qnsense mRNA reducing factor 1).

xx iv

INTRODUCTION

Nonsense codons are able to decrease the stability of mRNA (or premRNA) in simple and complex eukaryotic organisms.

Recently, the greatest

advances to understand how nonsense mRNA levels are reduced have been
made in yeast. For example, cis-specific nonsense mRNA targeting sequences
(Peltz et al., 1993) and genes whose products are required for reducing levels of
nonsense mRNA (UPFINMD genes) (Leeds et al., 1991, 1993; He and
Jacobson, 1995; Lee and Culbertson, 1995) have been discovered.

In

eukaryotic cells, it seems that the effect of a nonsense codon on mRNA depends
on its position and also that levels of nonsense mRNA are reduced in the
nucleus and cytoplasm (reviewed in Peltz et al., 1994). However, no mammalian
nonsense mRNA reduction factor (NORF) has as yet been identified.
Using a combination of searching

nucleic and protein sequence

databases with the UPF1 amino acid sequence and screening complementary
DNA (cDNA) libraries, I isolated a human cDNA clone that encodes a structural
homologue of yeast UPF1, a protein that rapidly induces the degradation of
nonsense mRNA.

I also showed in RNA antisense experiments that the

mammalian protein controls levels of nonsense immunoglobulin µ heavy chain

2
mRNA (nonsense µ mRNA).

Therefore, I named this protein NORF1 (for

nonsense mRNA reducing factor 1).

CHAPTER II

REVIEW OF RELATED LITERATURE
Nonsense Codons: Definition. Generation and Significance

Definition
Genetic information must be relayed through RNA (mRNA) before it is
disseminated within a cell as a functional protein. After mRNA is transcribed
from a gene, it is transported into the cytoplasm.

There, ribosomes use the

mRNA as a template and along with amino acid-charged t-RNAs, and
translational initiation, elongation, and termination factors, synthesize a complete
protein.

The ribosomes translate the mRNA from the authentic start to the

authentic stop signal as they move along the mRNA (a functional mRNA
molecule). Through a number of processes to be described below, a mRNA can
contain a premature stop signal (nonsense codon) that would end protein
synthesis (Crick et al., 1961). In this case, an incomplete, truncated, polypeptide
would be synthesized.

Analyses of lower eukaryotic and mammalian cells

containing mRNAs with nonsense codons (nonsense mRNA) have generally

3

4
found that the average (steady-state) level of nonsense mRNA is lower when
compared to the same mRNA without a nonsense codon.

Generation
Nonsense mRNAs can be generated by many different processes, such
as inaccurate or incomplete RNA splicing, incorrect RNA editing, mutations of
DNA or RNA, or the inaccurate assembly of DNA fragments leading to
nonproductive gene rearrangements. Studies of intron splicing in pre-processed
mRNAs (pre-mRNA) have found that incorrect splicing can lead to the imprecise
assembly of exons, exon skipping, or the failure to remove an intron altogether
(intron retention) (Senapathy, 1986; Senapathy et al., 1990; Carothers et al.,
1993; Stover et al., 1993).

All the events can lead to a change in the

translational reading frame of the mRNA and the new reading frame may contain
a premature translational stop, or nonsense codon (Legrain and Rosabash,
1989; He et al., 1993).
The rearrangement of immunoglobulin (lg) and T cell receptor gene
segments as well as hypermutation of immunoglobulin genes, may also result in
the production of a nonsense mRNA (Baumann et al., 1985, Lozano et al.,
1993).

Many mRNAs with nonsense codons can also arise from random

mutations occurring within the cell's genome.

Examples include single

nucleotide (nt) changes (Orkin and Kazazian, 1984; Satoh et al., 1988; Jack et
al., 1989; Kadowaki et al., 1990; Hamosh et al., 1992; Longo et al., 1992; Bach
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et al., 1993; Dietz et al., 1993; Gibson et al., 1993; Naylor et al., 1993; Das et al.,
1994), insertions (Myerowitz and Costigan, 1988; Naylor et al., 1993; Das et al.,
1994; Boles and Proia, 1995), or deletions (Krawczak and Cooper, 1991; Naylor
et al., 1993; Sherrat et al., 1993, Das et al., 1994).

Significance
The presence of a nonsense codon in an mRNA usually results in a
decrease in the steady state level of nonsense mRNA that is not due to
decreased transcriptional rates (Cheng and Maquat, 1993; Urlaub et al., 1989;
Jack et al., 1989; Paw and Neufeld, 1988). It has been hypothesized that this
process, which we call nonsense codon-mediated mRNA reduction, is used by a
cell

to

eliminate

nonsense

mRNAs

that

could

be

translated

into

a

shorter/truncated protein or a protein with a new amino acid sequence.
However, if nonsense mRNA levels are not decreased, shorter proteins with the
new amino acid sequence could interfere with the full-length corresponding
polypeptide. For example, when a nonsense codon is present in the human pglobin gene at certain positions, levels of the nonsense mRNA are not
decreased (Table 1) (Kazazian et al., 1992; Thein, 1992; Hall and Thein, 1994).
Because levels of nonsense p-globin mRNA increases, a truncated p-globin
encoded by the nonsense mRNA can accumulate in the cell.

Patients with a

heterozygous mutation in the p-globin gene produce the truncated and full length
P-globin protein, but still have p-thalassemia. It has been hypothesized that the

6
truncated p-globin protein is interfering in a dominant-negative fashion with the
function of the complete p-globin protein (Kazazian et al., 1992; Thein, 1992).
Humans with this heterozygous condition are diagnosed with partial

P-

thalassemia, a disease manifesting itself with symptoms of anemia and bone
deformation.
The

most striking

evidence that

nonsense

codon-mediated

RNA

degradation is important for an organism comes from experiments with the
nematode Caenorhabditis elegans (Pulak and Anderson, 1993). In C. elegans a
nonsense codon within one allele of the myosin heavy chain gene unc-54 has no
effect on the viability of the heterozygotic worm or on the ability of muscle cells to
form a functional muscle.

When the heterozygotic worm has a defect in the

nonsense codon-mediated RNA degradation system, (SMG2 mutation), the unc54 mRNA with the nonsense codon is not degraded and a truncated myosin

heavy-chain polypeptide translated from the nonsense mRNA interferes with the
assembly of muscular structure in the worm.

This leads to defective muscle

function so that the worms are unable to swim.

Pulak and Anderson (1993)

conclude that the shorter myosin heavy-chain polypeptide acts in a dominantnegative fashion and suggest that a nonsense mRNA surveillance mechanism is
important to avoid the accumulation of dominant-negative or gain-of-function
polypeptides.
There are also many other examples of human diseases that correlate
with the presence of nonsense mRNA and in some cases with the presence of a
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shorter polypeptide.

For example, certain mutations in the apolipoprotein E

(APO E) gene lead to the generation of a nonsense APO E mRNA. Individuals
with these mutations produce a truncated APO E receptor that is not able to help
remove cholesterol from the blood and suffer from elevated plasma cholesterol
levels and hyperlipoproteinemia (Lohse et al., 1992; see Table 1). The table lists
other examples where a nonsense mRNA is made but whether a shorter
polypeptide can cause the disease is not clear.

Nonsense mRNA Reduction: Who. Where and How (Translation. Location and
Models of Reduction)

Translation
How a cell is able to differentiate between a nonsense codon and a
normal translational stop codon is unknown.

Ribosomes, charged t-RNAs,

initiation, elongation, and termination factors are all thought to be essential to
recognize codon triplets and translate mRNA (reviewed in Stansfield and Tuite,
1994).

Therefore, it is thought that the same translational machinery is

necessary for the recognition of a nonsense codon. The inhibition of translation
using the translation elongation inhibitor cycloheximide results in increased
levels of nonsense mRNAs (Qian et al., 1993; Lozano et al., 1994; Menon and
Neufeld, 1994; Li et al., unpublished results).

These results support the

hypothesis that translation is needed to reduce levels of nonsense mRNA.

Table 1. --Human Diseases Associated With a Nonsense Codon Mutationa
Gene

p-globin

Nucleotide
Change

FS >NC, NC

Truncated
Protein

Nonsense
mRNA
Reduction

Reference

p-thalassemia I Cell membrane damage
and destruction of red cells

Yes

No

Hall & Thein, 1994

Vitamin E deficiency I Ataxia & Peripheral
neuropathy

N.D.

N.D.

Hentati et al., 1996

Disease Symptoms

alphaTTP

FS> NC

BRACA1

NC

Breast and Ovarian cancer

N.D.

N.D.

Serova et al., 1996

BRACA2

NC

Breast cancer

N.D.

N.D.

Tavtigian et al., 1996

apo E2

FS> NC

Type 3 Hyperlipoproteniemia I

Yes

N.D.

Feussner et al., 1996

RB

FS> NC

Retinoblastoma I retinal tumors that can
proceed to the brain

N.D.

Yes

Kato et al., 1994

NC

Schwannomas I benign tumors of the
cranium and spine, Neurofibromatosis

N.D.

N.D.

Bijlsma et al., 1994

gp91-phox

FS> NC

Chronic granulomatous disease
(superoxide deficiency) I recurrent lifethreating infections

N.D.

N.D.

Rabbani et al., 1993

hMLH1&2

NC

Heridetiary nonpolyposis colon cancer

N.D.

N.D.

Luce et al,. 1996

Metrochromatic leukodystrophy
(arylsulfatase A) I defective myelin sulfatide
degradation leads to demyelination and
death.

N.D.

Yes

Pastor-Soler et al., 1994

SCH

ARSA

FS> NC

I))

Table 1. cont --Human Diseases Associated With a Nonsense Codon Mutationa
GP 1b alpha

FS> NC

Bernard-Soulier syndrome (absence of
platelet glycoprotein lb/IXN complex) I
giant platelets that cannot promote clotting

Yes

N.D.

Simsek et al., 1994

CDKN2

FS> NC

Putative melanoma susceptibility gene

N.D.

N.D.

Walder et al., 1995

IL-2R y

NC

Severe combined immunodeficeincy I
immunodeficiency disease (T cell def.)

N.D.

N.D.

Noguchi et al., 1993

GHRH-R

NC

Laron syndrome I Pituitary adenomas and
severe growth failure

N.D.

N.D.

Hashimoto et al., 1995

FS> NC

Wiskott-Aldrich syndrome I X-linked
immunodeficiency, thrombocytopenia and
eczema

N.D.

N.D.

Wengler et al., 1995

X-linked agammaglobulinemia I inherited
immunodeficiency disease (B cell def.)

N.D.

N.D.

Duriez et al., 1994

Xeroderma pigmentosum I Skin cancer

N.D.

N.D.

Satokata et al., 1992

Herlitz's Junctional epidermolysis bullosa
(laminin-5) I skin blistering at sites of
pressure or trauma

N.D.

Yes

Vailly et al., 1995

Yes, No

No, Yes

Kawasaki et al., 1994

WASP

NC
btk
XPAC
LAMC2

FS> NC
NC
FS> NC

p53

NC

CMML, AML, CML, Burkitt's lymphoma,
Bladder cancer, endometrial carcinoma

PHKA2

NC

X-linked liver glycogenosis type 1 I
hepatomegaly, hypoglycemia, gout

N.D.

N.D.

Hendricks et al., 1995

WT1

NC

Denys-Drash syndrome I nephropathy, and
Wilms tumors

N.D.

N.D.

Baird et al., 1992

co
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HEXAand
HEXB

FS> NC

Tay-Sach or Sandhoff disease respectively
(lysosomal P-hexosaminidase) I motor and
mental deterioration, blindness

N.D.

Yes

Mcinnes et al., 1992

a-II p-3

FS> NC

Glanzmann's thrombasthenia I defect in
platelet alpha llb beta 3 protein

No

N.D.

Schlegel et al., 1995

subunit A

FS> NC

Subunit A coagulation factor 13 deficiency I
coagulation deficiency

N.D.

Yes

Vreken et al., 1995

CD18

FS> NC

Leukocyte adherence deficiency I recurrent
infections due to deficiency in surface
expression of leukocyte integrin molecules

N.D.

N.D.

Back et al., 1992

CHM

FS> NS

Choroideremia I X linked progressive
degeneration of the choroid and retina

N.D.

N.D.

Sankila et al., 1992

APKD1

NC

Autosomal dominant polycystic kidney
disease / 1: 1000 persons, massive
kidneys, hematuria, hypertension, and
renal failure

N.D.

No

Turco et al., 1995

ACTH-R

NC

Isolated gluocorticoid deficiency I
progressive primary adrenal insufficiency

N.D.

N.D.

Tsigos et al., 1993

COL7A1

FS> NC

Hallopeau-Siemens dystrophic
epidermolysis bullosa / loss of dermal
adherence with abnormal anchoring fibrils

No

Yes

Hilal et al., 1993

COL10A1

FS> NC

Schmid metaphyseal dysplasias (type 1O
collagen) I metaphyseal dysplasia, poor
collagen assembly

Yes

N.D.

Bonaventure et al., 1995

COL4A3

FS> NC

Alport syndrome (type IV collagen)/
Deafness, hematuria, proteinuria and renal
failure

N.D.

N.D.

Ding et al., 1995

......
0
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PBDA

FS > NC

lntermitent porphyria I skin lesions

N.D.

N.D.

Mgone et al., 1993

cytb5r

FS > NC

Cytochrome b5 reductase deficiency I
syanosis or mental retardation

N.D.

N.D.

Vieira et al., 1995

FBN1

NC

Marfan syndrome (aberrant fibrillin) I
connective tissue disorder affecting the
skeleton, eye, and cardiovascular system

Yes

No

Dietz et al., 1994

APOE

NC

Apolipoprotein E deficiency I elevated
plasma cholesterol levels,
hyperlipoproteinemia

Yes

No

Lohse et al., 1992

Spectrin-P

FS > NC

Hereditary elliptocytosis I

Yes

N.D.

Wilmotte et al., 1994

OA1

FS >NC

Ocular albinism I impaired visual acuity,
retinal hypopigmentation

N.D.

No

Bassi et al., 1995

ASM

FS>NC, NC

Niemann-Pick disease I neuronopathic

Yes

N.D.

Takahashi et al., 1992

SMN

FS >NC

Spinal muscular atrophy I degeneration of
motor neurons of the spinal cord

N.D.

N.D.

Bussaglia et al., 1995

8

This is a partial list of various human diseases correlating with the presence of a nonsense codon in a gene. Nucleotide
changes are either mutations that generate a nonsense codon (NC) or cause a frame shift (FS) that leads to the
generation of a nonsense codon. In both cases, translation is presumabely truncated and, thus, only a shorter
polypeptide could be produced. N.D., not determined.
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Although treatment of cells with cycloheximide seems to support the role of
translation in nonsense mRNA reduction, these experiments are difficult to
interpret, since the treatment itself may inhibit the production of (a) factor(s)
necessary during the process of nonsense mRNA reduction.

Other evidence

supporting the role of translation in nonsense mRNA reduction comes from
experiments using modified RNA constructs that contain a stem-loop structure
that inhibits translation by virtue of its strong secondary structure (Belgrader et
al., 1993). mRNAs containing these elements upstream of a nonsense codon do
not undergo nonsense mRNA reduction suggesting the importance of translation
in the nonsense mRNA reduction process.

Location of Nonsense mRNA Reduction
As mentioned above, the translational process is thought to be involved in
nonsense mRNA reduction. Because the translational process is only known to
occurs in the cytoplasm, it would be expected that the reduction of nonsense
mRNA also occurs in the cytoplasm. Indeed, a number of experiments in yeast
have found that nonsense mRNA reduction occurs in the cytoplasm and occurs
by degradation. First, the activity of a cytoplasmic yeast 5' to 3' exonuclease
(Xrn1p) correlates with the reduction of a nonsense mRNA.

When a mutant

strain lacks XRN1, cytoplasmic mRNA decay does not occur and a nonsense
mRNA (the PGK1 allele) has the same stability as a wild-type mRNA (Muhlrad
and Parker, 1994).

Second, the presence of a yeast factor associated with
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cytoplasmic ribosomes (Upf1 p) (Atkin et al., 1995) correlates with reduction of
nonsense mRNA. When yeast are missing Upf1 p, the levels of nonsense mRNA
associated with polyribosomes increases (He et al., 1993).

Both these

experiments suggest that a nonsense codon in an mRNA is recognized by the
translational machinery and that the reduction in the level of the message is due
to degradation.
There are also experiments in mammalian cells that suggest that the
reduction of nonsense mRNA occurs in the cytoplasm. Cytoplasmic nonsense
mRNA reduction has been demonstrated for p-globin mRNA (Orkin and
Kazazian, 1984 review) and lg µ mRNA (Li and Jack, unpublished observations).
In these experiments, p-thalassemic patients producing p-globin nonsense
mRNAs had no changes in the half-life of the nonsense pre-mRNA. But the halflife of mature nonsense mRNA was reduced to only 30 minutes when compared
to the wild type p-globin mRNA half life of 16 hours (Maquat, et al., 1981; Ross
and Pizarro, 1983). In the lg µ mRNA studies, northern blot analysis was used
to determine the levels of cytoplasmic µ and nonsense µ mRNA at different time
points after the addition of the transcripitional inhibitors actinomycin and 5, 6dichloro-1-beta-D-ribofuranosylbenzimidazole (ORB).

The result indicated that

nonsense µ mRNA had a half-life of 4 hours, whereas functional µ mRNA had a
half-life of 16 hours.

This suggests that the degradation of the µ nonsense

mRNA is occurring in the cytoplasm.
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Although the evidence discussed above suggests that nonsense codons
in mRNAs are recognized in the cytoplasm by the translational machinery, a
number of observations suggest that the levels of nonsense mRNAs are also
reduced in the nucleus of a mammalian cell.

Examples include the human

triosephosphate-isomerase (TPI) mRNA in both mouse and human cell lines
(Cheng and Maquat, 1993), the secretory major urinary protein (MUP) mRNA in
mouse cells (Belgrader and Maquat, 1994),

~-globin

mRNA in nonerythroid cells

(Takeshita et al., 1984; Baserga and Benz, 1992), viral nonsense mRNA
encoded by avian sarcoma virus (src) (Simpson and Stoltzfus, 1994) and lg µ
mRNA (Li and Jack, unpublished observations). However, differences in nuclear
levels of functional and nonsense mRNA can be explained by the presence of
small contaminants of cytoplasmic mRNA that co-purified with the nuclei during
the isolation procedure.

To address this problem, Belgrader and coworkers

examined purified nuclei by light and electron microscopy and found that the
nuclei were free of any detectable cytoplasmic remnants (Belgrader et al., 1994).
These observations do not, however, address the possibility that cytoplasmic
nonsense mRNA molecules are attached to the outside of the nuclei and, thus,
co-purify with nuclei and increase the signal of "nuclear" mRNA.
There are also observations suggesting that the presence of a nonsense
codon in a pre-mRNA may also affect its splicing. The presence of a nonsense
codon in an immunoglobulin kappa light-chain gene results in inefficient nuclear
pre-mRNA splicing (Lozano et al., 1994). This effect on splicing is thought to
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lead to the decrease in cytoplasmic levels of completely spliced kappa mRNA.
Splicing experiments using

K

nonsense pre-mRNA and lysates from either

mouse B cells or endothelial cells suggests that inefficient splicing of K nonsense
pre-mRNA can be reproduced in vitro (Aoufouchi et al., 1996) but only if B cell
extracts are used.

This suggests that the splicing inefficiency caused by the

nonsense codon can only occur in B cell splicing extracts.

Unfortunately, in

these in vitro experiments controls were done to test for the presence of possible
translational machinery molecules (ribosomes and other factors) that could
sterically inhibit the splicing machinery.

In addition to the ability of nonsense

codons to affect splicing efficiency, it has also been found that certain nonsense
codons can affect exon skipping, cryptic splicing, or intron retention (Naeger et
al., 1992, Dietz et al., 1993, Dietz and Kendzior, 1994, Lozano et al., 1994).
Dietz has proposed that nonsense codons could be recognized within nuclear
pre-mRNA by a nuclear scanner.

In this model, introns are "looped-out" by

splicing factors, which would align the exons as in an mRNA. A nuclear scanner
could look for nonsense codons within the exons of these pre-mRNA. But the
idea that a nonsense codon could influence exon skipping, cryptic splicing, or
intron retention is problematic considering that nonsense codon recognition is
thought to be recognized by translational machinery (in the cytoplasm).

It is

more likely that the nonsense codons that have these types of effects are
influencing the splicing process itself by changing splice site
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recognition, even if they are not located near a splicing junction. Until more is
known about how the splicing machinery works, it is difficult to understand
exactly how these nonsense codons are affecting the splicing process.

Models to Explain Nonsense mRNA Reduction
To determine how the translational machinery is able to recognize and
reduce the levels of nonsense mRNA, many experiments have manipulated the
location of nonsense codons in mRNAs.

Models to Explain Nonsense mRNA Reduction in Yeast

Model 1
It has been suggested that there might be a nonsense codon-recognition
factor associated with the translational machinery of yeast (Figure 1.4) and after
a certain percentage of the mRNA has been translated, this factor falls off
gradually or by encountering a cis-element in the substrate mRNA (Figure 1.5)
(Peltz et al., 1993).

After this nonsense codon-recognition factor is removed

from the translation machinery, the nonsense mRNA would not be targeted for
degradation. In support of this hypothesis it has been found that the position of a
nonsense codon determines whether nonsense mRNA levels are decreased
when compared to levels of functional mRNA. Levels of nonsense mRNA from
the yeast genes, URA3 (Losson et al., 1983), URA 1 (Pelsy and Lacroute, 1984),
PGK1 (Peltz et al., 1993), HIS4 (Hagan et al., 1995), and CYC1 (Yun and
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Figure 1. Models for the recognition and degradation of mRNA containing
nonsense codons in yeast. 1) Normal translation of a mRNA by ribosomes
2) A nonsense mRNA that is not protected by ribosomes is a target for
cytoplasmic nucleases. 3) A nonsense mRNA with a sequence downstream
of the nonsense codon acts as a target for a nonsense/sequence specific
decay. 4) Ribosomes containing a nonsense codon recognition factor
(Small diamonds) recognize a nonsense codon and target it for decay. 5)
Ribosomes containing the factor loose the factor after a certain distance or
after contact with a cis mRNA element. This renders the mRNA immune to
NMRD. Adapted from Peltz et al., (1993).
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Sherman, 1995), show almost complete decay when the nonsense mutation is in
the 5' regions of the mRNA and normal levels when the nonsense codon is in the
3' region of the mRNA. This is called the position effect of nonsense codons on
mRNA levels.

Model 2
Another hypothesis suggests that the presence of elements downstream
of a nonsense codon triggers rapid mRNA decay (Figure 1.3), possibly by
providing a site for 40S ribosomal translation reinitiation (Peltz et al., 1993).
Experiments supporting this hypothesis found that the removal of a specific RNA
sequence element 3' (an AUG rich region) from an early nonsense codon yeast
pgk1 mRNA eliminated the rapid decay of the message.

The authors' main

conclusion was that translational reinitiation is involved; first, because three AUG
codons lie within the downstream element; second, the insertion of a stem-loop
structure 5' of the downstream element inhibited the rapid mRNA decay; and
inhibitors of translation that reduce the ability of ribosomes to reinitiate translation
at downstream start codons also stabilize mRNA with nonsense codons without
affecting the stability of a wild type transcript (Peltz and Jacobson, 1993).

Model 3
Alternatively, recent work with the yeast CYC1 mRNA suggests a different
model, the translation initiation model (Figure 2) (Yun and Sherman, 1995). This
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Figure 2. Schematic representation of the translational initiation model to
explain effects of translation initation and termination changes on mRNA
stability. The distributaion of 40S and BOS ribosomal subunits on various
mRNA species are outlined. Adapted from Yun and Sherman (1995).

21
model describes a number of possible effects that cis-mRNA elements (including
a stability element) have upon the stability of the CYC1 mRNA. First, a CYC1
mRNA is transported out of the nucleus (Figure 2.A) and a 40S ribosomal
subunit scans the mRNA and begins translation at the bona fide AUG as a
complete BOS ribosome (Figure 2.8). When the normal initiator AUG codon is
changed (mutated), translation does not initiate (Figure 2.C), even when there is
an AUG codon within the coding region (Figure 2.0).

It may be possible that

translation initiation factors are only associated with the 40S subunit for a brief
period of time and are not present when a 40S subunit encounters a
downstream AUG. These mRNAs are stabilized by the 40S subunit that keeps
scanning down the mRNA and can cover the sensitive region.

Premature

termination can occur at UAA mutations at different locations (Figure 2.E, F, G)
but the mRNA is only degraded if the UAA lies inside the sensitive region (Figure
2.E and F), but not when it is outside this region (Figure 2.G). This degradation
occurs by exposing a sensitive element within the sensitive region.

The

scanning of the 40S subunit can be disrupted by inserting an ATG TAA
sequence, because of the formation and quick release of BOS ribosomes (Figure
2.H, I). These nonsense codons also cause degradation of the mRNA, because
they expose the sensitive element(s).

However, no premature termination or

destabilization occurs when the sequence ATGTAA is inserted outside of the
initiation region (Figure 2.J), because the scanning 40S subunit can protect the
message. The authors also suggest that the exposure of the stability element
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could lead to interactions of elements with the 5' cap or the poly(A)-tail, which
triggers decapping and degradation.

All these models have been formulated

considering results from experiments with yeast cells.

The same types of

elements and/or observations involving the nonsense mRNA reduction system
have not yet been found in higher eukaryotic cells. Nevertheless, these results
indicate that there may be special trans-acting factors and cis-mRNA elements
involved in the nonsense codon mRNA recognition system in yeast but these
results do not directly address how the reduction occurs.

Model 4
Experiments in yeast have addressed the question of how mRNAs
containing a nonsense codon are degraded. Using temperature sensitive mRNA
decay mutants, it has been found that the normal route of decay of wild-type
yeast mRNAs is 1) shortening of the poly(A)-tail, 2) removal of the 5' cap of the
mRNA, and 3) 5' to 3' exonuclease degradation (reviewed in Beelman ar.d
Parker, 1995) (Figure 3.A). Mulhrad and Parker (1994) demonstrated that the
decay process of yeast mRNA containing a nonsense codon is similar but not
identical to that of a wild-type mRNA. His lab demonstrated that the pgk1 mRNA
containing a nonsense codon does not have its poly(A)-tail shortened like a
normal PGK1 transcript but instead proceeds directly to the decapping step and
then is degraded by the same 5' to 3' exonuclease that degrades wild type PGK1
mRNAs (Figure 3.B) (Muhlrad and Parker, 1994). These results indicate that the
steps in mRNA degradation are not the same for nonsense and functional mRNA
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Figure 3. General mRNA decay pathway in yeast. (A) Pathway depicting what
is thought to be the common decay pathway of a mRNA in yeast. Breifly, the
process involves shortening of the poly (A) tail, deadenylation dependent
decapping and subsquent 5' to 3' exonucleitic decay. (8) Pathway depicting the
probable pathway for a nonsense codon mRNA in yeast. Breifly, the process
involves deadenylation independent decapping by the NMRD mechanism and
subsquent 5' to 3' exonucleitic decay similar to the decay of normal yeast
mRNAs. Figure adapted from Muhlrad and Parker, (1994).
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and that the recognition of the nonsense codon may be the key step to activating
the quick decapping of the mRNA and subsequent degradation by a common
yeast exonuclease.

However, it is not clear how the nonsense codon

degradation system is able to recognize the nonsense codon and then activate
the decapping of the mRNA.

Models to Explain Nonsense mRNA Reduction in Mammalian Cells

Model 1
As in yeast, it has been suggested that there might be a position effect of
a nonsense codon on mammalian mRNA levels. Studies involving the TPI gene
have shown that the levels of nonsense mRNA containing nonsense codons in
upstream exons are decreased when compared to levels of functional mRNA but
as the nonsense codon is relocated towards the 3' exons of the gene the levels
of nonsense mRNA increase (Cheng et al., 1994). From these results Cheng
and coworkers (1994) have concluded that there is also a position effect of
nonsense codons upon mammalian mRNAs. These results also suggest that
there may be a nonsense codon recgonition factor associated with a translated
mRNA but this mammalian system is more complex than studies of intron-less
yeast genes and could involve splice-site changes, possible TPI specific cismRNA elements, and other nuclear and/or cytoplasmic factors outlined in other
models described below.
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Model 2
Studies of a human nonsense 13-globin mRNA in transgenic mice as well
as a study done on mouse lg µ mRNA have given some clues to the process of
nonsense mRNA reduction in higher eukaryotic cells. Experiments that have
looked at the 13-globin mRNA and its mutant form have found that the 5' end of 13globin nonsense mRNAs have shorter, capped, 5' ends. Lim and Maquat (1992)
have suggested that these nonsense mRNAs were attacked by a 5'-3'
exonuclease and then capped or re-capped to confer immunity to further
exonucleolytic attack. Although this model remains to be tested, evidence for
the existence of a 5'-3' exonuclease has been strengthened by recent results
from the lab of Brawerman.

Coutts and Brawerman (1993) have identified a

mouse sarcoma 5'-3' exonuclease that appears to cleave capped and uncapped
mRNAs at either the first, second, or third nucleotide. Together, these results
implicate a 5' to 3' exonuclease in the degradation of nonsense codon mRNAs
in mammalian cells.
Li and coworkers studied the length of the poly(A)-tail in nonsense and
functional µ mRNAs.

In experiments using RNase H digestion followed by

northern blot analysis, they found that functional µ mRNA contains a shorter
poly(A)-tail than nonsense µ mRNA. This result suggests that the degradation
pathway of nonsense µ mRNA does not follow normal mRNA decay which is
thought to be initiated by the shortening of the poly(A)-tail (reviewed in Ross,
1995).

It is possible that the degradation of nonsense µ mRNA follows a
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pathway similar or identical to that of yeast pgk1 nonsense mRNA, in which the
nonsense mRNA does not have its poly(A)-tail shortened before quickly
decapping and degradation by a 5' to 3' exonuclease. Experiments have also
been performed to determine if other steps in the degradation of higher
eukaryotic nonsense mRNAs follow a pathway similar to that of yeast.

Model 3
To explain how a nonsense codon can trigger the reduction of nuclear
mRNA, Chasin and coworkers have proposed the nuclear co-translational export
model shown in Figure 4.2.

This model explains how nonsense codons in a

mRNA can be recognized by the translational machinery in the cytoplasm and
still result in a nuclear decrease in the nonsense mRNA level (Urlaub et al.,
1989). In this model, ribosomes encounter nascent, not completely spliced RNA
at the nuclear pore and begin the translation process (Figure 4.1 ).

When a

nonsense codon is encountered, the ribosomes activate the nonsense mRNA
reduction pathway either at the surface or inside the nucleus (Figure 4.2). This
could lead to the degradation of the mRNA or prevent further splicing, both of
which would account for a drastic reduction in cytoplasmic nonsense mRNA
levels.

Model 4
An additional model of nuclear degradation of nonsense mRNA has been
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Figure 4. Models for the recognition and degradation of mRNA containing
nonsense codons. 1) Export of a normal mRNA using the translationaltranslocation model. 2) Degradation of a nonsense mRNA during
translational-translocation by putative nucleases either outside or inside
the nucleus. 3) Cytoplasmic degradation of a nonsense mRNA. 4)
Nuclear scanning model where nonsense codons are recognized in the
exons of an mRNA which targets the mRNA for degradation.
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proposed by Chasin and coworkers.

In this model, which was termed the

nuclear scanning model, a hypothesized nuclear scanner identifies a nonsense
mRNA and targets it for degradation (Urlaub et al., 1989) (Figure 4.4). Because
the only known complex that can identify codons in a mRNA is tRNA,
cytoplasmic ribosomes and there associated factors, it is difficult to imagine how
the scanning occurs in the nucleus without a translation-like process. Recently,
this scanning model has been redefined to only effect completely spliced mRNA
(Zhang and Maquat, 1996).

Zhang and Maquat have used a site-directed

mutagenesis approach to generate a nonsense codon. that spans two exons (is
separated by an intron) in the triosephosphate isomerase (TPI) gene. In other
words, the nonsense codon is generated by splicing two exons together and is,
thus, only found in spliced mRNA. Although RT-PCR was used to determine
differences in nuclear TPI RNA levels, which leads to problems quantitating
exact differences in RNA levels, the evidence suggests that nuclear nonsense
mRNA reduction occurs only on the completely spliced TPI mRNA and not on
the TPI pre-mRNAs (Zhang and Maquat, 1996). These results suggest that if
nuclear scanning occurs it would only affect completely spliced nonsense
mRNAs and not nonsense pre-mRNAs. This hypothesis circumvents one of the
difficulties of the nuclear scanning model which was to explain why pre-mRNAs
that contain a nonsense codon within an intron are not targeted for nonsense
mRNA reduction. These results, however, do not prove the existence of nuclear
nonsense mRNA reduction. Once experiments are designed and carried out to
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directly test the nuclear co-translational translocation and nuclear scanning
models, these results may become clearer.

Genes Involved in Nonsense mRNA Reduction
Previously, researchers were only able to study the phenomenon of
nonsense mRNA reduction, but recently through the use of genetic systems,
researchers working with S. cerevisiae and C. elegans have identified a series of
genes that are directly involved in the nonsense mRNA reduction process. In S.

cerevisiae they are named UPF genes (.YQ-frameshift, once thought to be
frameshifting enhancers) and in C. elegans they are called SMG
morphogenesis mutations gene) genes.

(~uppressor

of

UPF1, 2, 3 and SMG 2, 3, 5, and 7

have been cloned. In any of the UPF mutants there is an increased steady state
level of mRNAs with nonsense codons and unspliced pre-mRNAs that contain a
nonsense codon within an intron (He et al., 1993). The best characterized of
these genes, and the only one that will be discussed in detail is the yeast UPF1
gene. By using genetic and molecular analysis, UPF1 was shown to be required
in the nonsense mRNA reduction pathway (Peltz et al., 1990, 1993). The levels
of nonsense mRNA return to that of the corresponding wild-type mRNA,
indicating that the UPF1 gene is involved in the nonsense mRNA decay process
but not in general mRNA decay.
The UPF1 gene encodes a 109-kDa protein (Figure 5). The UPF1 protein
(Upf1p) contains a number of motifs with interesting properties.

The mcst

Yeast UPF1 gene 1-3546 bp
"<o'

~

~
~~
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I -
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Yeast UPF1 polypeptide (109 kDa)
Zn Fingers
consensus
sequences

Figure 5. Schematic representation of the S. cerevesiae UPF1 gene and gene product.
· UPF1-D1 and UPF1-D4 are the locations of two missense mutations that lead to the production of a
dominant-negative UPF1 gene product.
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thorough sequence analysis of the putative Upf1 p has been performed by
Altamura and coworkers and is described here in detail (Altamura et al., 1992).
Within the UPF1 ORF (from the N- to C- direction) there is a highly acidic region,
a zn+ 2 finger motif, a NTP binding domain and a type 1 (superfamily 1) RNA
helicase domain (Leeds et al., 1992; Altamura et al., 1992).

It has been

suggested that the acidic regions of DNA-binding transcriptional factors are
required for their ability to act as transcriptional activators (reviewed in Struhl,
1989). Upf1 p also contains conserved cysteine residues found in a number of
zinc-finger DNA and RNA binding proteins (Burd and Dreyfuss, 1994).

It is

thought that these cysteine residues form structures that allow interaction with
helices of nucleic acids. It is possible that this motif in Upf1 p could interact with
ribosomal RNA (either double or single stranded) or with a nonsense mRNA.
The elongation factor elF-2P also has a zinc-finger motif. When this motif is
altered, the factor can no longer help the ribosome recognize the translational
AUG start codon. This suggests that a zinc-finger motif could help recognition of
a codon. It is therefore possible that the zinc-finger motif present in Upf1 p could
be directly involved in the recognition of a stop codon. Upf1 p also contains two
NTPase consensus motifs (Walker et al., 1982) that are the first and second
motifs (motif I and II) of the RNA helicase region of RNA helicases of the
superfamily I (Koonin, 1992). Many superfamily I putative RNA helicase genes
such as SEN1 (DeMarini et al., 1992) and MOV-10 (Mooslehner et al., 1991) all
contain a NTP binding domain and are thought to have NTP dependent helicase
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activity.

It has been proposed that the RNA helicase domain of Upf1 p could

facilitate the degradation of a nonsense mRNA by unwinding secondary structure
downstream of a nonsense codon thereby making the RNA accessible to
nucleases (Peltz et al., 1993).
Recently the functions of a number of these motifs have been confirmed
(Czaplinski et al., 1995).

Purified, epitope-tagged Upf1 p can bind to double

stranded DNA or RNA.

Upf1 p can be released from this substrate by the

addition of ATP and in doing so, it unwinds the dsDNA or dsRNA; presumably by
using its RNA helicase domain. Leeds and coworkers (1992) have shown that
certain mutations in the RNA helicase domain of the UPF1 gene confer a
dominant-negative effect upon cells transformed with the mutant upf1 (Leeds et
al., 1992).

These cells containing the wild-type UPF1 and the RNA helicase

mutant upf1 act as if they are upf1-null. These data support the hypothesis that
Upf1 p may be acting as a dimer and that the RNA helicase domain is critical for
the function of Upf1 p.
Experiments performed by Czaplinski and Peltz suggest an even more
complex picture of Upf1 p function (personal communication). An upf1 mutant
used in this study changed its growth on plates without leucine depending on the
levels of nonsense Jeu2-1 mRNA (e.g. yeast that have a wild type UPF1 gene
and a Jeu2-1 nonsense mutation do not grow in the absence of leucine, whereas
yeast that have a upf1 null allele and a leu2-1 nonsense allele grow in the
absence of leucine. In other words, the phenotype of a yeast cell with the leu2-1
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allele and an upf1 mutation changes from Leu- to Leu+ because, in the absence
of Upf1 p, nonsense leu2-1 mRNA is more stable and translational readthrough
generates enough functional Leu2p to grow in the absence of leucine). Recent
unpublished observations by Czaplinski and Peltz using various upf1 yeast
challenge this conclusion and shed some light on how Upf1 p may be actually
working. They have created a number of different upf1 mutants in the putative
zinc-finger and RNA helicase regions of the UPF1 gene and tested the ability of
the mutated Upf1 p to complement the function of wild-type UPF1 in vivo. Their
results are shown in Table 2.

Table 2. --Mutational analysis of UPF1 and its effects on a nonsense mRNA in vivoa
Mutation
Group

Phenotype

Specific Mutations Made
in UPF1

Nonsense leu2-1 mRNA
levels

Leu phenotype

A

Up

+

B

Down

c

Up

D

Down

H94-R I H98-R I
c122-s I C125-S I
K436 to P, E, D, Q, or A
C72-S I H11 O-R I
RR793-KK
DE572-AA I RR793-AA
/TR800-AA

+

C65-S I C84-S I
C148-S

aPhenotype indicates either high (up) or low (down) levels of the leu2-1 mRNA
containing a nonsense codon while a + indicates growth, or - indicates lack of
growth on drop-out medium. Specific mutations are indicated by their IUPC
amino acid code. The wild-type residue and location of changes are indicated
on the left before the arrow. The arrow(-) indicates the type of change that has
been made.
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These results demonstrate that Upf1 p is not only necessary for the decay of
nonsense mRNAs, (Group A and C), but it may also be involved, either directly
or indirectly, in modulating the recognition of the nonsense codon (Group A and
D).

Recently, UPF2/NMD2, whic.h is called NMD2 (for nonsense-mediated
mRNA decay gene 2) has been cloned with the yeast two-hybrid system using
the Upf1 p as "bait" (Cui et al., 1995; He and Jacobson, 1995). The way in which
Upf2p was found implies that it interacts with Upf1 p.

Additionally, dominant-

negative fragments of Upf2p expressed in the cytoplasm of yeast are able to
interfere with the nonsense mRNA reduction pathway.

However, the same

Upf2p fragment located to the nucleus does not prevent nonsense mRNA
degradation. This not only indicates that Upf2p interacts with Upf1 p and could
be a component that recognizes a nonsense codon, but it also shows that the
yeast nonsense mRNA reduction can occur in the cytoplasm. The identification
of the yeast UPF3 gene could also help researchers that study nuclear nonsense
mRNA reduction understand how this may occur.

Upf3p contains a bi-partite

yeast nuclear localization signal and, therefore, is thought to be present in the
nucleus. The mammalian homologue of this gene (if it exists) would become a
good candidate for a factor involved in nuclear nonsense mRNA reduction.
As mentioned above, Parker's studies of yeast genes involved in general
mRNA decay have indicated that the process involves 1) shortening of the
poly(A)-tail, 2) decapping of the message and finally 3) 5' to 3' exonuclease
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activity that degrades the mRNA. His studies of a mRNA containing a nonsense
codon (pgk1) also found that the decay proceeds directly to the decapping step
and then follows the normal decay pathway. His lab also studied whether the
UPF1 gene played a role in the decapping process.

In experiments using a

yeast strain containing an UPF1 mutation, a mutation in the 5' to 3' exonuclease,
and an mRNA with a nonsense codon, they found that the nonsense mRNA
contained a shortened poly(A)-tail and eventually was decapped at a rate similar
to a wild type mRNA. From this observation the authors concluded that UPF1 is
involved directly or indirectly in the quick decapping of the nonsense mRNA.
The intracellular location of Upf1 p is consistent with it being involved in
nonsense codon recognition and/or decay. Upf1 p is predominantly found in the
cytoplasm and has been shown to be associated with polysomes (Atkin et al.,
1995), and in this way, it could be involved in the recognition of a nonsense
codon. Yeast lacking Upf1 p also have an increase in pre-mRNAs that contain a
nonsense codon within an intron (He et al., 1993). Interestingly, not only is the
pre-mRNA level increased in upf1 mutant yeast, but these pre-mRNAs are also
associated with ribosomes in the cytoplasm.

This indicates that nonsense

mRNA reduction probably needs the translation process as well as the Upf1 p.

Similarities of Nonsense mRNA Reduction Between The Yeast and Higher
Eukaryotic Systems
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The model systems for nonsense mRNA reduction in yeast and higher
eukaryotic cells contain a number of similarities. First, translation is required for
nonsense mRNA reduction.

Compounds and RNA structures (cycloheximide

and stem-loops, respectively), both of which inhibit ribosomal elongation can
prevent nonsense mRNA reduction. Second, it appears that the poly(A)-tail of
both yeast and mammalian nonsense mRNA (e.g. pgk1 and mouse µ) is not
shortened before activation of nonsense mRNA reduction. This suggests that
after the recognition of a nonsense codon (by a still unknown mechanism), the
nonsense mRNA in yeast and mammalian cells might be degraded in a similar
fashion.

Third, not all nonsense codons can target an mRNA for nonsense

mRNA reduction. The position of a nonsense codon within yeast or mammalian
RNA determines whether a specific mRNA or pre-mRNA is targeted for
nonsense mRNA reduction.

Summary
Significant effort has been put forward to study the effects of a nonsense
codon on the stability of the afflicted mRNA (or pre-mRNA).

Recently, the

greatest advances have been made in the yeast S. cerevisiae. These systems
have discovered possible cis-specific nonsense mRNA targeting elements,
genes specifically involved in the nonsense mRNA reduction system ( UPF/NMD
genes) and insights into the decay of nonsense mRNA after the nonsense codon
has been recognized. Research of higher eukaryotic systems is still focused at
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nonsense mRNA reduction phenomenon such as nuclear v.s. cytoplasmic
nonsense mRNA reduction, the effects of a nonsense codon on pre-mRNA
stability and splicing, and the position effect of nonsense codons.

Until the

system itself is identified and studied biochemically, the process of nonsen::;e
mRNA reduction will remain an enigma. In order to understand the process of
nonsense mRNA reduction in higher eukaryotic cells work needs to be done to
identify the higher eukaryotic homologues of yeast nonsense mRNA reducing
factors.

The Hypothesis
Nonsense codons found within mRNA frequently lead to a decreased
steady state level of nonsense mRNA within an eukaryotic cell. This effect is
found in simple (S. cerevisiae) and complex eukaryotes (vertebrate).

Genes

required for nonsense codon-mediated mRNA decay have been identified in S.
cerevisiae and C. elegans through genetic screens.

However, no mammalian

nonsense mRNA reducing protein has yet been identified.

Because of the

general similarities between the nonsense mRNA reduction process in yeast and
higher eukaryotes, and the observation that a large number of yeast genes are
conserved in higher eukaryotic organisms (Tugendreich et al., 1994), I propose
that nonsense mRNA reducing factors similar to those found in the yeast S.
cerevisiae are present in mammalian cells and control levels of nonsense
mRNAs.

CHAPTER Ill

MATERIALS AND METHODS
Chemicals and Reagents

General Chemicals and Reagents
Ampicillin (Na Salt) and kanamycin from either Sigma Chemical (St. Louis,
MO)

or Boehringer Mannheim (lndianoplis, IN).

L-canavanine from Sigma

Chemicals; AGR501-X8(D) (Mix bead resin), BIS-acrylamide, gelatin, and Tween
20 from BioRad (Richmond, VA). Yeast extract, Bacto-agar, Yeast extract w/o
amino acids are from Difeo (Detroit, Ml). Agarose (ultra-pure), Geneticin (G-418
Sulfate), cesium chloride (ultra-pure), di-thiothreiotol (DTI), LB-media base,
Penicillin-Streptomycin (500 U/ml), L-Glutamine (200 mM), Glycerol (ultra pure),
and RPMI 1640 powder from Gibco-BRL Life Technologies, Inc. (Gaithersburg,
MD); dextran sulfate from Pharmacia (Uppsala, Sweden); fetal calf serum (FCS)
from HyClone (Logan, UT); universal autoradiography enhancer chemicals (Part
A and B) from DuPont NEN (Boston, MA); Triton X-100 from Serva (Heidelberg,
Germany);

ethyl

alcohol

(EtOH,

40

200

proof)

from
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paper Co. (Shelbyville, KY); Non-fat dehydrated milk from Carnation Food
Products, Nestle Food Co. (Glendale, CA); scintillation liquid (Econo-Safe) from
RPI (Mount Prospect, IL). All solutions were prepared in deionized water (dH 2 0)
filtered by a Millipore Milli-Q water filtering system (Bedford, MA).

Radiochemicals
32

[a- P] dCTP (Cat# PB10205)

Amersham, Arlington Heights, IL

Redivue [a-32 P] dCTP (Cat# AA0005)

Amersham, Arlington Heights, IL

[a-35 S] dATP (Cat# SJ1304)

Amersham, Arlington Heights, IL

Trans
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S-label (Cat# 51006)
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ICN Biomedicals, Irvine, CA

[y- P] dATP (Cat# 35020)

ICN Biomedicals, Irvine, CA

DNA 5'-end labeling kit (Cat#702757)

Boehringer Mannheim,
Indianapolis, IN

Enhanced Chemiluminescnce Kit

Boehringer Mannheim,

(Cat#1500694)

Indianapolis, IN

1-ethyl-3-(3-dimethylaminopropyl)

Pierce Co., Rockford, IL

carbodiimide/Diaminodipropylamine
Immobilization kit (Cat#44899)
Antigen Conjugation kit (Cat#77107)

Pierce Co., Rockford, IL

Nick-translation kit (Cat#18160-010)

Gibco BRL, Gaithersburg, MD
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pGEM-T vector system I (Cat#A3600)

Promega, Madison, WI

Sequenase kit (2.0) (Cat#US70770)

United States Biochemical,
Cleveland, OH

TNT in vitro translation kit (Cat#L4610) Promega, Madison, WI
Wizard mini-prep kit (Cat#A7100)

Promega, Madison, WI

Qiagen plasmid isolation DNA

Qiagen, Chatsworth, CA

kits (Cat#12143)
Qiagen total RNA kit (Cat#74104)

Qiagen, Chatsworth, CA

Antibodies

Antibodies Used for lmmunofluroescence Analysis
Rabbit anti-VH81X

Hartwell and Jack, unpublished;
Loyola University, Maywood, IL

FITC-labled goat anti-mouse µ

Fisher Biotech, Pittsburgh, PA

(Cat#1021-01)
FITC-labled goat anti-rabbit lgG
(Cat#9817SA)

Gibco-BRL, Gaithersburg, MD
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Antibodies Used for Western Blot Analysis
Rabbit anti-UPF1 peptide antiserum

Allan Jacobson, University of
Massachusetts Medical School,
Worcester, MA

Horseradish peroxidase conjugated

BioRad, Irvine, CA

(HRP) affinity-purified goat antirabbit lgG (Cat#170-6515)
Affinity-purified goat anti-

Bornemann et al., 1995

MOPC 104E (mouseµ)
HRP conjugated rabbit anti-Goat lgG

Fisher Biotech, Pittsburgh, PA

Affinity purified rabbit anti-NORF1/pep1 This work
Affinity purified rabbit anti-NORF1/pep2 This work

Molecular Weight Standards
1Kb DNA ladder

Gibco BRL, Gaithersburg, MD

'A DNA!Hindlll fragments

Gibco BRL, Gaithersburg, MD

Rainbow protein marker

Amersham, Buckinghamshire,
England

Bacteriophage <t>X 174 DNA

Gibco BRL, Gaithersburg, MD
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Enzymes
Restriction endonucleases were obtained form Boehringer Mannheim
Biochemicals

(Indianapolis,

IN),

Gibco

BRL

Life

Technologies,

Inc.

(Gaithersburg, MD) and New England BioLabs, Inc. (Beverly, MA); AmpliTaq
DNA polymerase from Perkin Elmer Cetus (Norwalk, CT) and Taq polymerase
and Superscript reverse transcriptase from Gibco-BRL Life Technologies, Inc. T4
DNA ligase and Kienow fragment from either Pharmacia (Piscataway, NJ) or
Promega (Madison, WI); RNasin and DNase I, from Promega (Madison, WI);
RNase H from Pharmacia (Piscataway, NJ); RNase A (bovine pancreas) and
lysozyme (chicken egg white) from Sigma Chemical Company (St. Louis, MO);
DNA Sequenase (polymerase) version 2.0 from United States Biochemical
(USS,

Cleveland,

OH);

and

Proteinase

K from

Boehringer

Mannheim

(Indianapolis, IN).

Oligonucleotides
Standard oligonucleotides were purchased from Promega Corp. and
United States Biochemical or were synthesized by Bio-Synthesis (Lewisville, TX),
Chander

Raman,

Gene

Napolitano

(Terrapin

Technologies,

South

San

Francisco, CA), or by the Macromolecular Core Facility at Loyola University
(Maywood, IL).

LAC primer: 17 mer 5'-TGTGGAATTGTGAGCGG-3'
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(Elledge et al., 1991 ), From Bio-Synthesis
GAL primer: 17 mer 5' -ACTTIAACGTCAAGGAG-3'
(Elledge et al., 1991), From Bio-Synthesis
GAL-UP.Fow: 18 mer; 5'-TTCGGTTIGTATTACTTC-3'
From Bio-Synthesis
SP6 primer: 19 mer; 5'-GATTIAGGTGACACTATAG-3'
From Promega
T7 primer: 20 mer; 5'-TAATACGACTCACTATAGGG-3'
From Promega
M13 primer (-40, forward): 17 mer; 5'-GTTTTCCCAGTCACGAC-3'
From USB
M13 primer, backwards: 16 mer; 5'-TTCACACAGGAAACAG-3'
From USB
TRAPa primer#1: 14 mer; 5'-CACTAATTCCCATA-3'
From Loyola Core Facility
TRAPa primer #3: 14 mer; 5'-CTGTTIGATTGAAG-3'
From Bio-Synthesis
TRAPa primer #4: 16 mer; 5' -CTCCCCCGCTTGCTTC-3'
From Bio-Synthesis
TRAPa primer#5: 15 mer; 5'-GTTAAGTCCCAAGCTG-3'
From Gene Napolitano
TRAPa primer #6: 13 mer; 5' -GCAAGATGAAGATG-3'
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From Gene Napolitano
1RGF.hyb primer: 19 mer; 5'-CCTCAGGTTCTATTATGTC-3'
From Loyola Core Facility
2RGF.hyb primer: 16 mer; 5'-GGCATGTTTTCAGTGC-3'
From Loyola Core Facility
UPF1-01 .Forward primer: 15 mer; 5'-GGAAAACAGAAGCAG-3'
From Bio-Synthesis
UPF1-01 .Backward primer: 15 mer; 5'-CGGGTTAGACCCACG-3'
From Bio-Synthesis
2.0H35hom.forward primer: 26 mer;
5'-GATGTTGACATGTGTTGGTGCTGGTG-3'
From Loyola Core Facility
2.0H35hom.backward primer: 26 mer;
5'-CACCAGCACCAACACATGTCAACATC-3'
From Loyola Core Facility
SAM#3.Fow: 20 mer; 5'-GCTGATCCTTGTAGGCGACC-3'
From Loyola Core Facility
SAM#4.Bak: 20 mer; 5'-GGTCGCCTACAAGGATCAGC-3'
From Loyola Core Facility
SAM#5.Bak: 18 mer; 5'-CCTGGGACAGCTCCGGCT-3'
From Loyola Core Facility
SAM#6.Fow; 18 mer; 5'-GGACAGCTCGACGCGCAG-3'
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From Loyola Core Facility
SAM#7.bak: 18 mer; 5'-CTGCGCGTCGAGCTGTCC-3'
From Bio-Synthesis
SAM#8.bak: 20 mer; 5'-GCGTCTGCGTCTGGCTAGGA-3'
From Bio-Synthesis
SAM#9.bak: 19 mer; 5'-CAAGCAGCTCGGCCTCCTC-3'
From Bio-Synthesis
SAM#10.Fow: 17 mer; 5'-GCGGGCCAACGAGCACC-3'
From Bio-Synthesis
SAM#11. Fow: 19 mer; 5'-TCGGAGCACACACCAGCAC-3'
From Bio-Synthesis
SAM#12.Bak: 18 mer; 5'-CGACGAAAGCACCCAGGC-3'
From Bio-Synthesis
SAM#13.Fow: 16 mer; 5'-ACGCCAGAAGAACCGC-3'
From Bio-Synthesis
LAC2: 20 mer; 5'-TGAGAGAAGGGCTGTGACGC-3'
From Chander Raman
SAM3-2: 20 mer; 5'-GCATCATCACGCCCTACGAG-3'
From Chander Raman
SAM4-2: 20 mer; 5'-ATCAGGCTCAGTGGTCTTTG-3'
From Chander Raman
GALP3: 20 mer; 5'-CCCTGATAACTATGGCGATG-3'

48From Chander Raman
GALP3.rev: 20 mer; 5'-TACTGGTAGGCGTCCTCGTA-3'
From Chander Raman
SAM3.rev: 20 mer; 5'-GAAGATGTTGGATGGGAAGG-3'
From Chander Raman
SAM4.rev: 18 mer; 5'-CGAGGCTGGCCAAGATGC-3'
From Chander Raman
Gal-UP.Forward: 18 mer; 5'-TTCGGTTTGTATTACTTC-3'
From Loyola Core Facility
A.GT1 OGENE.F: forward primer: 27 mer;
5'-CTTTTGAGCAAGTTCAGCCTGGTTAAG-3'
From Gene Napolitano
A.GT10GENE.B: backward primer: 24 mer;
5'-GGCTTATGAGTATTTCTTCCAGGG-3'
From Gene Napolitano
UPF1-5'-EcoRI primer: 29 mer;
5'-CGAATTCGAAATGGTCGGTTCCGGTTCTC-3'
From Bio-Synthesis
UPF1-3'- BsaBI primer: 30 mer;
5'-ATTGATCAGTATCCCAGTTCGCAI 111 ICG-3'
From Bio-Synthesis
SAM#3.Fow: 20 mer; 5'-GCTGATCCTTGTAGGCGACC-3'
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From Loyola Core Facility
SAM#4. Bak: 20 mer; 5' -GGTCGCCTACAAGGATCAGC-3'
From Loyola Core Facility
SAM#5.Bak: 18 mer; 5'-CCTGGGACAGCTCCGGCT-3'
From Loyola Core Facility
SAM#6.Fow; 18 mer; 5'-GGACAGCTCGACGCGCAG-3'
From Loyola Core Facility

Peptides
Peptides used in this study are of two forms.

First, multiple antigenic

peptide (MAPS) (Ponsette et al., 1988), or COCH-terminal branched peptides,
were synthesized by Ingrid Haas (University of Heidelberg, Germany). Second,
linear, non-branched peptides synthesized by Bassam Wakim (Loyola University
Macromolecular Core Facility).

UPF1#1; 16 mer; (GenBank #M76659:Codons 950 to 965)
NH 3-ARELQREEQKHELSKD - Poly-K
UPF1#2; 16 mer; (GenBank #M76659:Codons 920 to 935)
NH 3-KSAFSQKQNRNEIDDR - Poly-K
UPF1#3; 14 mer; (GenBank #M76659:Codons 635 to 648)
NH 3-EVQYRMNPYLSEFP - Poly-K
NORF1-pep#1 (Lab name: SAM-PEP#1 ); 18 mer; (Codons 106 to 122)
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NHTEEDEEDTYYTKDLPIHAC-COOH
NORF1-pep#2 (Lab name: SAM-PEP#2); 24 mer; (Codons 214 to 237)
NH 3-ASQSSLKDINWDSSQWQPLIQDRC-COOH

Plasmids and DNA Probes

Cloning Vectors and Plasmids
Plasmid clones are indicated by name and by file number in the Chicago
books in the laboratory of Dr. Hans-Martin Jack.

pSP73 (plasmid clone: Chicago # 499) Promega, Madison, WI
pUPF1 (plasmid clone: Chicago# 443) Dr. M. Culbertson (Leeds et al.,
1993)
pUPF1-D1 (plasmid clone:

Dr. M. Culbertson (Leeds et al.,

Chicago # 490)

1993)

pUPF1-D4 (plasmid clone:

Dr. M. Culbertson (Leeds et al.,

Chicago# 491)

1993)

pH~-Apr-1-neo

(plasmid clone:

1987)

Chicago # 412)
p73-UPF1~0.8

From Ron Corley (Gunning et al.,

(plasmid clone:

This work

p73-UPF1/-5'3' (plasmid clone:

This work

Chicago # 497)
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Chicago# 561)
pUPF1-5' end (plasmid clone:

This work

Chicago # 562)
pUPF1/p-actin (plasmid clone:

This work

Chicago# 564)
pUPF1-D1/p-actin (plasmid clone:

This work

Chicago # 609)
pR-TRAPa (p5.1.1.X and p7.1.1.X)

This work

(plasmid clone: Chicago # 533 and 533)
p2.0-Hindlll (plasmid clone:

This work

Chicago # 505)
p6.4-EcoRI (plasmid clone:

This work

Chicago # 525)
pNORF1 (p11.2 gene, 3.6-kb)

This work

(plasmid clone: Chicago # 579)
pNORF1 (p15.1.1.1. gene, 5.5-kb)

This work

(plasmid clone: Chicago# 610)
pR 13609 (plasmid clone:

Human EST sequencing project

Chicago # 592)

Boguski et al., 1993

pH11830 (plasmid clone:

Human EST sequencing project

Chicago # 593)

Boguski et al., 1993

pH11167 (plasmid clone:

Human EST sequencing project
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Chicago# 594)

Boguski et al., 1993

pH15581 (plasmid clone:

Human EST sequencing project

Chicago# 595)

Boguski et al., 1993

pNORF1/7Z (pGem7Z+3.5kb NORF1)

This work

(plasmid clone: Chicago #599)
p~-NORF1

antisense

This work

(plasmid clone: Chicago# 611)
p~-NORF1

sense

This work

(plasmid clone: Chicago # 612)

DNA Probes
rabbit GAPDH (plasmid clone:

1.2-kb Hindlll fragment from pR-

Chicago # 265)

GAPDH (Applequist et al., 1995)

yeast UPF1

3.2-kb EcoRl/Xbal fragment from
pUPF1 (a gift from M.Culbertson)

yeast UPF1 RNA helicase region

1.3-kb Oral fragment from pUPF1

yeast UPF1 5'-end region

1.4-kb EcoRl/Kpnl fragment from
pUPF1

yeast CAN1

1.3-kb Hindlll fragment from
pTLC-1 (Broach et al., 1987)

mouse µ cDNA (plasmid clone:
Chicago# 254)

1.4-kb Apal/Smal
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human cDNA fragment R 13609

1.6-kb Hindlll/EcoRI or
Hindlll!Notl fragment

human cDNA fragment H11830

1.4-kb Hindlll/EcoRI or
Hindlll!Notl fragment

human cDNA fragment H 11167

1. 7-kb Hindll l/Notl fragment

human cDNA fragment 11.2

3.5-kb Xhol fragment from
p11.2.2 and p11.2.1

human cDNA fragment 5' end of

1.3-kb Xhol/Sa/I fragment from
NORF1 pNORF1/7Z

human cDNA fragment 3' end of 11.2

600-bp BstXl/Xhol fragment from
NORF1 pNORF1/7Z

Analysis of RNA

Isolation of RNA from Mammalian Cells

Solutions and Reagents
guanidium isothiocyanate (GIT)

Mix 94.53 g guanidine

homogenization buffer

isothiocyanate (4 M final), 1.67
ml 3 M Na-acetate, (pH 6.0); and
add dH 20 to 200 ml. Add 8.35
µI/ml

~-ME

before each use.

o4
cesium chloride buffer

Mix 95.97 g CsCI (5.7 M); 0.83 ml
3 M Na-acetate, (pH 6.0); add
dH 2 0 to 100 ml, and sterile filter.

DEPC-TE

Prepare TE using stock Tris-HCI,
(pH 7.4); and 0.5 M EDTA using
0.1% DEPC-dH 2 0.

Total RNA Isolation
Total RNA was isolated from cultured cells by either the GIT/cesium
chloride method or by the Qiagen RNA preparation method (both described
below).

Guanidinium Thiocyanate/Cesium Chloride Method
Total RNA was prepared from cultured cells with GIT followed by
centrifugation through a cesium chloride (CsCI) solution (Chirgwin et al., 1979).
7

Briefly, 1-2 X 10 cells were removed and washed with ice-cold sterile phosphate
buffered saline solution (Dulbecco's PBS, Cat#21-031-LV, Gibco-BRL).

The

cells were transferred in 1 ml of PBS to a 15 ml-Falcon tube pelleted, decanted,
and resuspended in residual liquid by tapping the tube vigorously.
then resuspended in 2 ml of GIT homogenization buffer.

Cells were

The resulting cell

homogenate was layered on 2 ml of CsCI solution in a clear 13 X 51 mm thin
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wall/polymer open top

ultracentrifuge tube

(Nalgene

UltraTubes,

Nalge,

Rochester, NY). The tubes were balanced with GIT homogenization buffer and
centrifuged with 35,000 rpm for 18-20 hr at 20°C in a Beckman SW50.1 rotor and
Beckman Preparative Ultracentrifuge (Model L8-70, Beckman, Palo Alto, CA).
After centrifugation the supernatant was aspirated until the CsCI layer was
reached. CsCI was removed by gentle pipetting. The bottom of the tube was cut
off with a razor blade, and the clear RNA pellet (3-5 mm in diameter) was
resuspended in 3 X 100 µI of ice-cold DEPC-TE and transferred to an
autoclaved, chilled, 1.5 ml microcentrifuge tube.

The RNA was precipitated

overnight at -20°C after the addition of 1/10 volume of 3 M NaAc, (pH 5.2); and
2.5 volume of ice-cold EtOH. The RNA was collected by centrifugation at full
speed at 4°C for 2 hrs, washing with 70% EtOH, air-drying, and resuspended in
DEPC-TE at concentration of 1-5 µg/µI.

Qiagen Method
The method was performed exactly as described by the manufacturer. All
cell culture samples were disrupted by passing the GIT/cell resuspension
repeatedly through a 20G1 115 gauge needle until foamy. The mixture was then
processed as described in the RNeasy kit handbook.
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Cytoplasmic RNA Isolation
Cytoplasmic RNA was isolated by the Nonidet-P40/phenol method
6

(modified from Favaloro et al., 1980). Briefly, 5 X10 cells were pelleted, washed
once with ice-cold Oulbecco's PBS, transferred to a microcentrifuge tube and
lysed for 30 minutes on ice in 200 µI of cold lysis buffer (from 5 Prime-3 Prime,
Inc., Boulder, CO; 0.14 M NaCl, 1.5 mM MgCl 2 , 0.5% Nonidet-p40, 10 mM Tris,
(pH 8.6)) supplemented with 0.05 U/ml RNasin (Promega, Madison, WI). The
nuclei and unlysed cells were removed by centrifugation at full speed in a
microcentrifuge at 4°C for 30 seconds. 175 µI of the supernatant was transferred
to a new microcentrifuge tube.

RNA was then extracted twice with 300 µI of

phenol/chisam (1+1) heated to 65°C and once with chisam at room temperature.
RNA was precipitated with 1/10 volume NaAc and 2.5 volume ice-cold EtOH.
The RNA was collected as described above and resuspended in 25 µI of OEPC-

TE.

RNA Isolation from Yeast Cells
Total RNA was isolated from yeast by the method of Elion and Warner,
(1984).

Briefly, 10 ml overnight cultures of yeast cells with an 00600 of 1-1.5

were pelleted, washed with ice-cold dH 2 0, pelleted again, and decanted. The
pellet was resuspended in 200 µI of LET-1% SOS (10 mM Tris-HCI, (pH 7.4); 0.1
M EOTA, 0.1 M LiCI, 1.0% SOS) and frozen at-70°C overnight. The yeast were
thawed on ice, transferred to a cold micro-centrifuge tube, mixed with 120 µI of
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autoclaved glass beads, and vortexed for 30 sec.

25 µI of phenol/chloroform

(1+1) are added and vortexed again 4 X 30 seconds with the sample on ice
between vortexings. 480 µI of LET-0.2% SOS (same as above only to a final
concentration of 0.2% SOS) is added to the sample and mixed. The lysate is
removed and extracted twice with 400 µI of TE equilibrated phenol, (pH 7.0);
warmed to 65°C.

Place the samples on ice for 5 minutes between each

extraction. The aqueous phase is removed from the final extraction, precipitated
at -70oC the addition of 1/10 volume of 3 M LiCI and 2.5 volume of EtOH. The
precipitated RNA is collected by centrifugation at full speed for 1 hr at 4°C and
the RNA is dissolved in 50 µI of DEPC-TE. The quantitation is performed as in
section 2.14.

Quantitation of RNA
The concentration of RNA was determined by measuring the optical
density (OD) at 260nm using the following equation:
µg I µI RNA = 00 260 X 40 X dilution factor.
The purity of RNA was determined by comparing the ratio of the
absorbance of RNA at 260nm to that at 280nm. Samples in the range of 1.8 to
2.0 are considered relatively pure from protein contamination.
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Northern Blot Analysis

Solutions
10 X MOPS

Mix 41.9 g MOPS (sodium base),
3.72 g sodium EDTA, 4.1 g
sodium acetate, add 0.1 %
DEPC-dH 2 0 to 1 Land pH to 7.0
with glacial acetic acid.

5 X RNA loading buffer

12.5% Ficoll (Sigma)
0.4% bromophenol blue
1 X MOPS
DEPC-dH 2 0 to final
percentages

Gel overlay buffer

Mix 50 ml of 10 X MOPS, 89.3 ml
formaldehyde (37% from Sigma),
and add DEPC-dH 2 0 to 500 ml.

Deionized formamide (dFA)

Formamide (Boehringer
Mannheim) was deionized with
5g per 100 ml AG 501-X8(0)
mixed bead resins (Bio-Rad) by
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stirring slowly at room
temperature for 1 hour, filtered
through a coarse Whatman filter
disk and stored at -20°C in
aliquots.

1 M sodium phosphate buffer

200 ml 1 M NaH 2 P04

(NaP, (pH 7.0))

600-700 ml 1 M Na2 HP0 4
to 1 L with dH 2 0, (pH 7.0).

Prehybridization solution

Mix 2 ml dH 2 0, 200 µ110% SOS,
10 ml dFA, 5 ml 20 X SSC,
2 ml 50 X Denhart's solution, 1

ml 1 M sodium phosphate buffer,
(pH 7.0); 0.25 mg/ml denatured
sheared salmon sperm DNA
(from 10 mg/ml stock solution).

Hybridization solution

Mix 150 µ110% SOS, 7.5 ml dFA
(50%), 3.75 ml 20 X SSC, 300 µI
50 X Denhart's solution, 300 µI 1
M sodium phosphate buffer, (pH
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7.0); 3 ml 50% dextran sulphate,
0.3 mg/ml denatured sheared
salmon sperm DNA (from 10
mg/ml stock solution).

Agarose Gel Solution

Mix 2.4 g agarose with 144.3 ml
DEPC-dH 2 0. Microwave the
solution until the agarose is
completely melted. Add 35.7 ml
formaldehyde (37%), 20 ml 10 X
MOPS, mix and pour.

Procedure
This procedure is that as described by Jack and Wabl (1988) and the
hybridizations were performed as described by Meinkoth and Wahl (1984).

Electrophoresis
The appropriate amount of RNA (1-10 µg) was mixed with 10 µI of
deionized formamide (dFA}, 3.5 µI of 37% formaldehyde, 2 µI of 10 X MOPS
buffer, 2 µI of EtBr (1mg/ml), and filled with DEPC-dH 2 0 to a final volume of 30
µI. The mixture was heated to 65°C for 5 minutes and chilled on ice. 3 µI of 5 X
RNA loading buffer was added to each sample and loaded into sample wells of a
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formaldehyde

agarose

electrophoresis

gel

poured

in

a

horizontal

gel

electrophoresis chamber (Model H3, BRL) submerged in overlay buffer. The left
and right chambers were filled with 1 X MOPS buffer and electrophorised under
constant voltage of about 40 V for overnight (-16 hours) until the bromophenol
blue has migrated to the bottom of the gel.

Transfer of RNA
The RNA gel was photographed using an ultraviolet light transiluminator
and a Polaroid camera, rinsed with dH 2 0 and 1O X SSC. Capillary transfer to a
nitrocellulose membrane was performed overnight (BA85, 0.45 µm, Schleicher
and Schuell, Inc., Keene, NH) in 10 X SSC (Figure 6). Standards as well as 18S
and 28/26S RNA was labeled using a pencil. Filters were dried under a heat
lamp for 20 minutes, baked under high vacuum at 80°C for 2 hrs.

Hybridization
Filters were prehybridized and hybridized with either an Omniblot system
(ABN) or Hybaid brand hybridization oven according to the manufactures
instructions. The prehybridization was performed in the prehybridization mix for
over 1 hour at 42°C. The prehybridization was replace with the hybridization mix
7

containing approximately 3 X 10 cpm of denatured

32

P-labled probe and 500 µg

of denatured sheared salmon sperm DNA. Hybridization was carried out for 1248 hrs at 42°C. After hybridization, the filters were washed once with 2 X SSC at
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250 g
Weight

Paper
Towels--

Hybridization
Membrane
Glass Suspension
Plate

Gel
Capillary Wick

Figure. 6 Schematic diagram of a nucleic acid capillary transfer
apparatus.
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room temperature to remove free radioactive probe and then several times with
0.1 X SSC/0.1 % SOS for 20-30 minutes at 52-54°C.

The membrane was

washed until the background detected by a Geiger counter was considered low.
The washed blots were wrapped in plastic wrap and radioactivity on the blot was
determined with a Betagen Radioanalytic Imaging System (Betascope 603 Blot
Analyzer, Betagen Corp., Mountain View, CA). The blots were then wrapped in
plastic wrap and exposed to X-ray film (Kodak X-OMAT AR film, Eastman Kodak
Company, Rochester, NY) flanked by one intensifying screen (Fisher Biotech,
Pittsburgh, PA) for varying times at -70°C before processing by a X-ray film
processor (Model QX-60A, Konica, Tokyo, Japan).
The sizes of a RNA band was determined by measuring the distance
between the loading well and the band and comparing it to that of known RNA
molecular weight standards. The RNA size standard used was the RNA ladder
and ribosomal RNAs.
To control for RNA loading on each lane, northern blots were rehybridized with a 1.3-kb BamHl/EcoRI fragment of rabbit GAPDH (Applequist et
al., 1995).

RNase H Treatment of Total RNA
RNase H treatment of total RNA was used to identify regions where
RNA/DNA hybrids were formed. The procedure was performed as adapted from
and described by Qian et al., 1993.
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Solutions
10 X RNase H buffer

0.2 M HEPES, (pH 8.0);
0.5 M KCI; 0.1 M MgCl 2

RNase H mix

Mix 2.5 µI of 10 X RNase H
buffer, 2.5 µI of 10 mM DTI, 1.2
µI of RNase H (1 U/µI), and 8.8 µI
of DEPC-dH 2 0.

Procedure
Briefly, 10 µg of total RNA in 5 µI of dH 2 0 or TE was mixed with the
following; 2 µI of oligo-(dT) primer (0.5 µg/µI; Promega, Madison, WI) or with 0.2
µg of a DNA oligonucleotide. This mixture was incubated for 30 minutes at 45°C.
15 µI of the RNase H mix was added, incubated for 20 minutes at 37°C. The
mixture was extracted once with chisam, and the RNA was precipitated at -20°C
with 1/10 volume 3 M NaAc, (pH 5.2); and 2.5 volume of ice-cold EtOH. The
RNA was collected by centrifugation for 1 hr at maximum speed at 4°C, and
subjected to northern blot analysis as described in section Northern Blot
Analysis.
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DNA Manipulations

General Solutions
20 X SSC

Mix 525.9 g NaCl, 264.7 g Citric
Acid, and add 3 L dH 2 0.

50 X Denhart's solution

Mix 1 g polyvinylpyrrolidone, 1 g
of BSA, 1 g of Ficol (DL-400),
and add 100 ml of d H2 0. Store
Whatman filtered aliquots at
-20°C.

0.5 M EDTA

Mix 186.1 gin 800 ml dH 2 0, add
NaOH (1 ON) until clear. Fill to
1000 ml with dH 2 0.

2 M Tris-HCI, (pH 7.4)

Mix 12.114 g of Trisma-Base with
90 ml of dH 2 0. pH to 7.4 with 12
M HCI. Fill to 100 ml with dH 20.

3 M Sodium acetate

Mix 24.6 g of NaAc in 90 ml H20
and pH to 5.2 by using glacial
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acetic acid. Fill to 100 ml with
dH 20.

TE buffer

Mix 5 ml of 1 M Tris-HCI, (pH
8.0); 1 ml of 0.5 M EDTA, and
add 500 ml of dH 2 0.

Salmon Sperm DNA: Resuspend 1 g of salmon sperm DNA in 90 ml of
dH 2 0 and gently stir overnight. Sonicate the DNA solution on ice in 15 minute
intervals.

Test the average length of the DNA using TAE/agarose gel

electrophoresis.

Repeat the sonications until the average fragment length is

between 1-3-kb and add SOS to 0.5% and proteinase K until 100 µg/ml.
Incubate overnight at 42°C and then extract the DNA with

TE

equilibrated

phenol, phenol:chisam (1 +1 ), and then with chisam until the interphase is clear.
Collect the aqueous phase and precipitate the DNA with 1/10 volume of 3 M
NaAc and 2.5 volumes of EtOH. Collect the precipitate by centrifugation, wash
with 70% EtOH, and resuspend in 90 ml of dH 2 0. Quantitate the DNA and dilute
to obtain a stock concentration of 10 µg/µI, aliquot and freeze at -20°C.
TE-saturated phenol/chisam: Melt phenol in 65°C waterbath.

Add 8-

Hydroxy Qunoline (Sigma Cat #H-6878) to a final concentration of 1 mg/ml
phenol. Extract the phenol once with equal volumes of 1 M Tris-HCI, (pH 8.0);
and 3 to 5 times until the pH of the TE phase reaches 7-8.

Mix 1 part TE-

equilibrated phenol with 1 part of chisam (chloroform/isoamyl alcohol at 25:1)
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Amplification of Plasmid DNA

Plasmid DNA Preparations
Large preparations of plasmid DNA used for cloning, transfection and
transformation were performed by the alkaline lysis as described by Sambrook
and colleagues (1989) and also with a large scale plasmid kit from Qiagen as
described by the Qiagen plasmid preparations manual (Qiagen Plasmid maxi kit,
Cat#12162, Qiagen, Chatsworth, CA). Rapid, small scale plasmid preparations
were performed as described by the Promega Magic minipreps kit (Cat#A7100,
Promega, Madison, WI) according to the manufacturers instructions included
with the kit.

Solutions and Media
LB-antibiotic media

2.5% LB
5 mM Glucose
100 µg/ml ampicillin, 15 µg/ml
tetracycline, or 70 µg/ml
kanamycin

Lysis buffer

1% glucose
10 mM EDTA, (pH 8.0)
25 mM Tris-HCI, (pH 8.0)
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Lysozyme solution

30 mg/ml of lysozyme in lysis
buffer

Alkali solution (prepare fresh)

1%

sos

0.2% N NaOH

Potassium acetate, (pH 4.8)

Mix 60 ml of 5 M KAc, 11.5 ml
glacial acetic acid, and add 28.5
ml dH 2 0.

Proteinase K buffer

50 mM Tris-HCI, (pH 8.0)
10 mM CaCl 2 (store -20°C)

Proteinase K stock

10 mg/ml of lyophilized
proteinase K in proteinase K
buffer (store -20°C)

RNase A buffer

10 mM Tris-HCI, (pH 7.5)
15 mM NaCl (store at -20°C)

RNase A stock

10 mg/ml of lyophilized RNase A
in RNase A buffer (store -20°C)
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Bacterial Strains

Escherichia coli (E. colt) strains HB101, JM109, or DH5a are from the lab
stocks of the lab of Dr. Jack. JM110 was obtained from New England BioLabs.
All bacteria were made competent using a rubidium chloride/calcium chloride
procedure (Sambrook et al., 1989). All bacteria containing plasmids were grown
in either liquid culture or on agar plates in the presence of the appropriate
antibiotic. In order to select for the presence of the DNA fragment disruption of
the E. coli (3-galactosidase a-peptide gene present on some plasmids, they were
propagated in JM109 or DH5a were grown on Luria Broth (LB) agar plates (1.5%
Bacto-agar in LB-media, (pH 7.0)) supplemented with 100 µg/ml ampicillin, 40
µg/ml X-Gal, and 5 mM IPTG.

Small Scale Preparation of Plasmid DNA (Miniprep)
A fresh, single colony was inoculated into 5 ml of LB-media+glucose
containing the appropriate antibiotic.

The cultures were shaken vigorously

overnight at 37°C. 1.5-3 ml of the cultures were pelleted by centrifugation and
the plasmids were isolated from the bacteria pellet with Magic mini prep kit
(Promega, Madison, WI) according to the manufacturer's instructions.
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Large Scale Preparation of Plasmid DNA

Alkaline Lysis Method
2.5 ml of an overnight culture was inoculated into 250 ml of LB-media
+glucose medium containing appropriate antibiotic in a 1 L Erlenmeyer flask.
The culture was shaken vigorously at 37°C until it reached an OD 550 of 0.6-0.7.
Bacteria were pelleted by centrifugation in a swinging bucket rotor in a Beckman
table top centrifuge (Model GPR) at 3,200 rpm for 20 minutes at 4°C.

The

bacterial pellet was resuspended in 4 ml of lysis buffer. 1 ml of freshly prepared
lysozyme was then added to the suspension. These cells were transferred to a
50 ml high speed centrifuge tube and incubated for 5 minutes at room
temperature and 5 minutes on ice. The bacteria were lysed by the addition of 12
ml of alkali solution and subsequent incubation for 10 minutes on ice. Proteins
were then precipitated by the addition of 9 ml of ice-cold potassium acetate
solution for 20 minutes on ice.

The solution was gently mixed, balanced, and

then centrifuged in a Sorvall SS34 rotor at 12,000 rpm at 3°C for 30 minutes.
The decanted solution was transferred into a new 50 ml tube and the DNA was
precipitated with 1 volume of cold isopropanol for 20 minutes and collected by
centrifugation in a Sorvall SS34 rotor at 15,000 rpm at 3°C for 30 minutes. The
DNA pellet was partially dried by placing the tube in a Speed-Vac vacuum
evaporator (Savant, Farmingdale, NY) and the pellet was resuspended in 2 ml
TE. To eliminate the contaminating RNA the DNA was incubated with addition of
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RNase A.
minutes.

50 µI of RNase A was added and incubated at 37°C for 15-30
To remove contaminating proteins 100 µI of 10% SOS was added

followed by incubation with 40 µI of proteinase K at 42°C for 1 hour. The treated
DNA in TE was extracted 3 times with phenol/chisam and once with chisam.
DNA was precipitated with 1/10 volume of 3 M sodium acetate, (pH 5.2); and 2.5
volume of ice-cold EtOH for 20 minutes to overnight at -20°C. DNA was pelleted
a Sorval SS34 rotor with 12,000 rpm at 4°C. The DNA was washed with 70%
ethanol, dried in a Speed-Vac vacuum evaporator, and dissolved in 250 µI of TE.
1 µI of this DNA was quantitated by restriction enzyme digestion as described in
section Quantitation of DNA.

Qiagen Method
Large scale plasmid isolation by the Qiagen method was carried out using
100 ml bacteria cultures grown overnight in LB-media+glucose with antibiotics
according to the manufacture's instructions (Cat#12162).

'A Phage DNA Preparation
'A Phage DNA preparation was carried out according to Sambrook et al.,

(1989).

Briefly, eluted phage particles were titrated and infected into the
7

appropriate strain at a pfu of 5 X 10 phage per 10

10

E.coli cells. The cells were

grown in 500 ml of LB-media+glucose containing 10 mM maltose and 10 mM
MgS04 prewarmed to 37°C. Concomitant growth of bacteria and phages should
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occur, which results in lysis and a clearing of the culture after 9 to 12 hours. To
lyse residual bacteria, add 10 ml of chloroform to each flask and incubate for 10
minutes at 37°C with shaking. The culture is cooled to room temperature and
DNase I and RNase A are added to a final concentration of 1 µg/ml. The mixture
is incubated for 30 minutes at room temperature. NaCl is slowly added to the
culture to a final concentration of 1 M (29.2 g per 500 ml of culture). The NaCl is
dissolved by gentle swirling of the flask. The culture is incubated for 1 hour on
ice and residual debris are removed using a GSA rotor with 11,000 rpm for 1O
minutes at 4°C. Pool the supernatants in a clean flask and PEG 8000 is added
to a final concentration of 10% w/v (i.e., 50 g per 500 ml of supernatant) and
dissolve by slow stirring on a magnetic stirrer at room temperature. The phage
particles are precipitated overnight on ice and pelleted by centrifugation in a
GSA rotor with 11,000 rpm for 10 minutes at 4°C.
thoroughly.

Discard the supernatant

Gently resuspend the pellet in 8 ml of phage buffer using a

disposable plastic bulb pipette and extract the PEG from the suspension by
adding an equal volume of chloroform and vortexing for 30 seconds followed by
centrifugation in a Sorval SS34 rotor at 5000 rpm for 15 minutes at 4°C. 0.5 g of
CsCI per ml of the phage solution is added and gently dissolved and layer onto
CsCI step gradients prepared in a SW41 tube by adding the following CsCI
solutions in phage buffer into the SW41 tube from the bottom up: 1. 7 g/ml of
phage buffer, 1.5 g/ml, 1.45 g/ml and then on top the 0.5 g/ml solution containing
the resuspended bacteriophage pellets also in phage buffer.

The gradient is
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dialysis tubing and quantitate it as described in section Quantitation of DNA
before use.

Enzyme Restriction of DNA
0.5-1.0 µg of plasmid and phage DNA were digested with 2-5 U of
restriction enzyme in a 20 µI reaction volume in buffers provided by the
manufacturer under reaction conditions recommended by the manufacturer.
Digested DNA was analyzed on 0.8%-1.2% agarose gel as described in section
DNA Agarose Gel Electrophoresis, and DNA fragments were isolated as
described in section DNA Band Isolation from Agarose Gels.

DNA Agarose Gel Electrophoresis
DNA fragments were separated in 0.8%-1.2% TAE/agarose gels as
described by Sambrook et al, (1989).

The gels were prepared as follows.

Dissolve 1 g of agarose in 125 ml TAE buffer (40 mM Tris-HCI, (pH 8.0); 20 mM
sodium acetate, 2 mM EDTA) by boiling in a microwave oven, cooled to 60°C
and add 4 µI of ethidium bromide (EtBr) stock solution (10 mg/ml of dH 2 0). Mix
gently and pour into a horizontal gel casting tray (Wide Mini-Sub DNA
electrophoresis Cell, BioRad, Richmond, CA). Allowed the gel to solidify at room
temperature for 60 minutes and submerge it in the electrophoresis chamber
(Wide Mini-Sub DNA electrophoresis Cell, BioRad, Richmond, CA) containing 1
X TAE. Remove the comb before use. Add 1/5 volume of DNA loading buffer
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(0.025% bromphenol blue, 2.5% Ficoll, 1 X TAE)to the DNA sample, heat for 5
minutes at 65°C, chill on ice and load 20-25 µI on the gel. Separate the DNA
with 40-70 V until the bromphenol blue dye front reaches about 2/3 of the way
through the gel.
Lambda (A.) DNA cleaved with restriction endonuclease Hindlll,

~X

DNA

cleaved with Haelll and/or a 1 kb DNA ladder (all from Gibco BRL) were run
simultaneously to serve as DNA molecular weight standards. DNA bands were
viewed under an ultraviolet light box and photographed on Polaroid 667 film with
a Polaroid Camera (Model DS34, Polaroid Corp., Cambridge, MA).

DNA Band Isolation from Agarose Gels
Digested DNA was size fractionated by agarose gel electrophoresis. EtBr
DNA fragments were visualized using ultraviolet light.

The appropriate

fragments were isolated with a razor blade or scalpel and extracted from the gel
by one of the methods described below.

Elu-T rap Method
DNA was isolated from the agarose piece by electroelution using a an
Elu-Trap apparatus (Schleicher and Schuell, Keen NH, Cat#46178) according to
the manufacturer's instructions.

Briefly, the agarose piece was placed in the

elution cell and electroeluted from the agarose with 120 V for approximately 2-4
hrs into a small elution chamber.

The eluted DNA was removed from the
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isolation chamber and precipitated with 1/10 volume of 3M NaAc and 2.5 volume
EtOH overnight at -20°C. DNA was recovered by centrifugation and resuspend
in TE to obtain approximately 1-2 µg DNA/µI.

Sodium Iodide (Nal) Method (Super-Band isolation)
The excised gel piece containing the DNA cut into small pieces and
weighed. 2.5-3 volumes of 6 M Nal in dH 2 0 was added to the tube with the
minced agarose and DNA.

The mixture was incubated at 45°C for 10 to 20

minutes. The tubes are inverted to facilitate the dissolving of the agarose. 1 ml
of Magic mini-prep resin (Promega, Madison, WI) was added to the melted
agarose and incubated at room temperature for 15 minutes. The DNA fragments
bound to the DNA binding resin were then processed according to the protocol
provided by the manufacturer (Lit#TB117).

Quantitation of DNA
The concentrations of isolated DNA fragments, or plasmids, were
estimated by comparing their EtBr-staining to that of DNA fragments of known
amounts. Alternatively, optical densities at 260 and 280 nm were determined
and the concentration wad calculated with the following equation:
µg I µI DNA =OD260 X 50 X dilution factor.
Pure DNA is expected to yield a OD 2601280 of 1.8 to 2.0.
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Dephosphorylation of DNA Fragments
To

prevent

self-ligation

of

vector

fragments

a

nucleotide

dephosphorylation reaction was carried out as follows. Pipette into a autoclaved
microcentrifuge tube: digested DNA 20-30 µI, 1O X Calf Intestinal Phosphatase
(CIP) buffer 5 µI, CIP enzyme 0.01 U/pmol DNA, and dH 2 0 to 50 µI total
volume.
For 5'-overhangs, incubate the mixture at 37°C for 30 minutes, add
another aliquot of diluted CIP, and incubate for another 30 minutes.

For 3'-

overhangs or blunt ends, the reaction mixture is incubated at 37°C for 15
minutes and then at 55°C for 15 minutes.

Add another aliquot of CIP and

incubate again at the same temperatures.
Inactivate the CIP enzyme by addition of 20 µI of 500 mM EGTA, (pH 8.0);
followed by heat inactivation at 65°C for 45 minutes.

CIP treated DNA is

prepared for use by one phenol, (pH 8.0); extraction, one chisam extraction and
EtOH precipitation.

Precipitated DNA is resuspended in 10 µI of TE and

quantitated for use.

Ligation of DNA Fragments

Solutions
10 X Ligation buffer

300 mM Tris-HCI, (pH
7.8); 100 mM MgCl 2 , 100
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mM DTI, 5 mM ATP

10 X Kienow buffer

100 mM Tris-HCI, (pH
7.5); 500 mM NaCl
50mM

10 X T3 polymerase buffer

on

40 mM Tris-HCI, 6 mM
MgCl 2 , 10 mM DTI, 10
mM spermidine, 4 mM
ATP, CTP, GTP, and UTP
(pH 7 .2 at 37°C)

10 X dNTPs

0.125 mM of each dNTP

Sticky-End Ligations of DNA Fragments
A 5-10: 1 molar ratio of insert:vector DNA was used to obtain optimal
ligation efficiency.

Usually 0.1 µg of vector DNA was used in a 15 µI ligation

reaction. One Weiss U of T4 DNA ligase (e.g. 1 Weiss unit is the amount of
activity an enzyme can catalyze the ligation of greater than 95% of Lambda
Hindlll fragments of 1 µg of DNA at 16°C in 20 minutes) (Pharmacia or Promega)

was added to each ligation mixture and ligation reactions were carried out at
15°C overnight (10-14 hrs).
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Two-Step Ligations of DNA Fragments
Two-Step ligation is a procedure to ligate two fragments that are
compatible only at one of their free ends.
Reaction 1. Ligation of compatible ends:
GIP-treated vector

0.5 µg

DNA fragment

5-10:1 excess over vector

10 X ligase buffer

2 µI

T 4 DNA ligase

1 U (Weiss unit)

dH 2 0

to final volume of 20 µI

Incubate overnight at 15°C and heat inactivate the ligase at 65°C for 10
minutes.
Reaction 2. Creation of compatible blunt ends.
For 5' overhangs:
DNA ligation mixture

20 µI

10 X Kienow buffer

3 µI

0.125 mM dNTPs

3 µI

100 mM OTT

1.5 µI

Kienow enzyme

1 U diluted in 1 X Kienow buffer

dH 2 0

to final volume of 30 µI

Incubate at room temperature for 30 minutes.
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For 3' overhangs:
3' the 10 X Kienow buffer is replaced with T4 DNA
polymerase buffer and the Kienow enzyme is replaced with
T4 DNA polymerase. Proceed as described for the Kienow
reaction.

Reaction 3.

Ligation of the blunt ends:
1. Ligation mixture
10 X ligase buffer

10 µI

50% PEG

10 µI

100 mM OTT

1 µI

T4 DNA ligase

1 U (Weiss unit)

dH 2 0

to final volume of 100 µI

2. Add 40 µI of the ligation mixture to the Klenowrr4 DNA
polymerase reaction 2 mix and incubate at 15°C
overnight.
Transform the ligation mixture into competent E. coli cells as described in
Transformations of E. coli With Plasmid DNA using 50 ng of ligated DNA.

Polymerase Chain Reaction (PCR) Amplification
PCR was performed with purified plasmid DNA or with complete 'A phage
particles.

Either 1 ng of purified plasmid DNA or serial dilutions of 'A phage
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particles (eluted 2-6 hours) were used, as a template. PCR was performed with
the reagents and protocols as described below

Solutions
10 X PCR buffer

Mix 1ml of 1 M Tris-HCI (pH 8.3),
5 ml of 1 M KCI, 250 µI of 1 M
MgCl 2 , 50 ml of 20% gelatin
(BioRad), add dH 2 0 to 10 ml
final volume. Store at -20°C in
small aliquots.

10 X dNTPs (20 mM)

Mix 10 µI of 100 mM dATP, 10 µI
of 100 mM dCTP, 10 µI of 100
mM dGTP, 10 µI of 100 mM
dTTP, and add 500 µI of dH 2 0.
Store at -20°C in 50 µI aliquots.

Procedure
Pipette the following into a 0.5 ml autoclaved microcentrifuge tube:
Template DNA (about 1-5 µI)
1 ng of purified plasmid DNA or
10 fold serial dilutions of eluted

X µI
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phage particles (eluted 2-6 hours)
10 X PCR buffer

3.5 µI

10 X dNTPs

3.5 µI

forward primer (50 pmol/ml)

1 µI

backward primer (50 pmol/ml)

1 µI

Taq polymerase (5U/µI)

0.2 µI (1 U)

dH 2 0

to 35 µI final volume

Overlay the mixture with 25 µI of mineral oil (Sigma, Cat# M-3516). Place
the tubes in a thermal cycler (Perkin Elmer, Foster City , CA) and subject the
tubes to the following reaction; 1 minutes at 95°C, 1 minutes at 68°C, 3 minutes
at 72°C. The cycles were repeated 35 times, followed by a half hour at 4°C.
Amplification products were analyzed and or purified on an agarose gel as
described in DNA Agarose Gel Electrophoresis.

Under certain conditions the

annealing temperature of 68°C was lowered in order to allow primer annealing to
the target DNA.

Cloning of PCR Products
Purified PCR products were cloned into the PCR cloning plasmid pGEM-T
(Promega, Madison, WI) by the ligation methods described above and using the
amounts of template as described by the manufacturer (Lit.#TB150).
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Radio-labeling of DNA Probes

Nick Translation
Radioactive DNA probes were prepared by nick translation with a kit from
Gibco-BRL according to the manufacturers instructions except that half of the
volumes and a-32 P dCTP label were used. The labeled DNA was separated
32

from unincorporated a- P dCTP nucleotides by gel chromatography on a G-50
Sephadex (Fine) spin column according to the protocol supplied by the
manufacturer (Boehringer Mannheim) (Cat#1273-973). The radioactivity in 1 ml
of column eluate was measured in a liquid scintillation counter (window 0-1500,
Packard, Downers Grove, IL).

The specific activity was calculated using the

following formula:
cpm/µI x total eluate volume
incorporation in cpm I µg DNA =
µg input DNA.
The average specific activities of nick translated probes using this protocol were
0.5-1 X 108 cpm/µg DNA.

5' End Labeling of oligonucleotides
Oligonucleotides were phosphorylated with T4 polynucleotide kinase in
the presence of

32

P y-labeled dATP. The reaction was carried out as described

below.
100 pmol or 50 ng of

2 µI
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oligonucleotide with free 5' ends
10 X Kinase buffer "C" from

2 µI

Boehringer Mannheim
(500 mM Tris-HCI,, 100 mM
MgCl 2 , 1 mM EDTA, 50 mM
OTT, 1 mM spermidine, (pH 8.2

at 25°C)
32

P a-dATP (ICN > 7000

4 µI

Ci/mmol SA)
dH 20

11 µI

T4 poly-nucleotide Kinase

1 µI

(1 OU/µI, Boehringer Mannheim)
Incubate the mixture for 45 minutes at 37°C. After the reaction , fill to 50
µI with dH 2 0 and heat inactivate at 90°C for 5 minutes.

Apply the reaction

mixture to a G-25 Sephadex (Fine) spin column according to the protocol
supplied by the manufacturer (Boehringer Mannheim) (Cat#1522990).

The

specific activity of the probe was calculated as described above. The average
specific activities of labeled probes were between 1-2.4 X 109 cpm/µg
oligonucleotide DNA.
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DNA Sequencing
DNA sequencing was performed on double stranded plasmid templates
with the Sequenase 2.0 sequencing kit from USB (Sanger et al., 1977). Plasmid
templates were denatured by addition of 200 mM EDTA and 200 mM NaOH,
incubation at 65°C for 2 minutes. 1/10 volume 3 M NaAc and 2.5 volume EtOH
is added and the DNA is precipitated overnight at -20°C.

Denatured plasmid

DNA is resuspended in 5 µI of dH 2 0, 0.5 pmol sequencing primer, and 2 µI of 5
X Sequenase Reaction Buffer is added and the volume is filled to 10 µI with
dH 2 0. The mixture is warmed to 65°C for 2 minutes, allowed to cool slowly to
room temperature over a period of 30 minutes, and then chilled on ice.

The

Sequenase T7 DNA polymerase is diluted 1:8 in enzyme dilution buffer. To the
annealed DNA and primer add 1 µI OTT, 2 µI labeling nucleotide mixture, 2 µI
diluted Sequenase enzyme and 0.5 µI of
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S a-dATP. The mixture is incubated

at room temperature for 4 minutes. 3.5 µI of the sequencing reaction is added to
4 vials each containing 2.5 µI of either di-dioxy (dd) ddGTP, ddATP, ddTIP, or
ddCTP respectively.

The reaction is incubated for 5 minutes at 37°C and

stopped by the addition of 4 µI of stop buffer. These sequencing reactions can
be stored at -20°C for up to 4 days. Before loading onto the pre-heated
sequencing gel as described in chapter DNA Acrylamide Gel Electrophoresis
(Sequencing Gels), heat the samples to 90°C for 2 min.
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DNA Acrylamide Gel Electrophoresis (Sequencing Gels)
Acrylamide gels for the separation of DNA subjected to Sanger dideoxy
sequencing (Sanger et al., 1977) were prepared as described below.

Reagents
Acrylamide Stock Solution

Dissolve 40 g acrylamide and
2 g bis-acrylamide in 100 ml of
dH 20 and sterile filter.

10 X TBE

Dissolve 284 g Trisma base, 165
g boric Acid, 120 ml 0.5 M EDTA,
(pH 8.0); in 3 L of dH 2 0

10% Ammonium persulfate (APS)

Dissolve 100 mg of ammonium
persulfate in 1 ml dH 2 0
(can be used for up to 1 week)

Procedure
Clean 16 cm X 18 cm glass plates (Aladdin enterprise, San Francisco,
CA) first with soap and hot water.

Followed by dH 20 and finally with EtOH.

Wipe with lint-free cloth and assemble with 0.6 mm spacers. Tape the sides. and
bottom of the glass plates and clamp together with large paper binding clamps
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along each side.

To prepare a 6% acrylamide denaturing urea gel, mix the

following chemicals in a side-arm Erlenmeyer flask; 21 g Urea (Gibco-BRL), 7.25
ml acrylamide stock, 5 ml 10 X TBE, and 20 ml dH 20. Mix the reagents, degas
for 1O minutes, and add 400 µI of APS solution and 20 µI of TEMED (Sigma) with
gentle swirling. Quickly pipette the mixture between the glass plates, insert the
sharks tooth comb (Aladdin enterprise, San Francisco, CA) at the top of the gel,
apply clamps near the top of the gel and allow polymerization to occur. Wrap the
top of the polymerized gel in plastic wrap, apply 1 X TBE buffer to keep moist,
and store overnight at room temperature. Carefully remove the comb and set up
the glass plate in a electrophoresis apparatus (Aladdin enterprise, San
Francisco, CA). Fill the top and bottom buffer tanks with 1 X TBE and insert the
shark-tooth comb so that wells are formed.

Prerun the gel with a constant

voltage of 1000 V until the gel is warm and then increase the voltage to 13001800 V until the temperature of the gel is approximately 50°C. Flush the wells
with fresh 1 X TBE, heat the samples to 85°C for 2 minutes, and immediately
apply the sample to the gel. Run the samples until the xylene cyanole FF green
dye band has just run off the bottom of the gel. Remove the thin glass plate, lay
on top of the gel a 3 mm Whatman paper soaked in 10% acetic acid/ 10%
methanol and incubate for 10 minutes. Remove any free acid/methanol solution
by gentle blotting and then remove the Whatman (Note: the gel will stick to the
filter paper). Cover the gel side of the filter paper with plastic wrap, dry the gel
for at least 30 minutes at 80°C, and expose the gel to autoradiography.
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Southern Blot Analysis of DNA

Solutions
Lysis Solution

Mix 680 µI 1 M NaHC0 3 , 1.104
ml Na 2 C0 3 , 80 µI 0.5 M EDTA,
0.2 g N-lauroyl sarcosine (Na
salt), add dH 2 0 to 40 ml and add
12 mg of proteinase K.

Solution A

0.25 M HCI

Solution B

0.5 M NaOH
1.5 M NaCl

Solution C

0.5 M Tris-HCI, (pH 7.4-7.5)

3.0 M NaCl

Southern Hybridization Mix

Mix 70 ml dH 2 0, 20 ml
50% Dextran sulphate, 10 ml
10%

sos
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ONA Isolation
6

Pellet 3 X 10

cells and wash once with ice-cold Dulbecco's PBS.

Suspend the cell pellet and add 3 ml of lysis buffer, and using a 5 ml pipette,
gently pipette the cell lysate up and down 2-3 times to lyse cells. Incubate the
cell lysate at 37°C for 3-4 hr while periodically mixing the lysate. Transfer the
lysate to a 50 ml conical tube extract with phenol (TE equilibrated, (pH 7.0)),
chloroform, and isoamyl alcohol at a ratio of 25:24:1. Mix gently for 5-10 minutes
and then separate the phases by centrifugation at 2370 rpm in a Beckman tabletop centrifuge.

Repeat the extraction step one time. Extract once with

chloroform:isoamyl alcohol alone (24:1) and transfer the aqueous phase into a
sterile 25 ml Erlenmeyer flask with 0.2 volume 11 M ammonium acetate. Add
2.5 volume 95% EtOH and mix the flask gently until DNA precipitates. Spool the
DNA onto a Pasteur pipette and thoroughly wash the DNA in 70% EtOH.
Dissolve the precipitated DNA at 37°C in 400 µI of dH 2 0. Add 4 µI of RNase at
10 mg/ml and incubate at 37°C for 30 minutes. Extract the aqueous mixture as
above.

Precipitate DNA in a microcentrifuge tube by the addition of 1/10th

volume of 3 M NaAc and 2.5 volumes of EtOH, pellet, wash, and resuspend the
DNA in 400-600 µI of TE and incubate at 4°C overnight.

Restriction Digestion of DNA
Digest approximately 10 µg of DNA in appropriate restriction enzyme
buffer as described in section Enzyme Restriction of DNA. Extract the digested
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ONA twice with equal volumes of phenol/chloroform (1+1) and once with
chloroform. Precipate and wash the DNA as described above and resuspend in
7.5 µI of 10 mM NaP04 , (pH 6.8); in a volume suitable for application to
TAE/agarose gel electrophoresis. Heat the sample at 37°C for >30 minutes, add
5 X DNA loading buffer, heat to 65°C for 5 minutes, chill on ice.

Apply the

sample to a 0.7% TAE/agarose gel with 30 V for 16-18 hr in 1 X TAE.

Transfer of DNA
After completion of the electrophoresis soak the gel for 15 minutes in
solution A, 30 minutes in solution B, and in solution C for 45 minutes. Transfer
the DNA to Gene Screen Plus (DuPont, Boston, MA) as described for RNA and
then dry the membrane for 30 minutes at 37°C.
The filter is then prehybridized with the hybridization solution at 65°C and
then hybridized at 65°C overnight in the same solution containing radiolabled
probe boiled for 5 minutes with 100 µg of sheared salmon sperm DNA.

The

membrane is washed using high stringency conditions (68°C, 0.1 X SSC/0.1 %
SOS) for 10 minutes until washing is sufficient. The blot is then dried and put to
X-ray film at -70°C backed with a fluorographic enhancing screen.
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Bacterial Strains and Manipulations

Preparation of Transformation Competent Bacterial Cells
Solutions
Solution A

10 mM MOPS, (pH 6.5)
10 mM RbCI

Solution B

10 mM MOPS, (pH 6.5)
50 mM CaCI
10 mM RbCI

Solutions A and B are filter-sterilized by passage through a 45 µm filter
and stored at 4°C.

Procedure
The bacteria to be made competent are streaked from a frozen stock onto
a LB-media plate. A single colony is inoculated into 5 ml of LB-media containing
5 mM Glucose (LB-media+glucose) and shaken vigorously overnight at 37°C.
100 ml of LB-media is innoculated with 2.5 ml of overnight culture. The culture is
grown at 37°C until the 00600 is 0.13-0.15.

The cells are centrifuged for 5

minutes with 5,000 X g at 4°C in a sterile tube. The supernatant is decanted and
the cells are resuspended in 50 ml of solution A.

The cells are pelleted as

described above. The cells are resuspended in 5 ml of solution B and then up to
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50 ml with solution 8. The cells are incubated on ice for 30 minutes and then
pelleted as described above.

The supernatant is decanted and drained

thoroughly. The cell pellet is gently resuspended in 4 ml of solution B. 1 ml of
50% glycerol is added to the resuspended cells and 50 µI aliquots are frozen in
small tubes at -70°C.

Transformations of E. coli With Plasmid DNA
25 µI of competent E. coli cells in a microcentrifuge tube and 50-500 ng of
plasmid DNA, or 1-5 µI of ligation mixture were mixed gently and incubated on
ice for 30 minutes.

The mix was heat shocked in a 42°C water bath for 50

seconds and placed on ice for 2 minutes.

1 ml of SOC medium (2% Bacto-

tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCI, 10 mM MgCl 2 , 10 mM
MgS04 , 20 mM glucose) was added to the heat shocked cells, and the mixture
was incubated at 37°C for 45-60 minutes.

Aliquots of the transformation mix

were plated on LB-media plates containing 100 µg/ml ampicillin, 15 µg/ml
tetracycline or 70 µg/ml kanamycin. Transformants were screened as described
in the following section.

Screening of E. coli Containing Recombinant Plasmid Vectors
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Blue/White Color Screening
To screen transformed E.coli strains, JM109 and DH5a, for the presence
of p-galactosidase activity, 50 µI of 2% X-Gal (Boehringer Mannheim,
Indianapolis, IN, turns blue in the presence of p-galactosidase) and 100 µI of
1oo

mM

isopropylthio-p-D-Galactoside

(IPTG)

(Boheringer

Mannheim,

Indianapolis, IN, induces promoter activity and expression of p-galactosidase apeptide) were used.

If the plasmid contains a DNA insert within the multiple

cloning site, its presence will disrupt the a-peptide coding region and thus any
a-peptide activity. To prepare media to detect p-galactoside activity within an E.
coli strain containing a recombinant plasmid, the color inducing reagents were
spread on 1.5% agar/LB-media plates containing an appropriate selective
antibiotic (blue/white plates) for 30 minutes before transformed bacteria were
plated.

Recombinant plasmids are detected by their white color (lack of p-

galactosidase activity due to recombinant DNA within the coding region of the apeptide gene) while non-recombinant colonies (active p-galactosidase activity
and active a-peptide) were blue.

Bacterial Colony Lift
To identify bacterial colonies that carry recombinant plasmids, the
following protocol was adapted and modified from Buluwela et al., (1989).
Briefly, LB-media plates containing bacterial colonies were cooled to 3°C before
use.

A nylon membrane (HyBond-N, 0.45 µm, X 82mm, Cat#RPH.82N,
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Amersham, Arlington Heights, IL) was carefully laid onto the cold bacteria
colonies and incubated for 2 minutes. To mark the orientation of the filter on the
plate, filter and agar were punctured with a needle. The filter was removed and
placed bacteria side up for 2 minutes on a Whatman filter soaked in denaturation
solution (2 X SSC and 5% SOS). The filters were then placed on Whatman filter
paper and microwaved on high power (100%) for 2-2.5 minutes. The filters were
then soaked in 2 X SSC and the bacterial debris were gently rubbed off. The
filters were prehybridized in a solution containing 0.5 M NaP0 4 , (pH 7.0); 1%
BSA (Boehringer Mannheim, Indianapolis, IN), 7% SDS, 1 mM EDTA at 65°C for
at least 1 hour. 2 X 106 counts of denatured
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P-labeled DNA probe were added

to the prehybridization mix and incubation was carried out overnight at 65°C.
The filters were washed first with 2 X SSC at room temperature for 2-5 minutes
and then with 0.1 X SSC/0.1 % SOS at 55°C until the filter that serves as a
negative control (bacteria transformed with vector alone) is clear of radiation.
The punctures in the filter were labeled with radioactive ink and the filters were
autoradiographed overnight using an enhancing screen at -70°C.

'A Phage Infections

Phage Strains and Host Strains
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'A phage particles either from a purified plaque or as a whole library were
infected into host bacterial strain as described here. The host strain used with
each type of phage is indicated in Table 3.

Table 3. -- Bacteriophage and Host Strains Used
Phage Vector

Host Strain

Excision Strain

Reference

EMBL4

c600hfl

None

Woodcock et al.,
1989

'Agt10

LE392

None

Sambrook et al.,
1989

'A Zapll

XL1-Blue MRF'

SOLR

Stratagene

'A Zap Express

XL 1-Blue MRF'

XLOLR

Stratagene

'A Fixll

XL 1-Blue-MRA

None

Stratagene

Solutions
Solutions used in phage resuspension,

infection,

and plating are

described below.

Phage buffer

Dilute 5 ml of 5 M NaCl, 1 ml of
1 M Tris-HCI, (pH 7.4); and 0.5
ml of 1 M MgS0 4 in 25 ml of
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Top Agar

Autoclave 0.5 g of NaCl, 0.6 g of
agarose, and 1 g of Bactotryptone in 100 ml of dH 2 0.
After autoclaving and cooling to
55°C add 5 ml of 1 M MgS0 4 .

Phage Manipulation Protocols
Phage particles either undiluted or diluted in phage buffer were added to
the appropriate bacterial strain that was grown to an 00 550 of 0.6-0.7 in LBmedia supplemented with 0.2% maltose and 50 mM MgS04 . 100 µI of bacteria
was used when the infection was plated on a 82 mm diameter plate and 300 µI if
it was plated on a 137 mm diameter plate. Phage and bacteria were incubated
together for 30 minutes at 37°C. Top agar warmed to 42°C (3 ml for a 82 mm
plate and 7 ml for a 137 mm plate) was added to the bacteria/phage mixture
inverted once and quickly spread on pre-warmed (37°C) plates. The plates were
allowed to sit for 5 minutes at room temperature and then placed upside down at
37°C to allow plaques to form.

/. . . Phage Screening and Plaque Purification
LB-media plates containing lysogen plaques are screened for plaques
containing the desired cDNA/DNA insert by using the following reagents and
methods.
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Solutions
Alkaline solution

Mix 60 g NaOH, 262.9 g NaCl,
and add 3 L of dH 20.

Neutralization solution

Mix 181.7 g Tris-HCI, 525.9 g
NaCl, and add 3 L of dH 2 0. pH
to 7.4 using 12 M HCI.

3 X SSC/10% Dextran sulphate

Mix 150 ml 20 X SSC, 100 ml 50

hyb solution

X Den hart's solution, 10 ml 10%
SOS, 100 mg SS DNA
(denatured), 100 g dextran
sulphate and add dH 20 to 1 L

6 X SSC/10% Dextran sulphate

Mix 300 ml 20 X SSC, 100 ml 50

hyb solution

X Den hart's solution, 10 ml 10
% SOS, 100 mg SS DNA
(denatured), 100 g dextran
sulphate, and add dH 2 0 to 1 L

2 X SSC/0.1 % SOS

Mix 100 ml 20 X SSC, 10 ml 10
% SOS, and add dH 2 0 to 1 L
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1 X SSC/0.1% SOS

Mix 50 ml 20 X SSC, 10 ml 10%
SOS, and add dH 20 to 1 L

0.1 X SSC/0.1% SOS

Mix 5 ml 20 X SSC, 10 ml 10%
SOS, and add dH 2 0 to 1 L

Procedure
Cool plates containing plaques to 4°C.

Overlay plaques with a

nitrocellulose filter of the appropriate size (82 mm diameter, BA85 [0.45 µm, Cat#
20440] or 132 mm diameter, BA 85 [0.45 µm, Cat# 20570] Schleicher and
Schuell, Keene, NH) onto the plate until the filter is completely wet.

Make

alignment holes by puncturing the filter and agar plate with a needle. Lift filters
from the plate with forceps and place plaque side up on a Whatman paper and
dry for 5 minutes. Place the filters into alkaline solution for 1 minute and then
transfer them into neutralization solution for 2 minutes. Remove the filters, dry
them under a heat lamp, and then bake them at 80°C for 2 hrs. under high
vacuum.

Remove the filters and wet them in the appropriate hybridization

solution without the dextran sulphate (either 3 X SSC mix for high stringency
hybridization or 6 X SSC mix for low stringency hybridization).

Remove the

wetting solution and immerse the filters in the complete hybridization solution
containing dextran sulphate for at least 1 hour at the appropriate hybridization
temperature (64°C for high stringency [3 X SSC/10% dextran sulphate] or 55°C
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for low stringency [6 X SSC/10% dextran sulphate]). Perform the hybridization
6

overnight in the same solution and add 2 X 10 counts of denatured
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P-labeled

DNA probe per ml. Wash the filters in the 2 X SSC/0.1 % SDS solution at 55580C for low stringency screen and with 1-0.1 X SSC/0.1 % SDS solution at 64680C for high stringency screen until the radiation on the negative control (filter
with a lifted plaque or colony containing a known negative insert (e.g. GAPDH))
is minimal. Dry the filters, mark them with radioactive ink, cover them with plastic
wrap, and expose them to X-ray film overnight against 1 enhancing screen at 70°C. Positive plaques were picked by excising a small agar piece by using the
large or small end of a pasture pipette and placing the agar plug in 1 ml of phage
buffer. The above procedure was repeated with eluted phage until all plaques
screened positive with the radiolabled probe.

Plasmid excision from AYES phage by the ere/lox recombination system
A.-YES phage particle eluted from a plaque-purified single plaque and
were used to infect the E. coli strain BNN132. This bacteria strain contains the
ere recombinase protein that is able to recognize its cognate recombination site
(lox) within the A--YES phage DNA.

The recombination process yields an

ampicillin-resistant E. coli I yeast shuttle plasmid.

The process of obtaining

bacterial colonies containing the excised plasmid is described below.
The E. coli strain BNN132 was grown to an OD 550 of 0.6 in selective
media (LB, 0.2% glucose, 70 µg/ml kanamycin) to select for the presence of the
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ere gene present within a kanamycin containing transposon.

A-YES phage

particles are diluted in phage buffer and added to BNN132 at a ratio of 1 particle
8

to every 3 bacteria (an 00 550 of 0.2 contains 10 bacteria/ml).

Incubate the

phage and bacteria for 30 minutes at 30°C. Add 1 ml of selective media again,
incubate the mixture for 1 hour at 37°C, and plate aliquots on LBmedia+ampicillin agar plates to select for the presence of the excised plasmid.
Incubate the plates overnight at 37°C and analyze the colonies as described.

Excision of Plasmid DNA from A Zapll pahge by helper phage
Recombinant plasmids were excised from single cDNA phage clones
isolated from Stratagene (La Jolla, CA) libraries A-Zap Express or A-Zap II. This
was done exactly according to the Stratagene instruction manual (Cat#200253).

Hybridization with DNA oligonucleotides
Hybridization of nucleic acids supported on nitrocellulose membranes was
performed as described by and adapted from M. Shulman, Univ. of Toronto.

Solutions
Hybridization mix

Mix 50 ml 20 X SSC, 4 ml 1 M
Na 2 P0 4 , (pH 7.0); 14 g SOS, 40
ml 50 X Denhart's, and add
dH 20 to 200 ml final volume
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Mix 75 ml 20 X SSC, 100 ml 50 X

Wash solution

Oenhart's, 25 g SOS, 12.5 ml 1
M NaH 2 P0 4 , (pH 7.5); and add
dH 2 0 to 500 ml final volume at
37°C

Procedure
Prehybridize Southern, northern or phage plaque blots on nitrocellulose at
47°C for at least 1 hour. Add

32

P-labeled probe (boiled 10 minutes then iced)
6

directly to the prehybridization solution at a final concentration of 1 X 10 cpm/ml.
Hybridize overnight at 47°C with gentle shaking. Wash the blot with the wash
solution at 50°C for 10 minutes times until the negative control contains minimal
background. Wash once with rinse solution (1 X SSC/1 % SOS) at 50°C for 5
minutes and wrap the wet blot in plastic wrap and expose to film to test washing
or dry the blot and put to film at -70°C with enhancing screen. Calculate the Tm
of hybridization by the following equation: Add 2°C for each A or T and Add 4°C
for each G or C. Hybridization should be at least 15-20°C below Tm·

Mammalian Cell Culture Techniques
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Growth of Cells
All cell lines were grown in complete RPMI medium as described (Keyna
et al., 1995).

Breifly, all cell lines were maintained in RPMI 1640 medium

supplemented with 10% (volume/volume) fetal calf serum (FCS, HyClone
Laboratories), 4 mM L-Glutamine, 2.5 ml of penicillin-streptomycin solution (50
U/ml), 0.05 mM ~-mercaptoethanol and 1 mM sodium pyruvate at 37°C or 30°C
in a 5% COrhumidified incubator with copper lining (Model#B5060, Hereaus,
South Plainfield, NJ). This medium is referred to as complete RPMI medium.
Unless indicated otherwise, all cell culture reagents used were from Gibco-BRL.

Cell Lines Used For This Work
The cell lines used are described below.

Table 4. -- Cell Lines Used
Name

Type

Source

Reference

FH I LOCB 81.13.13

B cell hybridoma

Murine

Jack et al., 1989

VXH I GAMO 12.8.10

B cell hybridoma

Murine

Jack et al., 1989

NYC

B cell lymphoma

Murine

Jack et al., 1992b

MORK

B cell hybridoma

Murine

Jack et al., 1992a

U-937

Monocytic

Human

ATCC # CRL 1593

Raji

B lymphoma

Human

ATCC#CCL86

Jurkat

T lymphoma

Human

ATCC # TIB152

He la

Endothelial

Human

ATCC#CCL2
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Table 4. cont. -- Cell Lines Used
HA-VSMC

Heart Muscle Cell

Human

ATCC # CRL-1999

Gia

Glioma

Human

Established from a
grade 4
neuroblastoma by
LC. Erickson, Loyola
University

MC/CAR

Plasmacytoma

Human

ATCC # CRL8083

96-1

B cell hybridoma

Rabbit

Dr. Katherine Knight,
unpublished

Harvesting of Cells
Cells were pelleted by centrifugation with 1100 rpm at 4°C for 5 minutes in
a refrigerated table-top centrifuge (Silencer S-103 NA, , Rupp and Bowman,
Tustin, CA).

Freezing and Thawing of Cells
To freeze cells, approximately 2.5 X 107 cells were pelleted, resuspended
in 1.5 ml of RPMI freezing medium (RPMI 1640 supplemented with 30% FCS,
15% DMSO, and 0.05 mM

~-ME),

and transferred into a chilled cryogenic tube

(Vangard CRYOS, Sumitomo Bakelite Co., Ltd., Japan). The frozen cells were
kept at -70°C overnight and then transferred to liquid nitrogen for long-term
storage. To thaw cells the frozen tubes were removed from liquid nitrogen and
warmed in a 37°C water bath until most of the cells were thawed. The cells were
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transferred to ice cold complete RPMI 1640 media, pelleted by centrifugation,
and cultured in 15 ml of complete medium.

Counting of Cells
A aliquot of cells was removed from the flask and counted in a Neubauer
hematocytometer chamber (Bright-Line, 0.1 mm, American Optical Co., Buffalo,
NY). The cell number was determined by the following equation: Cells/ml = total
number of cells in 1 of the 9 large counting fields X 2 X 104 .

Transfection of Cells With Plasmid DNA
All cell transfections were carried out by electroporation as described
(Jack et al., 1992). 5 X 106 cells were collected and washed twice in ice-cold
FCS-free RPMI medium and resuspended in 500 µI of the same medium. 5-20
µg of DNA (in approximately 20 µI of TE) is added and mixed gently by pipetting.
The cell suspension is subjected to one electric pulse of 330 µF, 285 volts at low
conductivity on ice with a Cell Porator (BRL, Gaithersburg, MD).

The

electroporated cells were immediately transferred into 10 ml of complete RPMI
medium/20% FCS and grown for 2 days. To isolate stable transfectants, the
cells were diluted in complete RPMI containing 0.8 µg/ml G418 (Geneticin,
Gibco-BRL) to a density of 5 X 104 cells/ml media. 100 µI of the diluted cells
were plated per-well in 10, 96 well plates.

Wells were screened under the
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microscope for cell clones between days 7-10 and fed with RPMI containing 0.8
µg/ml G418 at day 10.

Protein Analysis

Generation of Antisera Against Synthetic Peptides
Peptides deduced from the aa sequence of a polypeptide were
synthesized, coupled to a carrier protein, and rabbits were immunized with the
peptide I carrier conjugate.

Linear polypeptides were coupled to a carrier

molecule and used as an immunogen as described below.

Branched

polypeptides (Figure 7) were used directly as an immunogen due to their natural
ability to prime an immune response without a carrier molecule.

Coupling of Non-branched Peptides to Carrier Molecules
Because small linear peptides of 15-30 amino acid residues are poorly
immunogenic, they were coupled to a large carrier protein (keyhole limpet
hemocyanin [KLH] or bovine serum albumin [BSA]) using commercially available
pre-activated KLH and BSA (Pierce Co., Rockford, IL). The chemical reaction
that leads to a covalent association of peptide and carrier is outlined in Figure 8.
The coupling between peptide and carrier was performed with a antigen-carrier
coupling kit (Pierce Co., Rockford, IL) according to the manufacturer's
instructions included with the kit.

Peptide-Lys4-Tentacles

Peptides

Polylysine
Scaffolding

Figure 7. Schematic diagram of a multiple antigenic peptide.
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Immunization
Rabbits were either injected with carrier-coupled peptide or with branched
peptides (antigen) as follows.

The antigen is resuspended in PBS to a final

concentration of 2 mg/ml and 1 ml of antigen is mixed with 500 µI of 0.9% NaCl
and 1 ml of Complete Freund's Adjuvant (CFA). The emulsion is mixed using an
emulsion mixer (5100 Mixer I Mill, Spex, Inc., Edison, NJ) for 5 minutes the
mixture is put into a 3 ml syringe with a small spatula avoiding air bubbles
whenever possible.

Inject the whole mixture sub-dermal into the rabbits at

different locations six times (by the rear legs, behind the neck and at their flanks)
using a 20 112 gauge needle. After 4-8 weeks boost the rabbits with the antigen in
the following mixture: 100 mg antigen in PBS, 1 ml 0.9% NaCl, and 1 ml
incomplete Freund's Adjuvant.

If more boosting is required, repeat the

procedure above.
One week after the second boost, the rabbits are bled from a small cut on
the ear (no more than 30 ml from a healthy rabbit). The blood is collected in a 30
ml glass corex centrifuge tube and left at room temperature overnight (clotting
occurs). Spin the mixture for 20 minutes at 2000 rpm in a table-top centrifuge
and remove the cleared top layer of sera. Test the sera for antibody reactivity
against the injected antigen.
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Affinity Purification of Anti-peptide Antisera
To isolate peptide specific antibodies from the antiserum, isolated rabbit
serum was applied to a peptide matrix column (Pierce Co., Rockford, IL). Briefly,
a pre-activated amine-containing agarose matrix was mixed with the peptide
containing at least one COOH group.
carbodiimide catalyst in order to

The mixture was treated with a

facilitate the formation of an amine bond

between the amine-containing matrix and the COOH containing peptide (Figure
9). The column is then washed of any free peptide. The prepared column is
then incubated with rabbit sera allowing specific antibody-peptide interactions.
Un-bound antibodys are washed from the column and then peptide-specific
antibodies are released from the column by a 0.1 M Glycine (in dH 20, (pH 2.5)).

ELISA Analysis of Antisera

Solutions
color reaction solution

Mix 10 mg Sigma 104
Phosphatase Substrate [Cat#1040] in 10 ml of ELISA substrate
buffer

ELISA substrate buffer

Mix 48.5 ml Diethanolamine, 400
mg MgCl2+6H 20, 100 mg NaN 3 ,
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and add 500 ml dH 2 0, pH to 9.8
with 12 M HCI.

erocedure
To determine the presence as well as the amount of specific antibodies,
an

~nzyme

described.

linked immunoab_s.orbant assay ELISA assay was performed as
96 well plates (Falcon #3912-Test Ill) are first coated with target

antigen at 10 µg/ml in PBS/0.1 % NaN 3 overnight at 4°C. The wells were washed
twice with antigen incubated plate is washed twice with PBST solution (1 X PBS,
0.05% Tween-20, 0.02% NaN 3) and then blocked with 200 µI of PBS + 1% BSA
for 2 hr at 37°C or overnight at 4°C. After blocking, the wells were washed once
with PBST, filled with serial dilutions of the antibodys solution and incubated for 2
hr at 37°C.

The wells were washed 5 X with the PSST.

Then 50 µI of the

secondary alkaline phosphatase antibody (diluted 1:2000 in PBS + 0.1 % NaN 3 )
is added and incubated for 2 hr at 37°C. The plates are washed 3 X with PBST
100 µI of color reaction solution is added. Incubate for 30 minutes and read in
ELISA reader at A.450 .

lmmunofluorescence Analysis of Cytoplasmic Proteins (CIF)
4

To detect cytoplasmic proteins, 1-5 X 10 cells in 200-300 µI of RPMI
were centrifuged onto a glass slide at 1100 rpm for 2 minutes in a Shandon
centrifuge (London, England). After briefly air-drying the pelleted cells, the slides
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(and the cells on them) were placed in EtOH for 5 minutes at room temperature
and rehydrated in PBSF solution (1 X PBS, 0.1 % BSA, 0.1 % NaN 3 ) for at least
20 minutes. For direct CIF the slides were then incubated with 10 µI of diluted
fluorescent-labeled antibodies for 10 minutes at room temperature (Burrows et
al., 1981). For indirect CIF, the slides were first incubated with 10 µI of primary
antibody, washed 3 X with PBSF, and then incubated with 10 µI of diluted
fluorescent-labeled secondary antibody. The slides were washed 3 X with PBSF
and the cells were mounted under a glass coverslip using Cytoseal 60 (Stephens
Scientific, Riverdale, NJ). Mounted cells were examined under a fluorescence
microscope (Leica Photofluorescence Microscope, Model LABOVERT FS, Leitz
Wetzlar, Germany).

lmmunoprecipitation of Metabolically Labeled Polypeptides

Solutions and Reagents
RPMI labeling medium

Mix 500 ml methionine-free RPMI
1640 (Gibco-BRL), 50 ml of
dialyzed Fetal calf serum
(HyClone), 10 ml of 200 mM LGlutamine (Gibco-BRL), 0.5 ml of
1 M sodium pyruvate, 5 ml of 500
U/ml Penicillin-Streptomycin
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(Gibco-BRL), and 2.5 ml of 10
mM

10 X NET

~-ME.

Mix 8.76 g NaCl, 1.86 g of
sodium EDTA, 6.06 g Trisma
base, 1 g NaN 3 , and add dH 2 0
to 100 ml. pH to 7.4 and store
aliquots at -20°C.

0.1 M (PMSF)

0.1 M in ethanol, store at -20°C

1 X NET lysis buffer

Mix 10 ml of 10 X NET, 2.5 ml
20% Triton X-100 in water, and
add dH 20 100 ml. Add 1 µI of
0.1 M PMSF to every 100 µI of
lysis buffer before use. Aliquot
and store at -20°C.

Washed 10 % Staphylococcus aureus

S. aureus in PBS and NaN 3 was
prepared as described in
Bornemann (pH.D. thesis). Cells
were collected, washed 2 X in S.
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aureus wash buffer and

resuspended in the original
volume of buffer.

S. aureus wash buffer

Mix 75 mg of methionine, 5 ml
0.5 M sodium EDTA, (pH 8.0);
12.5 ml 2 M Tris-HCI, (pH 8.0); 1
ml 10% NaN 3 , 12.5 ml 20% Triton
X-100, 25 ml 10% sodium DOC,
5 ml 10% SOS, 62.5 ml 4 M
NaCl, and add dH 2 0 to 500 ml,
pH to 8.3. Before each use add
1-1.2 mg/ml Ovalbumin (Chicken
Egg, Sigma, St Louis, MO)

SOS sample buffer (1 X)

Mix 2.5 ml of 0.5 M Tris-HCI, (pH
6.8); 2 g glycerol, 1 ml

~-ME,

200

µI 0.2% bromphenol blue, 5 ml
10% SOS, and add dH 2 0 to 20
ml.
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Procedure

Metabolic Labeling of Cells
6

1-10 X 10 cells were starved for methionine for 1 hr in 1 ml RPMI labeling
medium.

50 µCi/ml of Trans-[ 35 S] label (1076 Ci/mmol, ICN) was added and

cells were incubated for 60-180 minutes in 5% C0 2 at 37°C. Cells were washed
in ice-cold PBS and lysed with ice-cold NET lysis buffer (250 µI/ 1-5 X 106 cells)
and incubated on ice for 20 minutes. Nuclei and un-lysed cells were removed by
microcentrifugation at 4°C for 5 minutes. The lysate was then transferred to a
new microcentrifuge tube and placed on ice.

lmmunoprecipitation
Lysates were incubated for 4-16 hours at 4°C after the addition of the
appropriate antisera or monoclonal antibody (approximately 5 µg antibody) to
each 2 X 105 cells used (amount of the antibody may vary depending on the titer
of the precipitating antibody used). In some cases where the primary antibody
binds weakly or not at all to protein A, an appropriate secondary antibody was
added which reacted with the first antibody and the incubation was carried out
for 3 hrs at 4°C.

Ab-Ag conjugates were precipitated by adding 100 ml of

washed 10% S. aureus and incubated, the suspension was incubated for 30
minutes in ice.

S. aureus was pelleted in a microcentrifuge tube, washed 2-3

times in S. aureus wash buffer and once with low salt washing buffer (50 mM

116Tris-HCI, (pH 8.0)). S. arueus pellets were resuspended in 100 ml of 1 X SOS
sample buffer, boiled for 3 minutes, and cooled in a water bath to room
temperature. The S. aureus was pelleted and 50-75 ml of the blue solution was
analyzed by SDS-polyacrylamide gel electrophoresis.

Jn Vitro Translation of Proteins

In vitro translation of proteins from RNA templates transcribed from cloned

genes were performed with the TNT Coupled reticulocyte lysate system
(Promega, Madison, WI) as recommended by the manufacturer. Briefly, 1-2 µg
of linearized plasmid isolated from bacteria using magic mini-preps or from
Qiagen was mixed with the following reagents;
~ti

1-2 µg of linearized plasmid DNA

X

TNT rabbit reticulocyte lysate

12.5 µI

TNT buffer

1 µI

T7 DNA polymerase

0.5 µI

35

2 µI

S-methionine, cystine (Trans-label)

10 mM amino acids (-methionine)

0.5 µI

20 U of RNasin (RNase inhibitor from

0.5 µI

Promega, Madison, WI)
dH 2 0 to 25 µI final volume
The in vitro translation mixture is incubated at 30°C for 120 minutes. 5 µI
of the reaction was mixed with 1 X Laemmli reducing SOS sample buffer (see
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section SOS Polyacrylamide Gel Electrophoresis (SOS/PAGE)), incubated for 15
minutes at 37°C. And analyzed by SOS-PAGE. Extra samples were frozen at 70°C for later use.

SOS Polyacrylamide Gel Electrophoresis (SOS/PAGE)
Proteins were separated by molecular weight on a discontinuous SOS
polyacrylamide gel system described by Laemmli, (1970).

Reagents
acrylamide solution

Mix 40 g of acrylamide (40%),
1.07 g bis-acrylamide (1.07%),
and add 100 ml of dH 2 0.

8 X separating gel buffer (3M Tris)

Mix 72.7 g of Trisma base, and
add 200 ml of dH 20. pH to 8.8
with HCI.

4 X stacking gel buffer (0.5 M Tris)

Mix 6.05 g of Trisma base, and
add 100 ml of dH 20. pH to 6.8.

10 %

sos

Mix 20 g of SOS with 200 ml of
dH 2 0.
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10% Ammonium persulfate (APS)

Mix 100 mg of APS with 1 ml of
dH 2 0.

TEMEO

Stock solution from Sigma

10 X Laemmli solution

Mix 121.2 g of Trisma base, 577
g glycine, 40 g SOS, and add 4 L
of dH 2 0.

separating gel buffer

Mix 3.75 ml of 3 M Tris-HCI, (pH
8.8); 0.3 ml 10% SOS, and add
30 ml of dH 2 0.

1 X Laemmli sample buffer

Mix 2.5 ml of 0.5 M Tris-HCI, (pH
6.8); 2 g 100% glycerol, 1 ml

13-

ME, 200 µI 0.2% BPB, 5 ml 10%
SOS, and add 25 ml of dH 2 0.

3 X Laemmli sample buffer

Mix 7.5 ml of 0.5 M Tris-HCI, (pH
6.8); 6 g 100% glycerol, 3 ml

13-

ME, 600 ml 0.2% bromphenol
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blue (BPB), 15 ml 10% SOS, and
add 25 ml of dH 2 0.

Electrophoresis
16 X 18 cm glass plates were washed, dried, and assembled with 1.5 mm
plastic spacers and plate clamps in a Hoefer vertical gel casting stand
(Model#SE6015). The gel solution (7 .5 ml of acrylamide solution, 3. 75 ml 3 M
Tris-HCI, (pH 8.8); 18.135 ml dH 2 0) was prepared in a 100 ml vacuum
Erlenmeyer flask and degassed the solution under vacuum for 10 minutes. 300
µI of 10% SOS, 300 µI of 10% APS, and 15 µI of TEMEO are quickly added and
mixed by gentle swirling. The solution is then poured between the glass plates
and then overlaid with a few ml of butanol saturated with Tris-HCI, (pH 6.8). The
gel is allowed to polymerize overnight at 3°C. The stacking gel (2.5 ml 0.5 M
Tris-HCI, (pH 6.8); 875 µI monomer solution, 6.525 ml dH 2 0) is degassed for 10
minutes, and 100 µI of 10% SOS, 100 µI of 10% APS, and 6 µI of TEMEO are
added, mixed, and pipetted on top of the separation gel that has been washed
with dH 2 0. A 1.6 mm multi-well comb is carefully inserted between the plates
and the gel is allowed to polymerize for 20-30 minutes. The comb is removed
while applying 1 X Laemmli buffer to the top of the gel. The wells are flushed
and filled with 1 X Laemmli running buffer.

The samples in Laemmli sample

buffer are boiled for 4 minutes, placed in room temperature water and loaded
into the wells. The samples are separated with a constant current of 30 mA for 1
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gel until the BPS band has reached the bottom of the gel. The glass plates are
disassembled and the gel is either used for a western transfer (section Transfer
of Electrophoreticaly Separated Proteins to Nitrocellulose Filters) or is enhanced
and dried for fluorography.

SOS-PAGE was also performed using a mini-gel

system (Cat#67320). with the same solutions as described above.

Fluorography of Polyacrylamide Gels
To shorten film exposure time in the detection of radiolabeled compounds
in polyacrylamide gels. Incubate the gel in ENTENSIFY-Part A solution for 30
minutes, then in ENTENSIFY-Part 8 (NEN Research Products, Boston, MA) for
30 minutes. Rinse the gel in dH 2 0, place the gel on Whatman filter paper, dry
the gel for two hours at 80°C and place it to film at -70°C using one enhancing
screen.

Western Blot Analysis

Solutions
Transfer buffer

Mix 12 g of Trisma base, 57.6 g
glycine, 800 ml methanol, and
add 4 L of dH 2 0.

10 X Ponceau S solution

2% Ponceau S dye
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30% trichloroacetic acid
30% sulfosalicylic acid

Tris buffered saline

Mix 9.68 g of Trisma base,
116.96 g NaCl, and add 4 L of
dH 2 0. pH to 7.5 with 12 M HCI.

Blotto

Mix 5 g of dry, non-fat milk and
add 100 ml of TBS.

antibody dilution solution

Mix 500 mg of dry, non-fat milk
and add 100 ml TBS

Enhanced Chemiluminescence

EGL kit (Boehringer Mannheim)

Transfer of Electrophoretically Separated Proteins to Nitrocellulose Filters
Electrophoretically separated proteins were subjected to Western blot
analysis (Beck-Engeser et al., 1987).

Briefly, SOS gel was soaked for 10

minutes in 100 ml of transfer buffer. 3 Whatman pieces cut to the size of the gel
were wetted in transfer buffer placed on a semi-dry transfer apparatus (Model
#FB-SDB-2020, Fisher Biotech, Pittsburgh, PA) followed by the gel.
following sandwich was assembled.

The

The gel is followed by a sheet of
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nitrocellulose (BA85, 0.45 µm, Schleicher and Schuell, Keene, NH) cut to the
size of the gel. Above the nitrocellulose is placed 3 additional Whatman sheets
wetted in transfer buffer.

Air-bubbles between the sheets were removed by

rolling the sandwich with a pipette.

Proteins were then transferred with a

constant current of 10 mA-per cubic cm of sandwich for 2-2.5 hrs. The sandwich
is then disassembled and the transfer of the proteins to the nitrocellulose is
confirmed by Ponceau S staining for 10 minutes. The filter is then destained in
TBS.

lmmunodetection of Transferred Proteins on a Nitrocellulose Filter
The membrane is then destained and blocked in Blotto for greater than 1
hr, rinsed with TBS 2 X 15 minutes and incubated with the primary antibody (in
antibody dilution solution) overnight at 4°C.

After removal of the primary

antibody the membrane is washed twice with TBS + 0.1 % Tween 20 (BioRad,
Cat# 170-6531) for 15 minutes and incubated with the secondary antibody (in
antibody dilution solution) overnight at 4°C. Finally, the blots are washed twice
with TBS for 15 minutes and subjected to enhanced chemiluminescence (ECL)
as recommended by the manufacture (Boehringer Mannheim). Rainbow protein
molecular weight marker were included to determine molecular masses of
proteins and to control for protein transfer.
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Yeast Strains. Growth and Manipulation

Yeast Strains
The Saccharomyces cerevisiae yeast strains used in this work are listed
and discussed in Chapter 3.

Media and Reagents

YEPD (non-selective complete medium)
yeast extract (Difeo)

10 g

bacto-peptone (Difeo)

20 g

dextrose

20g

dH 2 0

to 1 L final volume

Autoclave aliquots. For growth on plates, add 25 g Bacto-agar per
liter of YEPD.

Selective media
a) Drop-out medium (single selective or multiple selective medium)
dextrose

20 g

yeast nitrogen base w/o

6. 7 g

amino acids
appropriate 10 X drop-out

100 ml
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stock solution
50 mM inositol

1 ml

dH 2 0

to 1 L final volume

Autoclave aliquots. For growth on plates, add 20 g Bacto-agar per
liter of YEPD.
1O X drop-out stocks: The 10 X drop-out solution will not contain the amino
acid for selection. For example ura3 yeast will be grown in media without uracil
to select for the presence of a plasmid containing the URA3 gene.

Add the

following volumes of each amino acid supplement except the one that is being
"dropped-out".

Table 5. --Amino Acid Supplements Used in Yeast Drop-out Media
Supplement

Stock concentration

500 ml total

adenine

5 mg/ml

20ml

arginine

20 mg/ml

5ml

histidine

20 mg/ml

5ml

leucine

10 mg/ml

30 ml

lysine

115 mg/ml

10 ml

methionine

20 mg/ml

5ml

threonine

60 mg/ml

25 ml

tryptophane

10 mg/ml

10 ml

uracil

2 mg/ml

50ml
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Add 340 ml of dH 2 0 to the indicated amounts of amino acids and in place
of the "dropped-out" supplement add the same amount of dH 2 0. Mix thoroughly,
make 100 ml aliquots, autoclave, and label according to the "dropped-out"
supplement (e.g. 10 X Ura-).
b) Media supplemented with canavanine
dextrose

20 g

yeast nitrogen base

6.7 g

arginine drop-out stock

100 ml

50 mM insitol

1 ml

Agar

20 g

dH 2 0

to 1 L final volume

Autoclave the mixture and cool to 57°C. Add the appropriate amount of
stock canavanine solution to the media or aliquot of media to make an arginine
dropout plate with the desired amount of canavanine. The average amount of
canavanine to select a can1 strain of yeast is 60 µg/ml.

Drop-out induction medium (Used to induce the transcription of genes driven by
the ga/1-10 promoter).
Drop-out induction media
glycerol (80% stock)

37 ml

10 X drop-out stock

100 ml

yeast nitrogen base w/o

6.7 g
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amino acids
50 mM inositol

1 ml

dH 2 0

to 1 L final volume

Autoclave the mixture and cool to 57°C before the addition of 10 ml of
100% EtOH. For plates add 20 g of agar per L of plates. Store at 4°C.

Introduction of Recombinant Plasmids Into Yeast

Solutions and Reagents
All yeast transformations described below were performed in the presence
of carrier DNA (section DNA Manipulations and General Solutions) except that
the average fragment length was approximately 2.0-0.7-kb.

Transformation buffer

Mix 2.4 g LiAc, 4 g PEG, (pH
5.0; MW 3550); 1.543 g OTT,
and 100 ml of dH 20. Freeze
aliquots at -20°C.

For transformation, 50 µg of the DNA was boiled for 10 minutes and then
put to ice. After this carrier was sufficiently cooled, 1 µg of the plasmid to be
transformed was added.
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Yeast Transformation
Yeast were transformed by the method of Chen et al., (1992). Resuspend
5 X 107 pelleted yeast cells in "One-step" transformation buffer.

Mix the

resuspended yeast with 1 µg of plasmid DNA and 50 µg of single-stranded
carrier DNA (boiled salmon sperm) in a total volume of 100 µI. Incubated the mix
at 45°C for 45 minutes and plate 10 µI and 90 µI of the suspensions directly onto
selective medium and incubate the plates at 30°C for 3-4 days. Usually 20 µI
and 80 µI were the plated cell volumes.

The same protocol was used to

transform DNA fragments into yeast.

Yeast Mating
The method used was adapted from a protocol by Rob Barrington (Dawes
and Hardie, 1979). Yeast strains to be mated were grown on YEPD plates for 3
days to obtain healthy yeast. These yeast were used in the protocol below.

Generation of Diploid Yeast and Isolation of Yeast Spores

Media
Sporulation Plates
KAc (1 % final)

10 g

yeast extract (0.1 % final)

1g

dextrose (0.05% final)

0.5 g
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Bacto-agar (1.5% final)

15 g

dH 2 0

to 1 L final volume

Procedure
Healthy yeast were picked from a YEPD plate using a toothpick. A 1 X 1
X 1 mm patch of each yeast (one strain a and one strain a) was mixed together
with 5 µI of sterile dH 2 0 (patch mating). The mixed yeast were allowed to mate
overnight at 30°C. The mixed yeast were streaked onto sporulation plates and
incubated for 4-5 days at 25°C. Haploid spores were identified by suspension of
a small amount of cells in a drop of water on a microscope slide and observed by
light-field microscopy. The haploid tetrads will appear as clusters of four smetil
spheres held within a barley discernible sphere.
extraction in ether (Dawes and Hardie, 1979).

Spores were isolated by

Briefly,

5 small patches of

sporulated yeast were picked and put into a microcentrifuge tube containing 100
µI dH 2 0. The yeast were resuspended by brief vortexing. 300 µI of Ether was
added to the mixture and vortexed once for 30 sec. The mixture was centrifuged
for 5 minutes and decanted. This extraction procedure was repeated twice. The
small pellet of material obtained after the final extraction contains separated
spores (almost invisible). These spores were then resuspended in 100 ml of
dH 2 0 and dilutions were plated onto the appropriate selective media to obtain
haploid yeast of interest.
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Replica Plating of Yeast
Yeast to be replica plated are grown on appropriate media. This master
plate containing the strain or strains of interest is printed onto a velveteen square
placed over a circular Plexiglas block by applying gentle pressure across the
whole plate. A copy of this impression is transferred to plates made with all the
relevant selective media including a plate identical to the one used as the master
plate (positive control).

Storage of Yeast Strains
Yeast were stored as frozen stocks as described by Ausbel et al., (1990).
Yeast were grown to late-log or early-stationary phase in appropriate media. 700
µI of the resuspenede culture was mixed with 300 µI of 50% glycerol and frozen
at -70°C. Cells are revived by taking a fraction of cells from the frozen stock and
plating on the appropriate media (usually YEPD).

CHAPTER IV

RESULTS
Rationale. Hypothesis and Overall Experimental Approaches
mRNAs

containing

nonsense

codons

(nonsense

mRNA)

encode

truncated polypeptides that can interfere with the function of their corresponding
full-length polypeptides. However, levels of most nonsense mRNAs are reduced
in prokaryotes and eukaryotes when compared to that of the corresponding wildtype mRNAs (reviewed in Brawerman and Belasco, 1993). Genes that encode
proteins responsible for the selective reduction of nonsense mRNA have been
identified only in lower eukaryotes (reviewed in Maquat, 1995). One example is
UPF1, a group I RNA helicase that is required to rapidly degrade cytoplasmic

nonsense mRNA (Leeds et al., 1991, 1992; He et al., 1993). Since the half-lives
of cytoplasmic nonsense p-globin mRNA (Cheng and Maquat, 1993; Belgrader
et al.,

1994) and immunoglobulin µ mRNA (Li and Jack, unpublished

observations) are decreased when compared to the corresponding wild-type
mRNA, I hypothesized that mammalian cells contain a UPF1-like system that
reduces levels of nonsense mRNA.

130

To clone, or identify, a mammalian
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gene required to reduce levels of nonsense mRNA, I chose the following
approaches, all of which make use of the yeast UPF1 gene.
•

First approach

Hybridize mammalian genomic and cDNA libraries with a yeast UPF1
DNA probe.
•

Second approach

Transfect a upf1 yeast strain with a mammalian cDNA expression library
and rescue yeast transformants with a UPF1-positive phenotype.
•

Third approach

Determine whether the expression of a dominant-negative form of yeast
Upf1 p in a mammalian cell correlates with increased levels of nonsense
mRNA.
•

Fourth approach

Search translated mammalian DNA and protein databases with the yeast
UPF1 amino acid sequence and determine whether identified genes are

structural and functional homologues of yeast UPF1.

Because only the fourth approach led to the isolation of a mammalian
UPF1 homologue, I will describe and discuss this approach in detail. However,

in the next three sections I will briefly review the results of the first three
approaches.

I will only discuss at length the data from the first approach,

because it resulted in the isolation of a rabbit TRAPa cDNA that encodes a
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protein thought to be involved in the translocation of nascent polypeptide chains
across the ER membrane.

Hybridize Mammalian Genomic and cDNA Libraries With a Yeast UPF1 DNA
Probe.
The strategy to clone a mammalian homologue of the S. cerevesiae UPF1
gene by hybridization was carried out using a number of straightforward
molecular biological techniques and approaches.

First, the yeast UPF1 gene

was used as a DNA probe to screen mammalian genomic DNA and cDNA
libraries. To detect genes that have partial homology to UPF1, the hybridization
was carried out under low stringency. Second, to determine whether the isolated
genes are structurally homologous to the S. cerevisiae UPF1 gene the nucleic
acid sequence of the clone was determined. This approach, however, did not
result in the isolation of a DNA clone with homology to UPF1. Instead, I cloned a
cDNA encoding rabbit TRAPa,

a protein that may be involved in the

translocation of cytoplasmic proteins into the lumen of the endoplasmic reticulum
(ER).

Isolation of a Rabbit Genomic Clone that Cross Hybridizes
With the Yeast UPF1 DNA Probe
To isolate a mammalian UPF1 homologue, I screened a human
complementary DNA (cDNA) phage library (Elledge et al., 1991) and a genorr.ic
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rabbit DNA phage library.

The human library was chosen because a yeast

expression plasmid containing the human cDNA insert can be easily excised
from the phage and tested for its ability to complement a upf1 allele yeast strain.
The rabbit genomic DNA phage library (in EMBL4) was chosen for the following
reasons. First, each gene should be represented in the library at least once, and
second, filters containing about 3 X 1as lifted plaques were made available to me
by Dr. Knight. The UPF1 probe used to screen the libraries was a 1.3 kb-Oral
fragment (Figure 1a.A).

This DNA fragment contains the entire UPF1 RNA

helicase region. Mutations in this region can lead to dominant-negative forms of
UPF1 that, when transformed into wild-type UPF1 strains, abolish the function of
the wild-type UPF1, that is, nonsense mRNA has the same turnover rate as the
corresponding functional mRNA.

Therefore, a mammalian UPF1 homologue

may have conserved this important functional region, and thus, may contain
enough nucleotide homologies that the human or rabbit homologue could be
detected by using the UPF1 helicase probe. The flow-chart in Figure 11 shows
the individual steps of the hybridization approach and summarizes the major
results. When I screened filters that contained 2.5 X 1as individual phage from
the human Hela cell cDNA phage library or the rabbit genomic phage library, I
identified 2 genomic rabbit phage clones (Figure 1a.B and Figure 11, box 2) and
no Hela cDNA clones that hybridized with the UPF1 RNA helicase probe. To
find the region of nucleotide homology within the two rabbit genomic phage
clones and the UPF1 RNA helicase probe, I proceeded to isolate total
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Figure 10. Schematic representation of the regions of the UPF1 gene used as probes in library and
Southern blot analysis. (A) The bar represents the UPF1 ORF. The regions used as probes are shown
below the UPF1 ORF. (B) Autoradiograph of rabbit genomic phage clones R1, and R5 after 1 round of
plaque purification. Phage clones were hybridized with UPF1 RNA helicase probe using low stringency
hybridization conditions as described in materials and methods.
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1
Screen the human cDNA and rabbit
genomic phage librarys with the UPF1
RNA helicase probe

2
Identified 2 overlapping rabbit genomic phage
clones that hybridize to the Yeast
UPF1 RNA helicase probe

3

4

Identified a 6.4-kb
fragment from both
phage clones

The 6.4-kb fragment does
not hybridize with the Yeast
UPF1 gene fragment
(5' end)

8
Identify in the 6.4-kb
that hybridize with
fragment a 2.0-kb Hindlll
the Yeast UPF1
fragment fragment that hybridizes with
RNA
1------~
the yeast UPF1 RNA
helicase probe
helciase probe

f

9
Subclone the 2.0-kb fragment
and identify a 560-nt fragment.
Subclone and sequence the
560-nt fragment.

5

Probe a human and rabbit cDNA
library with the 6.4-kb rabbit DNA
fragment

6

7

No
human
clones
identified

3000
rabbit
clones
identified

11
•A region of 61 nucleotides
shows a 72% identity
to part of the RNA helciase
region of UPF1
•25 nucleotides of a continous
26 nuclotide stretch within
the 61-nt region are found
in UPF1

10
Screen a rabbit cDNA
library with the 560-nt
fragment.
No clones identified

Continued on Next Page

Figure 11. Flow chart representing steps taken during the isolation of a
rabbit genomic clone that cross hybridizes with the yeast UPF1 DNA
probe and isolation of a rabbit cDNA.

12
Use 26-nt oligos in northern
blot analysis

13

14

Hybridization with sense oligo
does not detect yeast UFP1
or any rabbit RNA species from
total RNA

Hybridization with antisense
oligo detects yeast UPF1 and a
rabbit RNA species from total
RNAs

15
Screen Human and Rabbit cDNA
libraries with the 26-nt antisense
oligo

16

17

No positives
from the
Human cDNA
library

Identify 2 positives
clones from the
rabbit cDNA library

18
Mapping of the 2 positive
clones indicates that they are
identical. Sequence analysis of a
cDNA insert revealed that it encodes
the rabbit homologue of the
canine TRAPa gene.
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phage DNA and map the regions of the 2 clones. The results demonstrated that
although the two rabbit genomic clones are slightly different, they contain DNA
restriction sites at similar sites throughout their insert regions.
these two genomic phage clones are overlapping.

I conclude that

I also carried out low

stringency Southern blot analysis on the same restriction enzyme mapped DNA.
I was able to detect a 6.4-kb EcoRI fragment in both clones which hybridized
with the UPF1 RNA helicase probe under low stringency conditions (Figure 11,
box 3).

I conclude that the 6.4-kb EcoRI fragment contains a region of

nucleotide homology between the UPF1 probe and the fragment of rabbit
genomic DNA.

To determine if the rabbit genomic fragment also contains

nucleotide homology to the 5'-end of the yeast UPF1 gene I used the 5' end of
the UPF1 gene as a probe on the same Southern blot using low stringency
conditions.

From this Southern I conclude that the insert region of the rabbit

genomic phage clone does not specifically hybridize to the 5' end of the UPF1
gene (Figure 11, box 4).
I used the 6.4-kb EcoRI fragment as a probe to isolate a cDNA fragment
from a human or rabbit cDNA library (Figure 11, box 5). Unfortunately, I was not
able to identify any human cDNA clones (Figure 11, box 6).

However, by

screening the rabbit cDNA library I was able to identify approximately 3000
hybridizing phage plaques (Figure 11, box 7). It is possible that the hybridization
of most phage clones is due to regions within the 6.4-kb probe that have no
homology to the yeast UPF1 RNA helicase probe. To generate a smaller probe
that hybridizes to the UPF1 RNA helicase probe, I subcloned the 6.4-kb EcoRI
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fragment into a plasmid vector, digested the vector with restriction enzymes and
determined by Southern blot analyses which of the rabbit fragments hybridized
to the UPF1 RNA helicase probe (Figure 11, box 8) (data not shown). A 2.0-kb
Hindlll DNA fragment was identified, isolated and subcloned into a plasmid

vector.

Southern blot analysis of restriction digestion of the 2.0-kb Hindlll

fragment identified a 0.56-kb EcoRl!Pstl fragment that still hybridized with the
UPF1 RNA helicase probe (Figure 11, box 9). The EcoRI site comes from the

vector and the Pstl site is located within the 2.0-kb Hindlll fragment about 500-bp
downstream of the vector SP6 site. I, therefore, predicted that if I sequence the
plasmid that contains the 2.0-kb Hindlll fragment with a SP6 primer, I would be
able to find the region of nucleotide identity between the UPF1 RNA helicase
probe and the rabbit genomic DNA fragment.

832 nucleotides of the 2.0-kb

insert were sequenced and confirmed the presence of a Pstl site 560-nt
downstream of the SP6 site of the vector.

When I searched the GenBank

nucleic acid sequence database with the 832-nt rabbit sequence using the
FASTA program (GCG Program Manual, 1994), I found that 72% of a 61-bp
region (underlined position 399-460, Figure 12) of the 832-nt sequence are
identical to the corresponding region in UPF1
region

of identity,

there is a 26-nt region

(Figure 13).
of 96%

Within the 61-nt
identity to

UPF1

(position 399-424 of the rabbit genomic fragment, position 2051-2077 of
UPF1, Figure 14) (Figure 11, box 11 ). Additional analysis of the rabbit sequenr.e

revealed

the

presence

of

a

putative

splice

donor

and

splice
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20h35ssr.Txt

Length:

~

February 3, 1995

HindIII
AAGCTTATCGATTTCGAACCCGGGGTACCGAATTCTCCTATCCCATGCAT
GTGACTTCTAATATAATTATCAAATGTAGGACAGTGATACTGGACTTCAG
GTGTTACTTAAATCCCATCAGTTTTCCCACTTGTATTCTTTTTCAGACCC
AAGATCCTACACTGCGTTTGTCATTTCTCCCTGGTTTCCTGTAATCTGTG
AGAGTTCCTAGGCCTCCCAGTCACTCCCCGTCTTTTATGATCTTAGTACT
TTGACAGAATATTGGGCATTTTTTTTGGACCATGTCCTCAGGTTCTATTA
TGTCTTTTTATTTTTTTTGTGATTGAAGAGAATTTTTGCATTTGTGGCGA
GAAACAAATGATACAGTGTCCTTGGTGCAGGGTGTAAAGGGTTCTGTGA,T
GTTGACATGTGTTGGTGCTGGTGACGTTAAQT.TTGAT.cACTTGGT'.rG~

TG1'.12AGQTTTGGACTCTAAAGCTGCTGCCCCTCCCTTTGCAGTTGGTAGA
TATCTTGGGGGCATGTTTTCAGTGCAAATATGACTCCTCTCACATGTTCA
TGTACTGATTTCAGCNTCGCTCGGTGGGGCTTGTCTGCAGCACTGAGGAG
TTCCCTTTCCCTTCATTACCCTTGTTGAGTGGAGTCTTCTCAAGGAGGAG
CTGTCCTTNNCCCGCATTTNTTTGCTTCTTAGCTCATCTCTGACTATGGA
TATGGATTCAAGGGTACTTGCATNTTTCTNTNNGTCCACACCTACTACTT
TCATGGTTTATTTNCTCAGATTGTGCAATTGTTGATCACGAGGAGCTCCT
TCAGTTTGCCTCCTGTTTTCTTTCTAAAAGCC

Figure 12. Partial nucleotide sequence of the 2.0-kb Hindi II fragment
of the genomic rabbit clone R5. The Pstl restriction site is indicated
in bold and the Hindlll cloning site is underlined. The region with
nucleotide identity to the UPF1 probe is underlined. The identity was
determined with a FASTA analysis using the 832-nt sequence.
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Yscupfl. Gb_Pl
phage clone #5
SCORES

Initl: 80 Initn: 80 Opt: 107
72.1% identity in 61 bp overlap

~
TCVGAGDK
Yscupf AGCAGAAATTCTCAATAAGGCAGATGTCGT TGTTGCACATGTGTTGGTGCTGGTGATAA
RGF

TCCTTGGTGCAGGGTGTAAAGGGTTCTGT
polyT--NCAGG

i

11111 111111111TIT11111111

TGTTG-ACATGTGTTGGTGCTGGTGACGT
T C V G A G D V

~

R L
. . . . . TTGATGAAAGTACTCAAGCTTCTGAGC
Yscupf GCGCTTAGA-CACTAAATTTAGGACTGTGTT
11 I

RGF

I I

I 111

11

111

I I

I

I

TAACTTTGATCACTTGGTTGAGGTGTGAGGT TGGACTCTAAAGCTGCTGCCCCTCCCTT
N F
CAGGTGAG

Figure 13. Original printout of the result of a FASTA analysis using 832
nucleotides of the 2.0-kb Hindi II fragment of rabbit clone RS. Yscupf is part
of the S. cerevesiae UPF1 DNA sequence and RGF (rabbit genomic
fragment) is part of the sequence of DNA shown in Figure 12. Underlined are
the putative splice donor and acceptor sites found within the rabbit genomic
fragment flanking the region of identity. The splice consensus sequences are
shown below the underlined region (reviewed in Genes IV, Lewin, 1994).
The putative amino acid sequence encoded by the rabbit genomic DNA and
UPF1 is shown above and below the respective nucleotide sequences. The
aa changed in the D1 dominant- negative form of UPF1 is in bold and
underlined. The region with 72% identity is shown betwee~ the arrows.
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20h3prim.For
Gb_Pl:Yscupfl
3546 bp ds-DNA
YSCUPFl
PLN
12-MAY-1992
LOCUS
DEFINITION Saccharomyces cerevisiae zinc finger protein (UPFl) gene,
complete eds.
ACCESSION
KEYWORDS
SOURCE

M76659
UPFl gene; zinc-finger protein.
Saccharomyces cerevisiae (strain GRF88)

SCORES

Initl: 80 Initn: 80 Opt: 92
96.3% identity in 27 bp overlap

20h3pr

(library: Ycp50) DNA.

10
20
ATGTTG-ACATGTGTTGGTGCTGGTGA
111111

11111111111111111111

Yscupf AGCAGAAATTCTCAATAAGGCAGATGTCGTATGTTGCACATGTGTTGGTGCTGGTGATAA
2030
2040
2050
2060
2070
2080

Yscupf GCGCTTAGACACTAAATTTAGGACTGTGTTAATTGATGAAAGTACTCAAGCTTCTGAGCC
2090
2100
2110
2120
2130
2140

Figure 14. Origional printout of the result of a FASTA analysis using the
26-nt sequence (nt position 399-424 in Figure 12). Yscupf is the
S. cerevesiae UPF1 DNA sequence and 20h3pr is the sequence of the
26 bp oligonucleotide used to perform the analysis.
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acceptor site (Lewin, Genes IV, 1995). Between the putative splice sites, one of
the possible ribosomal reading frames could translate a putative protein
encoding amino acids identical to those of UPF1 (Figure 13). I conclude from
these results that the cloned region of rabbit genomic DNA could contain an
exon of a gene that is the rabbit homologue of the yeast UPF1 gene, or a least a
rabbit RNA helicase. Translation of an mRNA encoded by this region could lead
to the production of a protein that has Upf1 p like functions or RNA helicase
activity.

Isolation of a Rabbit cDNA
To avoid extensive sequencing and exon/intron mapping of my genomic
clone, I attempted to isolate a cDNA clone by screening appropriate libraries with
a 26-nt oligomer that is identical to the 26-nt region (Figure 14). A 26-nt oligomer
complimentary to the putative coding region of the rabbit genomic fragment was
synthesized (26-nt antisense oligo) and used as a probe to determine if a RNA
species can be detected in total spleenic RNA. When I performed northern blot
analysis of total rabbit RNA from various tissues using the 26-nt antisense oligo
as a probe, I detected a 1.3-kb band in total spleen RNA and a 3.6-kb band in
yeast RNA with the 26-nt antisense oligo (Figure 11, box 14). The 3.5-kb band is
very likely UPF1 mRNA because a UPF1 probe detects a band of the same size
(data not shown). I screened 2.5 X 105 phage from a rabbit spleen cDNA library
(a gift from Dr. Chander Raman) and from a human Hela cDNA library with the
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26-nt antisense oligo (Figure 11, box 15). I identified two rabbit cDNA clones
that hybridized with the 26-nt antisense oligo (Figure 11, box 17) but no phage
clones were identified from the human cDNA library (Figure 11, box 16). cDNA
inserts from the two rabbit phage clones were rescued from the page particles by
using PCR and a primer set p.gt1 O.fow0.gt1 O.bac) that flanks the cDNA insert.
Agarose gel electrophoresis of the PCR product from each phage clone revealed
a product of 1.2-kb (data not shown). I predicted that if the 1.2-kb PCR product
actually contains regions of nucleotide identity with the UPF1 gene it should be
able to hybridize with a UPF1 RNA helicase probe. The PCR products were,
therefore, subjected to Southern blot analysis under low stringency conditions
using the UPF1 RNA helicase region probe. The results demonstrated that all
PCR products as well as the original rabbit genomic phage clone are able to
hybridize with the UPF1 RNA helicase probe while a DNA fragment amplified by
PCR from a rabbit GAPDH cDNA or A--phage clones did not hybridize (data not
shown). To determine whether the clones were identical, A- DNA was digested
with various restriction enzymes. The results revealed the presence of identical
restriction enzyme sites within both 1.2-kb inserts (Figure 11, box 18; data not
shown). DNA sequencing of both clones was performed and revealed that their
sequences are identical. The nt sequence of the 861 bp ORF of the two rabbit
cDNA inserts differ by only one nucleotide (a wobble base leading to no aa
change) and encodes for 286 aa (34.5-kDa). However, a poly(A)-addition signal
sequence could not be located and comparison of the TRAPa sequence with the
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putative RNA helicase region of UPF1 revealed that TRAPa does not contain a
helicase domain. FASTA and TFASTA analysis (GCG Program Manual, 1994)
showed that the rabbit sequence has a high degree of nucleotide and amino acid
identity to that of the canine translocon-associated protein alpha (TRAPa) gene
(GenBank accession #X51367; Figure 11, box 18) (Figure 15) a gene product
found to be associated with the translocon and associated proteins (Figure 16)
(Hartmann et al., 1993).
The ORF has 89% and 94% identities to the canine TRAPa gene at the nt
and aa level, respectively (Figure 15). The deduced aa sequences of both rabbit
and canine TRAPa share conserved hydrophobic as well as acidic aa regions
(Figure 15). Therefore, I conclude that I have isolated a full-length cDNA clone
encoding rabbit TRAPa. Finally, part of the 26-nt antisense oligo sequence

us~d

to screen the rabbit cDNA library was located within the rabbit sequence
(underlined and bolded in Figure 15), however, the sequence was translated in a
reading frame that was different from that of yeast UPF1 (compare aa sequence
250-255 in Figure 13 with aa sequence 551-555 in Figure 15). These results
indicate that I have isolated a rabbit cDNA with a very high degree of nucleotide
and amino acid identity to that of the canine TRAPa gene. Therefore, I conclude
that I have cloned the rabbit homologue of the canine TRAPa gene whose gene
product might be important for translocating nascent polypeptide chains from the
cytoplasm across the ER membrane.
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Figure 15. Comparison of nt and deduced aa sequences of rabbit and canine
TRAPa. The nt sequence of rabbit TRAPa (rTRAPa) was determined as described
(Sanger et al., 1977) from two cloned cDNA inserts. The nt sequence of canine
TRAPa (cTRAPa) was retrieved from the GenBank database (accession no.
X51367). In the alignments, a period indicates nt identity and a star a break in the
nt sequence. The aa sequence predicted from the nt sequence of rTRAPa is
shown above the codons in the single letter IUPC format, whereas only canine aa
residues that are different from that of the rabbit aa sequence are shown below the
canine nt sequence. The putative hydrophobic leader and transmembrane regions
are underlined and the translational start and termination codons are double
underlined. Acidic(-) and basic(+) aa residues are indicated and stretches of
acidic aa residues, which are shared by rabbit and canine TRAPa.
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Characterization of the Rabbit TRAP a cDNA
I carried out experiments in various mammalian cells to analyze the
expression of TRAPa on the mRNA level in various mammalian cells (see Table
4). I analyzed total RNA from a rabbit (B cell hybridoma, 96-1), mouse (B cell
lymphoma, NYC) and the human (T cell line, Jurkat) by northern blot analysis
using high stringency conditions and the complete rabbit TRAPa cDNA clone as
a probe. Figure 17.A shows the results from this experiment. In rabbit lanes I
detected bands of 1.3, 2.8 and 3.7 kb (lane 2), in mouse 1.3, and 2.8 kb (lane 6),
and in human lanes bands of 1.3, 3.7, and 2.7 kb in size (lane 4). From these
results, I assume that the 1.3-kb band most probably represents TRAPa mRNA
because its size corresponds very well with that of my rabbit TRAPa cDNA
clone.

Because I detect in the rabbit, human, and mouse cells very slmilgr

bands with the rabbit TRAPa probe, this gene is very likely conserved during
evolution. This is further supported by the fact that TRAPa of other species such
as human and trout (Hartmann and Prehn, 1994) are very similar to the canine
and rabbit TRAPa.
To determine if the mRNA species larger than 1.3-kb are TRAPa mRNA
precursors, I carried out northern blot analysis on the same cell lines using RNA
isolated from the cytoplasm where only completely spliced TRAPa mRNAs
should be present. Figure 17 .A shows the results from this experiment. After
probing the blot with the complete rabbit TRAPa gene, I was able to detect the
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same bands in both total and cytoplasmic RNA from rabbit, mouse and human
tissues (Figure 17 .A, lanes 1, 5, and 3 respectively).

The purity of the

cytoplasmic RNA was confirmed by absence of rRNA precursors (35S) in the
EtBr stained gel (Figure 17.B). I conclude from these results that it is unlikely
that the bands larger than 1.3-kb are TRAPa pre-mRNAs. Instead, they could
represent alternatively spliced forms of TRAPa mRNAs or transcripts encoded
by genes that are different from TRAPa but contain stretches of nucleotide
identity to the TRAPa cDNA probe.

TRAPa mRNA Expression In B Lymphoid Lines Representing a B and Plasma
Cell
Although TRAPa is not required in vitro for translocating nascent peptides
across the ER membrane (Migliaccio et al., 1992), its close proximity to the
translocon suggests a role in this process (Mathes et al., 1994). If TRAPa is
involved in the translocation process of nascent polypeptide chains into the ER
lumen, I would predict that TRAPa is expressed at higher levels in a cell with an
extensive network of ER, which is characteristic for secretory cells. To test the
idea, I analyzed TRAPa mRNA levels in antibody-producing cell lines that differ
in their amount of ER and immunoglobulin secretion rate.

I found that the

antibody-secreting hybridoma cell NYCH, which represents a secretory plasma
cell with an abundant network of ER (Jack et al., 1992), expressed 2-3 X times
more TRAPa mRNA (1.3-kb) than the B lymphoma line NYC, which represents
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a mature B cell with a less developed ER network (Jack et al., 1992) (Figure 18).
Although it remains to be shown that TRAPa is required for polypeptide
translocation across the ER membrane in vivo, our findings support the idea that
it may play an important role in protein translocation.

Whether the 2.8-kb

species of RNA in mouse (2.8- and 3.7-kb in rabbit) play a role in producing
TRAPa protein that aids in protein translocation is unknown.

Conclusion
The work above describes my attempt to clone the mammalian
homologue of the S. cerevesiae UPF1 gene using low-stringency hybridization.
When an expressed gene (cDNA) was finally isolated, I found that the rabbit
cloned encoded a homologue of the canine TRAPa (Figure 15). The exact
function of the canine TRAPa gene is not known. It is known to be a protein
found to span the membrane of the endoplasmic reticulum (ER) (Wiedmann et
al., 1987). Though its function is not known, it is possible (as deduced from its
location) that it is involved with the process of protein translocation across the
ER membrane (Prehn et al., 1990).
proteins called TRAP

~' y

It is in close proximity with three other

and 8 and are thought to be part of the translocon

(Hartmann et al., 1993), a group of proteins found at the site of protein
translocation.

So far there is evidence for and against the participation of

TRAPa in the translocation of proteins with leader sequences across the
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membrane of the ER. Cross linking experiments have identified TRAPa as a
protein residing in the vicinity of the signal sequence of a polypeptide chain
during the TRAPa-dependent targeting event (Wiedmann et al.,

1987).

Additionally, lgG or Fab fragments directed against the cytoplasmically exposed
carboxy terminus of TRAPa block translocation of a secretory protein (Hartmann
et al., 1989). Conversely, by using microsomal membranes made from TRAPa
depleted detergent extracts of canine pancreas show that the depletion of
TRAPa had no effect on the translocation of a secretory precursor (Migliaccio et
al., 1992). However, so far no molecular analysis of TRAPa at the mRNA level
have been investigated.

If TRAPa is involved in the translocation process of

nascent polypeptide chains, one prediction would be that TRAPa is expressed at
higher levels in a cell with a secretory phenotype (an extensive network of ER).
To test this hypothesis I analyzed TRAPa mRNA levels in antibody-producing
cell lines that differ in the amount of their ER and potential to secrete antibodies
(Jack et al., 1989). I found that the antibody secreting B cell hybridoma, (NYCH)
which represents a secretory plasma cell with extensive ER produces 5 times
more 1.3-kb TRAPa mRNA than its parent B cell line (NYC) (Figure 18).
Although it remains to be shown that TRAPa is directly required for
polypeptide translocation across the ER membrane in vivo, my findings support
the idea that it may be important in protein translocation. The above conclusion
is, however, based on mRNA expression analysis. First of all, the increase in
1.3-kb mRNA levels have not been confirmed on the protein level using an
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antibody against the TRAPa protein.

Second, although there was a 5 fold

increase in 1.3-kb mRNA level, there was no difference in 2.8-kb mRNA level. It
appears that this mRNA is not under the same type of control as that of the 1.3kb species.

This could be due to differential transcription rate or to different

mRNA stability between the two cell types. Finally, it is not clear whether TRAPa
protein is indeed transcribed from the 1.3-kb transcript.

The 1.3-kb transcript

could also be encoded by a cross-hybridizing gene. In this case, TRAPa would
be encoded for by the 2.8-kb or 3.4-kb transcript.
As mentioned above there is evidence for and against TRAPa's role in the
translocation of nascent polypeptide chains into the lumen of the ER.

The

evidence described here indicates that when a cell secretes more proteins
(immunoglobulin in this case) it makes more 1.3-kb TRAPa mRNA. Based on
the assumption that the 1.3-kb TRAPa mRNA encodes the TRAPa protein, it is
tempting to speculate that as a cell increases the size of its ER (and thus its
secretion potential), it increases TRAPa production to facilitate the translocation
process of secreted proteins. As mentioned above, TRAPa may not be essential
for protein translocation.

However, it could, together with essential proteins,

serve as a translocation enhancer.
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Transfect an upf1 Null Yeast Strain With a Mammalian cDNA Expression Library
and Rescue Yeast Transformants With a UPF1-Positive Phenotype.
Mammalian homologues of the yeast S. cerevisiae genes can be isolated
by complementation of a mutant yeast strain with a candidate mammalian gene
or a mammalian expression library. This process has a number of steps. First,
the identification or generation of a strain that doesnt express the gene of
interest (mutant allele) and changes its phenotype, for which one can select,
depending on the presence or absence of the gene of interest.

Second, the

mutant yeast is then transformed with a cDNA library generated from the
organism from which the homologue will be cloned. Third, yeast transformants
are selected, or screened, for a positive phenotype. Fourth, the introduced gene
is isolated from the yeast and analyzed for structural (sequence) and functional
homology (antisense expression in mammalian cells).

This approach is only

successful if the mammalian gene product replaces the function of the absent
yeast protein.
The first goal was to generate a UPF1 mutant yeast strain (upf1) that
changes its phenotype depending on the presence or absence of Upf1p, e.g.
doesn't grow in the absence of an essential nutrient.

For example, when the

HIS4 gene contains a nonsense codon the mRNA is usually degraded and the
yeast is unable to grow in the absence of histidine (Leeds et al., 1992), however,
when the UPF1 gene is absent from this yeast cell the mRNA becomes stable
leading to an increase in his4 mRNA levels and, due to a subsequent ribosomal
read-through of the nonsense codon, an increase in the level of His4p. Although
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this selection scheme is useful to isolate upf1 mutant yeast strains, it might be
difficult to use it for isolating a mammalian homologue.

This is because the

complementation of a upf1 mutant would render a His+ cell His-, which would
require the replica-plating of thousands of transformants on His- and His+ plates.
The selection system I have devised uses negative selection marker in S.
cerevisiae, the CAN1 gene product. The CAN1 gene encodes arginine permase,

a outer transmembrane protein that transports the amino acid arginine.

The

CAN1 gene product can also import the toxic arginine analogue canavanine.

Canavanine is able to act as a chain terminator during protein translation and
leads to the death of the yeast cell. As expected, cells that have a functional
CAN1 gene are sensitive to medium containing canavanine and cannot grow

whereas can1 yeast (CanR) are able to grow in canavanine (reviewed by
Rosenthal, 1977). My selection system employs the CAN1 gene to select for
upf1 mutant yeast cells that have been complemented with a mammalian UPF1

homologue. I proposed to generate a yeast strain containing a can1 gene with a
nonsense codon (canavanine resistance) and a defective UPF1 gene. If the loss
of UPF1 leads to an increase in nonsense can1 mRNA and if there is enough
translation read-through, more Can1 p should be synthesized, leading to a
canavanine sensitive phenotype. Or in other words, the yeast cells should not
grow in the presence of canavanine (Figure 19). The complementation of this
sensitive strain with a mammalian UPF1 homologue would then lead to the
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Inactivate UPF1 in yeast containing
a can 1 gene with a nonsense
codon (nonsense can1 mRNA)

Test whether yeast is
If S o / sensitive to canavanine

~Not

,

Stop Approach
'-.... Transform Cans, upf1 yeast with
mammalian cDNA yeast expression
library and plate transfectants on
plates supplemented with canavanine

Transformants that complement t h e /
upf1 defect will degrade the can1
nonsense mRNA and survive

/

Rescue the complementing
cDNA for further analysis
Figure 19. Schematic diagram of the complementation approach to
isolate a mammalian UPF1 homologue by complementation of a UPF1yeast strain. Can1R, grows in canavanine, Can 5 , doesn't grow in
canavanine, UPF1-, UPF1 is deleted.
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degradation of the nonsense can1 mRNA and thus, to decreased Can1p levels.
Consequently, yeast cells that have been complemented with a functional UPF1
homologue, should grow in the presence of canavanine (Figure 19). In this way
only yeast receiving a mammalian homologue of the UPF1 gene would grow and
these cells could easily be isolated for study. Because I was unable to generate
a suitable upf1, can1 nonsense, yeast strain, I will only briefly discuss this
approach in the following sections.

Creation of a Selectable Yeast Strain That Changes Its CAN1 Phenotype
Depending on the Presence of Upf1 p
To carry out this approach I obtained yeast strains that contain can1
genes with different nonsense codons (Ono et al., 1983) and a UPF1 mutant
strain (Table 6) (Leeds et al., 1991). These strains were tested and have the
correct phenotypes (data not shown). One important part of the UPF1 positive
selection system is that the levels of can1 nonsense mRNAs are decreased in
the presence of the Upf1 p.

Because at the beginning of these experiments I

didn't have an antibody against the Upf1 p, I performed northern blot analysis and
found that nonsense can1 mRNA levels in the three strains Ono 279, 280, and
284, were approximately 50% lower when compared to the steady state level of
functional CAN1 mRNA in the parent strain Ono26 (data not shown).
these results I conclude that the presence of an UPF1 mRNA correlates

From
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Table 6. Yeast Strains
Strain

Genotype

Source

Ono 26

MA Ta leu2-1, 112 metB-1

B.I. Ono

Ono 280

MATa leu2-1, 112 can1-204 metB-1

B.I. Ono

Ono 284

MATa leu2-1, 112 can1-202 metB-1

B.I. Ono

PLY154ura3::his4

MATa upf1-D1 ura3-52 trp1-D1 rpb1-1 his4-38
leu2-1 ura3::HIS4

This work

PLY154

MATa upf1-tl 1 ura3-52trp1-tl1 rpb1-1 his4-38
leu2-1

M. Culbertson

Y06-15C

MATa ade2-1 arol-1 can1-100 leu2-2 ilv1-2
his4-166 lys2-101 metB-1

SL988-11A

MATa leu2-1 Jys2-1his3-tl1 ura3-52 trp1

B.I. Ono

S. Liebman

with a decrease in the steady state level of can1 mRNA containing a nonsense
codon when compared to the parent strain. This result raises the possibility that
upon elimination of the UPF1 gene in the can1 nonsense codon yeast strains,
the level of can1 nonsense mRNA will increase and that this increase combined
with possible ribosomal read-through of the nonser.ise codon will lead to the
production of enough Can1 p to change the phenotype of the UPF1 mutant strain
from canavanine resistant to canavanine sensitive.
The following briefly describes the steps involved in the generation of a
suitable yeast strain that can be used to select for the presence of a mammalian
UPF1 homologue (Figure 20). First, I inactivated the URA3 gene by insertion of
a selectable marker. This will allow selection of transformants containing URA3
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Ono strains containing a can 1 gene
with a nonsense codon

upf1- Strain

I
'

KO
URA3

Make Diploids
and Sporulate

DJ

A+a

/

Select for presence of His+ (50% are UPF1-)

~
Screen Ura3- yeast by replica plating to Ura- plates

Select for Upf1- yeast colonies
by plating on leu- plates

/I\
Confirm absence of Upf1 gene by
northern blot analysis

~

Study Further

f

Test upf1 (Upf1-), ura3 (Ura3-) yeast for canavanine sensitive. If yeast are only
canavanine sensitive, it indicates that the absence of UPF1 may be de-suppressing
the can1 nonsense mRNA leading to the production of CAN1 protein and thus,
canavanine sensitivity. Confirm this effect by UPF1 transformation and
complementation. If both canavanine sensitive and canavanine resistant yeast exist
it indicates that the absence of upf1 cannot de-suppress the can1 nonsense mRNA
and the yeast cannot be used to identify a UPF1 mammalian homologue by
complementation.

Figure 20. Flow chart to generate a suitable yeast strain to isolate a
mammalian UPF1 homolgue by complementation.
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plasmids (data not shown).

To generate a upf1, ura3, nonsense can1 strain

which will finally be used as the recipient for the mammalian cDNA library, I used
a mating and sporulation approach.

To do this the appropriate yeast strains

(PLY154 ura3::HIS4, with Ono 26, 280, 284) were mated, sporulated, and
selected for the presence or absence of appropriate markers according to the
protocol described in materials and methods. To select for the presence of the
upf1 gene disrupted by an insertion of the HIS4 gene, the haploid segregates
were screened for the ability to grow in His- media. Because the can1 nonsense
codon strains (Ono 26, 280, 284) all contain a wild-type HIS4 gene, I expected
that only 50% of the His+ yeast would contain a disrupted UPF1 gene.

To

identify the yeast with a disrupted UPF1 gene I replica-plated the His+ yeast
colonies on plates without leucine.

Because the haploid segregates contain

either a UPF1-suppressable (leu2-1) or UPF1-non-suppressable (leu2-1, 112)
allele of the leu2 gene, only cells that do not have UPF1 and contain the
suppressible allele of leu2 can grow in the absence of leucine. The Leu+ yeast
colonies were then replica plated onto Ura- plates to obtain yeast that are
auxotrophic for the library selection marker (URA3). To confirm the absence of a
functional UPF1 gene, RNA from these yeast colonies was subjected to northern
blot analysis using a UPF1 probe (Figure 21). The results demonstrate that the
Ura-, His+, Leu+ yeast colonies do not express UPF1 mRNA when compared to
the parent Ono strains. These yeast colonies will contain either a wild-type or
nonsense

codon

CAN1

allele

(to

be

discussed

below)

(Figure

20).

CV

~·

~

Cb

~·

~

<t>

~·

~

....

"-

~·

~

o.i

l"o

<t>

....

"-

.....: ..._. ..._. ..._.
~ ~ ~ ~

<::::>

<o

CV
()

"<t>
"~· ~· ~·
l"o

~ ~ ~ ~ ~ ~ ~ ~ o~ ~ ~

~

~~~"

l"o

CV

~·

~·

~·

~·

<t> ~cv..:--~<t>
,,,,. ,,,,. ,,,,. ,,,,. CV ~·

~~~~~~~~

()

o~

~ ~

c0' c0'

~~(°()

,,,,.

CV

()~~()

~ ~ ~ ~ o~

<V <V

CV

()

o~ o~

kb

kb

- 9.4

- 9.4

- 7.5

- 7.5

- 4.4

- 4.4

- 2.4
- 2.4

- 1.4

- 1.4

Blot A

Blot B

Figure 21. Northern blot of total yeast RNA using a UPF1 probe. 5 µg of total RNA from HIS+, URA+, LEU+ yeast
colonies was subjected to northern blot analysis using a complete UPF1 probe. Filters were exposed for 2 days at -70°C
using one enhancing screen. Ono 279, 280, 284 contain a nonsense can 1 mRNA and Ono 26 contains a functional
CAN1 gene and serves as a positive control for hybridization. Sizes (in kb) of molecular size markers are indicated on
the right of the blots. EtBr staining (not shown) verified that about the same amount of RNA was loaded in all lanes.
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To test whether the upf1 mutant yeast is able to suppress a can1
nonsense codon allele and change the phenotype of the yeast from canavanine
resistant to canavanine sensitive, I determined the sensitivity of the yeast
colonies to canavanine.

Briefly, yeast were grown overnight in liquid cultures

and counted according to the optical density.

Ten-fold dilutions of cells were

spotted onto plates containing increasing levels of canavanine from 0 µg/ml to
150 µg/ml. All the parent strains used to create the new haploid crosses were
also plated on these plates to control for a wild type CAN1 or a nonsense can1
gene. Each cross of the upf1 null strain with Ono 280 as well as Ono 284, both
of which contain nonsense can1 genes, yielded colonies that are completely
resistant to canavanine, or that are completely sensitive to canavanine (Figure
22). This suggests that all yeast colonies received a CAN1 allele from either the
upf1 parent (PLY154 ura3::H/S4, CAN1), or from the Ono strains (Ono nonsense

strains, can1). Further, I conclude that the absence of Upf1p does not lead to
the suppression of the can1 nonsense codon mRNA in Ono 280 and Ono284.
Thus, none of the crossed yeast strains, although some of them contain a
nonsense can1, and each of them upf1, are suitable for the selection of a
functional UPF1 gene or mammalian homologue.

Conclusion
I have shown here that the presence of a UPF1 gene correlates with the

PLY 167 (UPF1- I Can1 +)
Ono 26 (UPF1+ I Can1+)
Ono 26 (UPF1- I Can1 +)
Ono 280 (UPF1 +I Can1-)
Ono 280 (UPF1- I Can1-)
Ono 284 (UPF1+ I Can1-)
Ono 284 (UPF1- I Can1-)

0

20

40
60
80 100 120 140
Canavanine concentration µg/ml

160

Figure 22. Growth of various yeast strains on canavanine . Bars represent the degree of growth of
various mutant UPF1+1-, CAN1+1-yeast strains on canavanine plates.
......
0)
(;.)
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decreased steady state level of a can1 mRNA containing a nonsense codon.
Unfortunately when the UPF1 gene is absent, the phenotype of the mutant yeast
cells does not change from canavanine resistant to canavanine sensitive.
Because this change does not occur, it is not possible to use these yeast strains
as recipients for a mammalian cDNA library to select for cDNA clones that
complement the upf1 defect.

Two explanations might be that levels of can1

nonsense mRNA do not significantly increase in upf1 cells or that an increase in
Can1p is not enough to confer canavanine sensitivity.
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Determine Whether the Expression of a Dominant-Negative Form of Yeast Upf1 p
In a Mammalian Cell Correlates With Increased Levels of Nonsense mRNA

Overall Approach and Rational
The use of dominant-negative genetic systems has become widespread in
identifying the function of a gene in lower eukaryotic and mammalian organisms.
This technique involves the expression of a truncated or mutant form of a gene
whose product can interfere with the normal function of its corresponding wild
type gene. The mutant gene is thought to interfere by competing for interacting
molecules, thereby inhibiting the ability of the wild type gene product to carry out
its intended function, or by interacting directly with the wild type gene product
and, thereby, eliminating its function.

Alternatively, a truncated or wild-type

polypeptide could gain a function, which interferes with other physiological
processes within a cell.
It is possible that dominant-negative forms of Upf1 p (Upf1-D1 p), which
have been identified in yeast cells, could also act dominant-negative in a higher
eukaryotic cell. If mammalian cells contain a UPF1-Like protein, I expect that the
expression of yeast Upf1-D1 p in a mammalian cell could result in increased
levels of nonsense mRNA (Figure 23). If this is the case, it would be the first
evidence that a UPF-Like system exists in mammalian cells.

UPF1-D1

p~-actin
-A...._

j

5,

r::-caplntron

p:!~~~~r~~-vf . . j
3'

bla
poly(A)

'''·;m 3'

Mouse Hybridoma VXH

-----Stable
Transfectants

Measure UPF1-D1 mRNA,
µ nonsense mRNA,
• and Upf1-D1p levels in
stable transfectants

Figure 23. Strategy to identify a UPF1-like system in a mammalian cell by expression of a dominantnegative form of UPF1. The Schematic representation of the cloning of UPF1-D1 into the expression
vector pHp-APr-1-neo and subsequent transfection into the mouse B cell hybridoma VXH. Structure of the
nonsenseµ mRNA in VXH is shown in the cell. The exons are indicated by boxes (VH variable; C,
constant) and the length of translation products by lines below the mRNA. The position of the nonsense
codon at the end of the VH exon is represented by the X.
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Generation of a Mammalian UPF1-D1 Expression Vector
To determine if a dominant-negative form of the yeast Upf1 p can block the
function of a putative mammalian factor that controls nonsense mRNA levels, I
obtained a dominant-negative UPF1 mutant gene. This gene called UPF1-D1,
contains a missense mutation within the RNA helicase region (Gly556Asp). Wild
type yeast transformed with this mutant UPF1-D1 behave as if they lack the
UPF1 gene, that is, they grow in the absence of leucine, although they still
contain a nonsense leu2-1 mRNA (see page 34 for explanation).

From these

results it was determined that this UPF1 mutant acts in a dominant-negative
fashion on the wild type UPF1 expressed within the same cell (Leeds et al.,
1992). To carry out this approach, I cloned the UPF1 and UPF1-D1 genes into a
mammalian expression vector as described in Figure 24. To confirm that the
UPF1-D1 construct was not altered during the cloning procedure, I confirmed the
01 mutation by DNA sequencing and performed western blot analysis on in vitro
transcribed-translated products generated from an UPF1-D1 plasmid. I was able
to detect the 01 mutation after the swapping of the 01 fragment (Figure 25) and
a radiolabeled band of the same size produced from in vitro transcribedtranslated UPF1 and UPF1-D1 plasmids (Figure 26).
cloning of UPF1 and UPF1-D1 did not alter the ORF.

This indicates that the
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1
Eco47111
Eco47111
3' UTR

BamHI
To remove the 3' UTR, partially digest p73+UPF1 with Eco47111,
isolate the 8.9-kb fragment and completely restriction digest the
fragment with BamHI. Blunt the ends of the fragment and ligate the
product.

2

'

PCR amplify the 5' ORF using a
chimeric 5' end primer that adds a
EcoRI site immediately upstream
of the ATG translation start site.
EcoRI l!!I BsaBI
Digest p73+UPF1/-3'UTR with /
EcoRI and BsaBI and remove
the 5' UTR fragment. Replace
the missing region of ORF with
the new PCR product

3
Isolate the DNA fragment containing
the UPF1-D1 mutation on a BstXl/Nrul
fragment from the plasmid pUPF1-D1
BstXI !!!!!!!I Nrul
Digest p73+UPF1/-5'3' with
BstXI and Nrul and remove
/
a region of the ORF. Replace
the missing region with the
UPF1-D1 mutant fragment

4

•

Remove UPF1 and UPF1-D1 on a
Sall/Xbal fragment and ligate into
pHb-APr-1-neo prepared with
Sall/BamHI using a two step ligation.

Figure 24. Schematic representation of the steps taken to clone UPF1 and
UPF-01 ORF into the mammalian expression vector pH~-APr-1-neo. The
restriction enzyme sites used are listed and a Sall and Xbal sites are
represented by a (S) and (X) respectively.
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UP Fl

ATGTCGTATGTTGCACATGTGTTG~TGCTGGTGATAAGCGCTT

UPFl-Dl

ATGTCGTATGTTGCACATGTGTTGATGCTGGTGATAAGCGCTT

UPFl-Dl
swap sequence

ATGTCGTATGTTGCACATGTGTTGATGCTGGTGATAAGCGCTT

Figure 25. Partial sequences of the wild-type UPF1 and
corresponding sequences in a dominanat-negaitive form of UPF1
(01). The UPF1 and UPF1-D1 sequence are described in Leeds et
al., 1991; UPF1-D1 swap sequence was deduced by sequencing
p73+UPF1-01/-5'3' with the primer UPF1 .bak.
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Figure 26. Western blot analysis of yeast cell lysates and UPF1 IVTL products. (A) Various amounts of
total yeast lysate (as indicated) and (B) 5 or 10 µI of whole UPF1 or UPF1-D1 IVTL product were
separated on a reducing 10% SDS/PAG. The gel was transferred to nitrocellulose and incubated with antiUPF1 rabbit antisera (from Jacobson) at 1:200. The rabbit anti-UPF1 antibodies were detected using a
HRP-labled goat anti-rabbit lgG (1:7000) followed by ECL detection. The total yeast lysate western was
exposed for 5 minutes to film and the UPF1 IVTL western was exposed for 30 minutes.
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Expression of UPF1 and UPF1-D1 in Mouse B cells
Containing a Nonsense mRNA
To test whether either the wild-type UPF1 or the dominant-negative UPF1
interfere with a putative mammalian UPF1 homologue, I individually transfected
the UPF1 or UPF1-01 expression vectors into a mouse B cell hybridoma that
contains a nonsense codon within the second exon of the lg µ heavy chain
mRNA (indicated with an X Figure 23) (VXH, Jack et al., 1989). VXH cells stably
transfected with the UPF1, UPF1-01, as well as an empty vector were screened
by northern blot analysis for their ability to express the UPF1 or UPF1-01 mRNA.
Northern blots revealed the same size band in VXH transfected cells and yeast
cells (Figure 27, lanes 1-7 and 10-15). From this I concluded that my transfected

UPF1 and UPF1-D1 genes can be transcribed into mRNA. The same northern
blot was also subjected to probing with a mouse µ cDNA probe as well as a
GAPDH probe to control for total RNA loading. The levels of hybridization of
these

probes

were

quantitated

using

Betascope

blot

analysis.

After

normalization for RNA loading I found that the level of µ nonsense mRNA was
unchanged in cells transfected with the UPF1-D1 expression vector when
compared to the negative control (VXH with vector alone) (Table 7).

To test

whether the UPF1 and UPF1-01 mRNAs can be translated, I performed weste:-n
blot analysis of the transfected cells. I found that I could also detect a protein of
the same molecular weight in my UPF1-01 expressing cells (Figure 27, lanes 2,
4, and 14; and Figure 28 1-3) using an anti-UPF1 antibody (gift from A.
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Figure 27. Northern blot analysis of VXH cells stably transfected with UPF1-D1
expression vector and vector alone. 1Oµg of total RNA from VXH (lab
nomenclature: GAMO 12.8.10) stably transfected with UPF1-D1 (lanes 2, 3, 4, 5,
6, 7, 11, 12, 13, 14, 15) and vector alone (~-actin) transfectants (lanes 8, and 16)
as well as the VXH parent cell line FH (lab nomenclature: LOCB 83.13.13.1)
(lanes 9, and 17) were subjected to northern blot analysis as described in
materials and methods and first, probed with a mouse µ cDNA, and second, a
UPF1 probe. RNA from yeast Y06-15C in lanes 1, and 10 served as a positive
control for UPF1 hybridization. To control for RNA loading, the blot was finally
hybridized with a rabbit GAPDH cDNA probe (data not shown).
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Table 7. --Quantitation of Northern Blot Analysis in Figure 27a
Hybridomas

RNA
loaded

µ

pre-µ

GAP DH

[CPM]

[CPM]

[CPM]

rel [µ]
[µ/GAP DH]

rel [pre-µ]
[pre-µ/GADPH]

%µ
%VXH

% pre-µ
%VXH

FH Blot A
VXH/p-actin (#4)
VXH/UPF1-D1 (#2)
VXH/UPF1-D1 (#3)
VXH/UPF1-D1 (#7)
VXH/UPF1-D1 (#10)
VXH/UPF1-D1 (#11)
VXH/UPF1-01 (#13)

5 µg
5 µg
5 µg
5 µg
5 µg
5 µg
5 µg
5 µg

455.5
21.2
12.7
21.5
16.3
24.8
23.6
13.5

6.3
3.9
4.3
6.7
4.1
5.1
6.5
5.5

8.2
8.0
9.3
10.4
14.7
10.2
11.2
16.0

55.5
2.7
1.3
2.0
1.1
2.4
2.9
0.8

0.77
0.50
0.46
0.64
0.28
0.50
0.58
0.34

2000%
100%
48%
74%
40%
88%
107%
29%

154%
100%
92%
128%
56%
100%
116%
68%

FH Blot B
VXH/p-actin (#4)
VXH/UPF1-D1 (#15)
VXH/UPF1-D1 (#16)
VHX/UPF1-D1 (#17)
VXH/UPF1-D1 (#19)
VXH/UPF1-D1 (#20)

5 µg
5 µg
5 µg
5 µg
5 µg
5 µg
5 µg

245.5
11.9
10.5
13.4
9.8
22.2
20.7

5.7
2.4
6.6
8.7
4.0
7.7
7.8

7.8
6.4
8.6
10.5
12.8
13.9
10.9

31.5
2.3
1.1
0.9
0.5
0.9
1.4

0.73
0.45
0.77
0.82
0.31
0.55
0.71

1350%
100%
48%
39%
21%
40%
61%

160%
100%
171%
182%
68%
122%
157%

aRadioactivity of respective bands in each Northern blot (CPM) was determined by using a betascope blot analyzer.
Relative steady-state level of respective RNA was calculated by dividing CPM of µ by that of GAPDH in the same lane.
% [µ] is the percent of[µ] relative to that of untransfected hybridoma FH by setting FH (cells containing the same µgene
as VXH cells except that the stop codon TAG reverted to AAG) value equal to 100%.
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Figure 28. Western blot of protein lysates of VXH cells stably
transfected with a UPF1 or UPF1-D1 expression vector. Protein from 8
X 105 cells was separated by reducing SOS/PAGE, transferred, and
probed using an rabbit anti-UPF1 peptide antiserum (1 :200). The
antibody-antigen complex was detected using a HRP labled-goat antilgG antiserum (1:10,000) followed by ECL detection. The bands were
detected by fluorography using a 5 minute exposure. Lanes 1-3, UPF1D1 transfected cells; lane 4, UPF1 transfectants. Lane 5, untransfected
VXH and lane 6, total yeast lysate. Bands detected within the
bracketed region are mouse y2b heavy chains that cross react with the
goat anti-rabbit lgG secondary antibody.
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Jacobson). It is possible that the yeast Upf1 p or Upf1-D1 p folded at 37°C are
unable to act in a dominant-negative fashion. Therefore, I repeated the northern
blot analysis with cells that were grown at 30°C, a temperature at which yeast
cells are normally cultured in the lab.

Northern blot analysis of these

transfectants revealed the same results as obtained with cells grown at 37°C
(data not shown). From these results, I conclude that the amount of Upf1-D1 p,
or wild-type Upf1 p that is synthesized in stable VXH transfectants does not result
in a decrease of nonsense µ mRNA.

Conclusions
If mammalian cells contain a UPF1-Like protein, I expected that the
expression of yeast Upf1-D1p in a mammalian cell could result in increased
levels of nonsense mRNA. If this is the case, it would be the first evidence that a

UPF-Like system exists in mammalian cells.

To test this hypothesis, cells

containing a µ nonsense codon-containing mRNA were transfected with a
construct designed to promote high level expression of Upf1-D1p, a dominantnegative form of Upf1p.

Stable transfectants expressed the UPF1-D1 mRNA

and low levels of Upf1-D1 p.

No change in nonsense µ mRNA was observed.

This result could be due to a number of reasons. First, the level of Upf1-D1 p
produced was not high enough to interfere with the mammalian nonsense mRNA
reduction system.

Second, the levels of Upf1-D1p were sufficient to have a

presumed effect but a UPF-Like system does not exist in mammalian cells.
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Search Mammalian DNA Databases With the Yeast UPF1 Amino Acid Seguence
and Determine Whether Identified Genes are Structural and Functional
Homologues of Yeast UPF1.
To identify human or other mammalian homologues of genes that have
been previously cloned in lower organisms, one could compare the cloned
sequence to mammalian nucleic acid and protein databases. If a human gene
fragment is found, it could then be used to isolate the complete gene from a DNA
library. A complete gene could then be sequenced and tested for its function as
discussed below.

Using the XREFdb to Search for Mammalian Homologues of the Yeast UPF1
Gene
Recently a number of new search programs and databases have been
developed for researchers who want to find a human, rat, or mouse homologue
of genes cloned from lower eukaryotic organisms. One such search program is
the XREFdb program (Basset et al., 1995) which is accessible via the world wide
web (http://www.ncbi.nlm.nih.gov/XREFdb/).

The XREFdb provides BLAST

similarity searches (TBLASTX; Altschul et al., 1990) with an amino acid
sequence provided by the user.

XREFdb searches databases that contain

Expressed Sequence Tags (EST) (Boguski et al., 1993) and Sequence Tagged
Sites (STS} (Green et al., 1989) of cloned DNA and cDNA fragments. The query
sequence submitted to the XREFdb is compared once a month with the rapidly
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and ever expanding database of DNA sequences generated from the human and
mouse genome projects and a report of the identified genes is sent to the user
who submitted the search.
To identify mammalian homologues of the S. cerevisiae gene UPF1, I
submitted the Upf1 p sequence (SwissProt accession #P30771) to the XREFdb
for the first time in September 1995.

In both September and October 1995,

XREFdb E-mail reports were sent to me with no significant matches. In
November 1995, a XREFdb report was received that contained a number of
alignments between amino acid sequences deduced from human EST cDNAs
clones and the Upf1 p.

Analysis of Clones Whose Sequence Matched That of UPF1
The original data report that was sent in November, 1995, by the XREFdb
is shown in Figure 29. When I located the regions that matched with the EST
sequences in the UPF1 sequence, I found that all EST sequences aligned with
the RNA helicase region of the Upf1 p (Figure 30).

Further analysis of the

alignments revealed three subsets of matched sequences.

The first subset

contains the first two genes identified in the XREFdb report (GenBank accession
#F06433 and #R13609). These two human EST cDNAs, which were derived
independently from same library (a human fetal brain cDNA library constructed
by Benito Soares, M. Fatima Bonaldo, Hillier, L., The WashU-Merck EST Project,
unpublished, 1995) share a large amount of identical amino acid residues
(Figure 29).

This suggests that they originated from the same transcript.
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Figure 29. XREFdb announcement that my UPF1 query sequence has been
matched to a number of recently sequenced human cDNA EST clones. Sbjct
indicates the marked EST sequence; query, the submitted UPF1 sequence;
positives, the number of identical and similar amino acid matches between the
indicated sbjct and query.
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EST Similarity Search Report:
Gene name(s): NAM7/UPF1

(TBLASTN vs. human/mouse/rat dbEST subset)

Searched: 28 Oct 95

New?

NCBI_ID:

GenBank
Accession: P value:

N:

Matrix:

New

122095

F06433

2

BLOSUM62

4.le-38

Hiscore:

Mapped?
(Probe #)

183

Yes(#l65)*

H.sapiens
normalized infant brain cDNA
Genethon
genexpress@genethon.fr
33169472800
FAX: 33160778698

Organism:
Library:
source:
E-mail:
Phone:

Score = 183 (83.9 bits), Expect
4.le-38, Sum P(2)
4.le-38
Identities= 37/68 (54%), Positives= 43/68 (63%), Frame= +2
624 LISLGHVPIRLEVQYRMNPYLSEFPSNMFYEGSLQNGVTIEQRTVPNSKFPWPIRGIPMM 683
L+ LG P RL+VQYRM+ LS FPSN+FYEGSLQNGVT
R
F WP
PM
146 LVXLGIRPXRLQVQYRMHSALSAFPSNIFYEGSLQNGVTAADRVKXGFDFQWPQPDKPMF 325

Query:
Sbjct:

684 FWANYGRE 691
F+
G+E
326 FYVTQGQE 349

Query:
Sbjct:

Score
174 (79.8 bits), Expect= 4.le-38, Sum P(2) = 4.le-38
Identities = 32/47 (68%), Positives = 40/47 (85%), Frame = +3
576 QASEPECLIPIVKGAKQV!LVGDHQQLGPVILERKAADAGLKQSLFE 622
Q +EPEC++P+V G KQ+ILVGDH QLGPV++ +!CAA AGL QSLFE
3 QXTEPECMVPVVLGGKQLILVGDHCQLGPVVMCKKAAKAGLSQSLFE 143

Query:
Sbjct:

New

184188

Rl3609

4.6e-30

2

BLOSUM62

165

No

H.sapiens
Soares inf ant brain lNIB
Wilson RK
est@watson.wustl.edu
314 286 1800
FAX: 314 286 1810

Organism:
Library:
Source:
E-mail:
Phone:

Score= 165 (75.7 bits), Expect
4.7e-30, Sum P(2) = 4.7e-30
Identities= 33/52 (63%), Positives= 37/52 (71\), Frame= +2
Query:

624 LISLGHVPIRLEVQYRMNPYLSEFPSNMFYEGSLQNGVTIEQRTVPNSKFPW 675
L+ LG PIRL+VQYRM+P LS FPSN+FYEGSLQNGVT
R
F W
143 LVVLGIRPIRLQVQYRMHPALSAFPSNIFYEGSLQNGVTAADRVKXGFDFQW 298

Sbjct:

Score
133 (61.0 bits), Expect = 4.6e-30, Sum P(2) = 4.6e-30
Identities= 24/37 (64%), Positives= 32/37 (86%), Frame= +l
Query:

578 SEPECLIPIVKGAKQVILVGDHQQLGPVILERKAADA 614
+EP C++P+V GAKQ+ILVGDH QLGPV++ +!CAA A
7 TEPXCMVPVVLGAKQLILVGDHCQLGPVVMCKKAAKA 117

Sbjct:

New

271744

Organism:
Library:

Rll830

2.2e-ll

3

BLOSUM62

83

H.sapiens
Soares infant brain lNIB

Score= 83 (38.l bits), Expect= 2.2e-ll, Sum P(3) = 2.2e-ll
Identities• 17/27 (62\), Positives= 22/27 (81%), Frame= +2
Query:
Sbjct:

758 EVASVDAFQGREKDYIILSCVRANEQQ 784
EV +VDAFQGR+KD +I++ VRAN Q
167 EVDTVDAFQGRQKDCVIVTXVRANSIQ 247

Score • 71 (32.6 bits), Expect = 2.2e-ll, Sum P(3) = 2.2e-ll
Identities= 15/23 (65%), Positives= 19/23 (82\), Frame• +3
Query:
Sbjct:

793 RRLNVGLTRAKYGLVILGNPRSL 815
+RLNV +TRAKY L ILG+ R+L
276 QRLNVTITRAKYSLFILGHLRAL 344

No
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sum p( 3 ) = 2.2e-11
wll• (S 4 t), Frame = +2
• 12/22

118

w11.

No

sum p(2) = 3.Je-ll
l

-. 31/62 (SH)• Frame = +

LVGDHQQLGPVILERKAADAGLKQSLFERLI 625
VGD +QL p ++
KA + G QS+ R

++i~VGDPKQLPPTVISMKAQEYGYDQSMMARFC

18 6

= 3.Je-11
Frame = +l

114

No

VGDHQQLGPVILERKAADAGLKQSLFERLISL 627
ILVGD +OL P ++ KA + G QS+ R
L
LVGDPKQLPPTVISMKAQEYGYDQSMMARFCRL 224

= 6.3e-ll
(72lr), Frame = +3
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Figure 30. Schematic representation of the yeast UPF1 protein and alignments with the
putative translation products deduced from from cDNA EST clones identifed by the XREFdb
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I, therefore, decided to obtain the clone that was the most accessible (GenBank
accession #R13609).

The second subset contained only clone H11830

(GenBank accession #H11830).

The third and final subset contained clones

H15581 and H11176 (GenBank accession #H15581, #H11167).

These two

human EST cDNAs overlap completely. Therefore, only clone H11167 was used
in all subsequent experiments. The human EST cDNA clones mentioned above
were requested and upon arrival, all four clones were renamed (Table 8). The
insert size of clones 1, 2, and 3 was determined by restriction enzyme digestion.
Even though the GenBank sequence of each clone was between 250 and 400 nt
long, the actual insert size of the clones was between 1.3-kb and 1.6-kb in
length. Clone 1 (R13609) had an insert size of approximately 1.5 kb. To verify
the identity of clone 1, both ends of this clone were sequenced.

The 5'

sequence of clone 1 could be aligned with the published GenBank sequence of
clone 1 (#R 13609) (Figure 31 ). The 3' end of the clone contained nucleotides
compatible to the oligomer used to generate the first strand cDNA synthesis
during the cDNA library construction (data not shown). Therefore, my clone 1
contains a 1.5-kb insert whose 5' sequence is identical to that published in
Gen Bank file #R 13609. Next, I isolated the 1. 5-kb insert from the plasmid and
used it as a probe in northern blot analysis of total human RNA. Inserts were
also prepared from clones 2 and 3 (Gen Bank clones #H 11830 and #H 11167,
respectively) and used as probes for northern blot analysis.

However, the

sequences of inserts 2 and 3 were not confirmed by DNA sequencing.

The
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R 13609 =
SEA
Rl3609

=

Sequence obtained from Gen Bank file #R 13609
Sequence by SEA

CCAGGCACCGAGCCGNAGTGCATGGTTCCCGTGGTCCTCGGGGCCAAGC
111111

SEA

CCAAGC

Rl3609 AGCTGATCCTTG-AGGCGACCACTGCCAGCTGGGCCCAGTGGTGATGTGC
111111111111

SEA

11111111111111111

11111111 I 1111111

11

AGCTGATCCTTGTAGGCGACCACTGCCAGCAGGGCCCAGTGGTGATG-GC

Rl3609 AAGAAGGCGGCCAAGGCGGNCTGTCACAGT-CGCTCTTCGAGNCCTGGTG
111111111111111

SEA

111

1111111111

I

I

AAGAAGGCGGCCAAG-CGG-CTGTCACAGTCCG-T

Rl3609 TGCTGGGCATCCGGCCCATCCGCCTGCAGGTCCAGTACCGGATGCACCC
Rl3609 AATGGTGTCACTGCAGCGGATCGTGTGAAGAAGGGATTTGATTTCCAGT
Rl3609 CAAGAGGGAGATTTGCCAGTTTGGGGCAACTTCTTACCTTGAACAGGGA
Rl3609 CC

Figure 31. Alignment of nucleotide sequences from the 5' end of clone 1 (SEA)
and GenBank clone #R13609. Sequence of the 5' end of clone R13609 was
obtained by double stranded sequencing of plasmid containing insert of clone 1
by the Sanger didioxy method (Sanger et al., 1977) using primer M13.back
primer. Alignment errors may be due to errors in the automated sequencing of
the EST clone or by incorrect reading of data by (SEA).
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results from these three northern are shown in Figure 32. Northern blot analysis
using clone 1 revealed in human cells, two bands of 3.6 and 5.5 kb, whereas
probing blots with both clones 2 and 3 revealed in human cells bands of 8.0 and
11.0 kb in size. Interestingly, in mouse cells, clone 1 detected a weak band of
4.5 kb in size and clone 2 detected a weak band of 10.8 kb. Whether or not
these bands represent murine homologues of human clone 1 and 2 remains to
be seen.

From these experiments, I conclude that clone 1 might represent a

homologue of the yeast UPF1 gene because the size of the transcripts (3.7- and
5.5-kb) are closest in size to those encoded by UPF1 (3.2-kb).

Isolation of a Human cDNA Clone Using a Clone 1 Probe
To isolate a full length human cDNA representing the human clone 1
cDNA fragment (R13609), I screened approximately 2.5 X 105 individual plaques
of a human oligo-d(T)-primed cDNA library prepared from Hela cell RNA
(Elledge et al., 1991) with the isolated 1.5-kb fragment of clone 1 under high
stringency conditions. Seven hybridizing phage clones were identified, plaque
purified, and used to infect an E. coli strain able to excise a yeast/E. coli shuttle
vector from the phage DNA.

The shuttle vector can be used to express the

cDNA from an inducible promoter in yeast cells (Figure 33). Plasmids could be
excised from seven (clone numbers 8.1.1/2, 11.1.1/2, 11.2.1/2, 13.1.1/2,
15.1.1/2, 21.1.1/2, 22.1.1/2) of seven clones and the size of their cDNA inserts
was determined by restriction digestion (Appendix Figure 1.A). Six of the seven
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Figure 32. Northern blot analysis of human and mouse RNA using
probes isolated from human cDNA EST clones. Indicated amounts
of total RNA were subjected to northern blot analysis using the
probes called clone 1 (R13609), 2 (H11830) and 3 (H11167).
Arrows indicate the position and size of RNA bands detected in
human cells. An asterisk indicates faint bands detected in mouse
cells that are 11.0-kb band with the H11830 probe (lane 4) and a
4.6-kb band with the R13609 probe (lane 1).
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Transform the plasmid into yeast under inducing conditions
(2% galactose) to test if the cDNA product can complement a
defective yeast gene.

Figure 33. Schematic diagram of pYES plasmid excision from phage A-YES and subsquent test of
human cDNA for complementing ability.
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clones contained detectable inserts.

One clone (clone 11.2.1/2) contained an

insert of 3.6-kb (called clone 3.6)., whereas the other clones contained smaller
inserts (Appendix Figure 1.A, 1.C). Restriction mapping revealed that three of
the clones with smaller inserts (21.1.1, 8.1.1, 13.1.1) overlapped with the insert
of clone 3.6 (Appendix Figure 1.B, 1.0).

These clones were not examined

further.
When I sequenced the 3' end of clone 3.6, I found that the nucleotide
sequence was identical to that of the original clone 1 (GenBank clone #R13609)
(data not shown). When I used the 3.6-kb insert as a probe in a northern blot
analysis of human total Hela RNA, I detected bands of 5.5- and 3.6-kb (Figure
34). Because the original 1.5-kb clone 1 probe also detected 3.6-kb and 5.5-kb
bands in Hela RNA (Figure 32), I conclude that I have cloned a 3.6-kb cDNA
that very likely represents a full length cDNA of the original 1.5-kb clone 1 probe.

Sequence Analysis
The insert of the 3.6-kb clone (clone 3.6) was sequenced by Sanger
dideoxy chain termination method (Sanger et al., 1977) and primer-walking
(Slightam et al., 1994) with the ABI Cycle Sequencing kit from Perkin Elmer
(Branchburg, NJ) and an ABI automated DNA sequencer.

The sequence of

clone 3.6 was 3602 bp in length and contains the poly(A)-signal sequence
AATAAA and from nucleotide 176 to nucleotide 3529 a 3354-bp open reading
frame (ORF) that could encode a 123-kDa polypeptide (Figure 35).

The first

amino (N)-terminal ATG codon of clone 3.6 is very likely the true translational
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Figure 34. Northern blot analysis of total and cytoplasmic RNA using
the 3.6 clone probe. (A) Northern blot of 5 µg of total RNA from the
mouse B cell hybridoma FH (Lane 1) and human endothelial cell line
HeLa (lane 2). Blot was exposed to film 2 days at -70°C with one
enhancing screen. (8) Northern blot of 10 µg of cytoplasmic (C, lane
3) and total (T, lane 4) HeLa RNA. Blot was exposed to film 3 days at
-70°C with one enhancing screen.
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Figure 35. Nucleotide and predicted amino acid sequence of the human NORF1
gene.
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gcggcggctcggcactgttacctctcggtccggctggcgccgcgggcggtttggtcctttccgggcgcgcgggggcgaca 80
gcggcagcgacccgaggcctgcggcctaggcctcagcgcggcggcgggctcgagtgcagcgcggaaccggcccgagggcc 160
ctacccggaggcaccatgagcgtggaggcgtacgggcccagctcgcagactctcactttcctggacacggaggaggccga 240
M S V E A Y G P S S Q T L T F L D T E E A E 22
gctgcttggcgccgacacacagggctccgagttcgagttcaccgactttactcttcctagccagacgcagacgccccccg 320
L L G A D T Q G S E F E F T D F T L P S Q T Q T P P
48
gcggccccggcggcccgggcggtggcggcgcgggaagcccgggcggcgcgggcgccggcgctgcggcgggacagctcgac 400
G G P G G P G G G G A G S P G G A G A G A A A G Q L D 75
gcgcaggttgggcccgaaggcatcctgcagaacggggctgtggacgacagtgtagccaagaccagccagttgttggctga 480
A Q V G P E G I L Q N G A V D D S V A K T S Q L L A E 102
gttgaacttcgaggaagatgaagaagacacctattacacgaaggacctccccatacacgcctgcagttactgtggaatac 560
L N F E E D E E D T Y Y T K D L P I H A C S Y C G I
128
acgatcctgcctgcgtggtttactgtaataccagcaagaagtggttctgcaacggacgtggaaatacttctggcagccac 640
H D P A C V V Y C N T S K K W F C N G R G N T S G S H 155
attgtaaatcaccttgtgagggcaaaatgcaaagaggtgaccctgcacaaggacgggcccctgggggagacagtcctgga 720
I V N H L V R A K C K E V T L H K D G P L G E T V L E 182
gtgctacaactgcggctgtcgcaacgtcttcctcctcggcttcatcccggccaaagctgactcagtggtggtgctgctgt 800
C Y N C G C R N V F L L G F I P A K A D S V V V L L
208
gcaggcagccctgtgccagccagagcagcctcaaggacatcaactgggacagctcgcagtggcagccgctgatccaggac 880
C R Q P C A S Q S S L K D I N W D S S Q W Q P L I Q D 235
cgctgcttcctgtcctggctggtcaagatcccctccgagcaggagcagctgcgggcacgccagatcacggcacagcagat 960
R C F L S W L V K I P S E Q E Q L R A R Q I T A Q Q I 262
caacaagctggaggagctgtggaaggaaaacccttctgccacgctggaggacctggagaagccgggggtggacgaggagc 1040
N K L E E L W K E N P S A T L E D L E K P G V D E E
288
cgcagcatgtcctcctgcggtacgaggacgcctaccagtaccagaacatattcgggcccctggtcaagctggaggccgac 1120
P Q H V L L R Y E D A Y Q Y Q N I F G P L V K L E A D 315
tacgacaagaagctgaaggagtcccagactcaagataacatcactgtcaggtgggacctgggccttaacaagaagagaat 1200
y D K K L K E S Q T Q D N I
T V R W D L G L N K K R I 342
cgcctacttcactttgcccaagactgactctgacatgcggctcatgcagggggatgagatatgcctgcggtacaaagggg 1280
A Y F T L P K T D S D M R L M Q G D E I C L R Y K G
368
accttgcgcccctgtggaaagggatcggccacgtcatcaaggtccctgataattatggcgatgagatcgccattgagctg 1360
D L A P L W K G I G H V I K V P D N Y G D E I A I E L 395
cggagcagcgtgggtgcacctgtggaggtgactcacaacttccaggtggattttgtgtggaagtcgacctcctttgacag 1440
R S S V G A P V E V T H N F Q V D F V W K S T S F D R 422
gatgcagagcgcattgaaaacgtttgccgtggatgagacctcggtgtctggctacatctaccacaagctgttgggccacg 1520
M Q S A L K T F A V D E T S V S G Y I Y H K L L G H
448
aggtggaggacgtaatcaccaagtgccagctgcccaagcgcttcacggcgcagggcctccccgacctcaaccactcccag 1600
E V E D V I T K C Q L P K R F T A Q G L P D L N H S Q 475
gtttatgccgtgaagactgtgctgcaaagaccactgagcctgatccagggcccgccaggcacggggaagacggtgacgtc 1680
V y A V K T V L Q R P L S L I Q G P P G T G K T V T S 502
ggccaccatcgtctaccacctggcccggcaaggcaacgggccggtgctggtgtgtgctccgagcaacatcgccgtggacc 1760
A T I V Y H L A R Q G N G P V L V C A P S N I A V D
528
agctaacggagaagatccaccagacggggctaaaggtcgtgcgcctctgcgccaagagccgtgaggccatcgactccccg 1840
Q L T E K I H Q T G L K V V R L C A K S R E A I D S P 555
gtgtcttttctggccctgcacaaccagatcaggaacatggacagcatgcctgagctgcagaagctgcagcagctgaaaga 1920
V S F L A L H N Q I R N M D S M P E L Q K L Q Q L K D 582
cgagactggggagctgtcgtctgccgacgagaagcggtaccgggccttgaagcgcaccgcagagagagagctgctgatga 2000
E T G E L S S A D E K R Y R A L K R T A E R E L L M
608
acgcagatgtcatctgctgcacatgtgtgggcgccggtgacccgaggctggccaagatgcagttccgctccattttaatc 2080
N A D V I C C T C V G A G D P R L A K M Q F R S I L I 635
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gacgaaagcacccaggccaccgagccggagtgcatggttcccgtggtcctcggggccaagcagctgatccttgtaggcga 2160
D E S T Q A T E P E C M V P V V L G A K Q L I L V G D 662
ccactgccagctgggcccagtggtgatgtgcaagaaggcggccaaggccgggctgtcacagtcgctcttcgagcgcctgg 2240
H C Q L G P V V M C K K A A K A G L S Q S L F E R L
688
tggtgctgggcatccggcccatccgcctgcaggtccagtaccggatgcaccctgcactcagcgccttcccatccaacatc 2320
V V L G I R P I R L Q V Q Y R M H P A L S A F P S N I 715
ttctacgagggctccctccagaatggtgtcactgcagcggatcgtgtgaagaagggatttgacttccagtggccccaacc 2400
F Y E G S L Q N G V T A A D R V K K G F D F Q W P Q P 742
cgataaaccgatgttcttctacgtgacccagggccaagaggagattgccagctcgggcacctcctacctgaacaggaccg 2480
D K P M F F Y V T Q G Q E E I A S S G T S Y L N R T
768
aggctgcgaacgtggagaagatcaccacgaagttgctgaaggcaggcgccaagccggaccagattggcatcatcacgccc 2560
E A A N V E K I T T K L L K A G A K P D Q I G I I T P 795
tacgagggccagcgctcctacctggtgcagtacatgcagttcagcggctccctgcacaccaagctctaccaggaagtgga 2640
Y E G Q R S Y L V Q Y M Q F S G S L H T K L Y Q E V E 822
gatcgccagtgtggacgcctttcagggacgcgagaaggacttcatcatcctgtcctgtgtgcgggccaacgagcaccaag 2720
I A S V D A F Q G R E K D F I I L S C V R A N E H Q
848
gcattggctttttaaatgaccccaggcgtctgaacgtggccctgaccagagcaaggtatggcgtcatcattgtgggcaac 2800
G I G F L N D P R R L N V A L T R A R Y G V I I V G N 875
ccgaaggcactatcaaagcagccgctctggaaccacctgctgaactactataaggagcagaaggtgctggtggaggggcc 2880
P K A L S K Q P L W N H L L N Y Y K E Q K V L V E G P 902
gctcaacaacctgcgtgagagcctcatgcagttcagcaagccacggaagctggtcaacactatcaacccgggagcccgct 2960
L N N L R E S L M Q F S K P R K L V N T I N P G A R
928
tcatgaccacagccatgtatgatgcccgggaggccatcatcccaggctccgtctatgatcggagcagccagggccggcct 3040
F M T T A M Y D A R E A I I P G S V Y D R S S Q G R P 955
tccagcatgtacttccagacccatgaccagattggcatgatcagtgccggccctagccacgtggctgccatgaacattcc 3120
S S M Y F Q T H D Q I G M I S A G P S H V A A M N I P 982
catccccttcaacctggtcatgccacccatgccaccgcctggctattttggacaagccaacgggcctgctgcagggcgag 3200
1008
I P F N L V M P P M P P P G Y F G Q A N G P A A G R
gcaccccgaaaggcaagactggtcgtgggggacgccagaagaaccgctttgggcttcctggacccagccagactaacctc 3280
G T P K G K T G R G G R Q K N R F G L P G P S Q T N L 1035
cccaacagccaagccagccaggatgtggcgtcacagcccttctctcagggcgccctgacgcagggctacatctccatgag 3360
P N S Q A S Q D V A S Q P F S Q G A L T Q G Y I S M S 1062
ccagccttcccagatgagccagcccggcctctcccagccggagctgtcccaggacagttaccttggtgacgagtttaaat 3440
Q P S Q M S Q P G L S Q P E L S Q D S Y L G D E F K
1088
cacaaatcgacgtggcgctctcacaggactccacgtaccagggagagcgggcttaccagcatggcggggtgacggggctg 3520
S Q I D V A L S Q D S T Y Q G E R A Y Q H G G V T G L 1115
tcccagtattaaaaggtggcggcggaagagctaagcaacgtggcttagtccatcagcatcttattctgggtaataaaaaa 3600
s Q y
1118
tg

3602

193
initiation codon, because it is flanked by sequences that predict strong
translational initiation (Kozak, 1994) and is preceded by an in-frame TAG stop
codon from nucleotide positions 107 to 109.

As mentioned above, clone 3.6

could encode a protein of approximately 123-kDa. To determine if this is the
case, in vitro transcription-translation (IVTL) was performed using a linearized
NORF1 cDNA plasmid preceded by a T7 polymerase promoter.

When

radiolabeled IVTL products were subjected to SOS/PAGE, I detected a band with
an apparent molecular mass of 130 kDa (Figure 36). This result indicates that
the ORF of the 3.6-kb NORF1 clone (clone 3.6) can be translated into a protein
product of approximately 130-kDa. This corresponds well with the calculated
molecular mass of 123 kDa. The difference between predicted and apparent
molecular weight might be due to the fact that acidic polypeptides run aberrantly
in SOS polyacrylamide gels (Koshland, 1985; Bornemann et al., 1995).

Comparison of NORF1 Polypeptide Sequence to Sequences in Databases
When the translated non-redundant GenBank, PDB, SwissProt, and PIR
databases (release date: July 22, 1996) was searched with the deduced amino
acid sequence of clone 3.6 using the BLAST program (Altschul et al., 1990), the
results revealed that the human protein showed the highest degree of homology
to yeast UPF1 (Leeds et al., 1991 ), which is also known as NAM7 (Altamura et
al., 1992). First, 71% of the human coding sequence from codon 121 to codon
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Figure 36. In vitro transcription-translation (IVTL) of UPF1 and
NORF1 RNA transcribed from plasmid DNA. 5 µg of linearized
plasmid was subjected to in vitro transcription-translation in the
presence of 35S-labeled methionine and cystine using the TnT
coupled transcription-translation kit (Promega, WI) as suggested by
the manufacturer. 10 µI of reaction product was separated by 10%
SOS/PAGE and subjected to flurography for 16 hours.
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918 is 60% identical and 74% similar to the corresponding UPF1 (NAM7) coding
sequence from codons 60 to 856. Second, both proteins contain at their amino
(N)-terminal ends an acidic stretch followed by a cysteine-rich region and in their
middle parts, an RNA helicase region (Figure 37.B).
The RNA helicase region of the human polypeptide from codons 489 to
875 is 63% identical and 85% similar to that of Upf1 p (codons 427 to 811) and
contains in the same order all seven RNA helicase motifs that are found in Upf1 p
(Altamura et al., 1992; Leeds et al., 1992), and other group I RNA helicases
(Koonin, 1992).

Remarkably, the distances between six of the seven RNA

helicase consensus motifs are preserved between the human protein and yeast
Upf1 p and the distances between domains lb and II differ only by two amino acid
residues (Figure 37.B). The BLAST search revealed also that all seven RNA
helicase consensus motifs in the human protein are very similar to that of other
putative eukaryotic group I RNA helicases (Koonin, 1992) such as S. cerevisiae
SEN1, mouse MOV-10, the putative S. pombe UPF1 homologue, the human and
mouse µ switch region binding proteins SMBP-2, a putative human DNA
helicase, and an insulin enhancer binding protein (Figure 37, Table 9). Thus, I
conclude that the human 3.6-kb cDNA clone encodes a putative group I RNA
helicase.
In contrast to the seven RNA helicase motifs, which are present in all
group I RNA helicases, a cysteine-rich region is found only in the human protein
and Upf1 p but not in other members of the group I RNA helicase family. The
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Figure 37. Sequence comparison of human NORF1 and yeast UPF1. (A) Partial
complementary nucleotide and entire deduced amino acid sequences of human
NORF1 and comparison with the S. cerevisiae UPF1 amino acid sequence
(SwissProt accession # P30771 ). The numbers at the right indicate nucleotide
and amino acid positions. Untranslated regions are shown in lowercase and
translated regions in uppercase letters. Arrows indicate the region of the NORF1
nucleotide sequence that was omitted from the figure and can be retrieved from
GenBank file #U59323. The start and stop codons of NORF1 are in bold and the
in-frame stop codon upstream of the ATG as well as the poly(A)-addition signal
site are underlined and italicized. The glycine/praline-rich regions and the
serine/glutamine (SQ) and serine/glutamine/proline (SQP) repeats are
underlined. The deduced amino acid sequences of NORF1 and UPF1 (in single
letter IUPC code) are shown below the partial nucleotide sequence. In the
alignments (top, NORF1 and bottom, UPF1 ), a period indicates an identical
amino acid residue and a forward slash a gap of one amino acid introduced for
optimal alignments. Charged amino acids at the N-terminal ends are indicated
by + and -. The cysteine-rich putative zinc finger motifs are underlined in bold, a
putative tyrosine phosphorylation site is boxed and the seven group I RNA
helicase motifs (I, lb, II-VI) are indicated by gray-shaded boxes. (B) Domain
maps of human NORF1 and yeast UPF1. The domains are indicated by boxes.
Numbers between and below the domains and at the ends indicate amino acid
distances, and numbers in the boxes the net charge of the domain. "PG",
praline/glycine-rich; "SQP" serine/glutamine and serine/glutamine/proline
repeats.
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cysteine-rich region in the human protein extends from codons 123 to 213
(Figure 37.A) and is 63% identical and 90% similar to that of Upf1 p (residues 62
to 152). The cysteine-rich region in both the human and Upf1 p is preceded by
an acidic stretch of 47 and 55 amino acids, respectively, with a net charge of -9.
Two motifs within the cysteine-rich region of the human protein (starting at codon
123 and codon 183, respectively), as well as Upf1 p (starting at codon 62 and
122, respectively), can be written as CysX2 CysXnCysX3 Cys (X represents any
amino acid and n is 6 for the first and 26 for the second motif). The distances
between the two motifs are preserved in both the human protein and Upf1 p and
the distances between their cysteine-rich and RNA helicase regions differ only by
one amino acid residue (Figure 37.A and B). Alternatively, starting with the first
cysteine at codon 122, or 62 in Upf1 p, another putative zinc finger motif can be
written as CysX2 CysX26 HisX3 His. All three motifs can be partially aligned with the
zinc finger/knuckle motif CysX2_5 CysX4 _12 Cys/HisX2_4 Cys/His, which is found in
some zinc finger DNA binding proteins as well as in polypeptides that interact
with RNA (Burd and Dreyfuss, 1994 ).
Because the human protein exhibits the highest degree of homology to
the group I RNA helicase Upf1p (Figure 37.A) and contains a very similar overall
polypeptide domain structure as Upf1p (Figure 37.B), I conclude that the human
protein, which I named NORF1 (nonsense mRNA reducing factor 1), is a putative
group I RNA helicase and the first mammalian structural homologue of yeast
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Upf1 p, a yeast protein responsible for reducing nonsense mRNA levels (Leeds et
al., 1991).
Compared to Upf1 p, NORF1 has 63 and 83 more amino acids on its Nand carboxy (C) -terminal ends, respectively.

These extra tails contain motifs

that are absent from yeast Upf1 p, such as an additional acidic stretch of 34
amino acids with a net charge of -9 followed by three repeats of a
praline/glycine-rich motif (PGGXG) at the N-terminal tail. This glycine-rich region
could be involved in RNA binding (Burd and Dryfuss, 1994).

There are also

multiple SQP and SQ repeats at the C-terminal tail (Figure 37.B) but a structural
or functional role for this motif has not been determined.

Expression of NORF1
If NORF1 is involved in degrading nonsense mRNA, I would expect that it
is expressed in every tissue, because any cell can potentially generate nonsense
mRNA, for example via imprecise pre-mRNA splicing.

Northern blot analysis

was performed using total RNA from several human cell lines representing
various human tissues and probed with the human 3.6-kb NORF1 probe.

A

predominant -5.5-kb and a minor -3.7-kb transcript in all samples (Figure 38),
suggesting that NORF1 is expressed in many tissues.
The size of the 3. 7-kb transcripts corresponds very well with the size of
the 3.6-kb cDNA clone and, therefore, could represent mature NORF1 mRNA.
The 5.6-kb mRNA might represent an incompletely spliced precursor of the
mature 3.7-kb NORF1 mRNA. If this is true, I would expect that levels of the 5.6-
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Figure 38. Northern blot analysis of NORF1 mRNA in human cell lines. (A)
5 µg of total RNA was subjected to northern blot analysis and hybridized
with the complete human clone 3.6 probe. The blot was subjected to
flurography for 2 days. RNA size markers are indicated in kilobases (kb) on
the left and the position of the 18S and 28S RNA and the two NORF1
transcripts on the right. (B) Photograph of the ethidium bromide stained gel.
The arrows point to the hybridizing bands at 5.5 and 3.6 kb.
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kb transcript would be lower in both total and cytoplasmic total RNA preparations
when compared to the signal of the 3.7-kb band.

However, as detected by

northern blot analysis, levels of the 5.6-kb transcripts are higher in both total and
cytoplasmic RNA preparations than levels of the 3.6-kb transcript (compare in
Figure 34 lane 4 with lane 3).

Therefore, it seems more likely that the two

transcripts represent mature mRNA that was generated from a common premRNA by either differential splicing or differential usage of polyadenylation sites.
To isolate a cDNA clone that might represent the 5.5-kb transcript, I screened a
human Jurkat A.-phage cDNA library with a 5' probe of

clone 3.6 (Xhol-Sa/I

fragment in Figure 39). I identified 22 clones; eight of these clones were plaque
purified and plasmids were excised from plaque-purified phage.

Restriction

enzyme digestion of plasmids prepared from the 8 clones (3.1.1.1/2, 3.2.1.1/2,
9.1.1.1/2, 15.1.1.1/2, 17.1.1.1/2, 19.1.1.1/2, 21.1.1.1/2, 27.1.1.1/2) identified
inserts of different sizes (Appendix Figure 2). The largest insert (clone 15.1.1/2)
was 5.5-kb in length. This clone, whose size corresponds very well with that of
the 5.5-kb transcript, was named clone 5.5 and used for further analyses.
Restriction mapping analysis (Appendix Figure 3.A, 3.8) and partial DNA
sequencing of clone 5.5 revealed that clone 3.6 overlaps with clone 5.5 . For
example, I identified in clone 5.5 all restriction enzyme sites that were found in
clone 3.6 (Figure 39). Moreover, I verified in clone 5.5 sequences of clone 3.6
that contain the translational start and stop sites and the polyadenylation signal
site AATAAA (Figure 39). I also detected at the 3' end of clone 5.5 a second
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classical polyadenylation signal site (AATAAA). I, therefore, propose that both
the 3.7-kb and 5.5-kb transcript contain the same ORF and differ in their 3'
untranslated region. Thus, the two transcripts might have been generated from
the same pre-mRNA by differential polyadenylation signal site usage. However,
I cannot completely exclude that clone 3.6 represents a truncated cDNA
fragment of the 5.6-kb transcript. It may be possible that the 3.6-kb transcript is
encoded by a gene that is different from NORF1 but shares with NORF1 some
DNA sequence identity.

Expression of NORF1 Protein
To determine if a NORF1-like protein of about 130-kDa is present within
human cells, I generated a rabbit antiserum reactive against peptides deduced
from hydrophilic regions of the putative ORF of NORF1 (underlined in Figure 40).
The synthesized peptides (NORF1/pep#1 and #2) were coupled to keyhole
limpet hemocyanin (KLH) and used to immunize rabbits. The antibodies vvere
affinity-purified from serum on the respective NORF1-peptide columns and used
in western blot analysis.

The affinity purified anti-NORF1-pep#1 antibodies

stained on a western blot the radiolabeled 130-kDa protein that was in vitro
translated from a clone 3.6 template (Figure 41). This antibody also detected a
130-kDa protein in both mouse (lane 3) and human cells (lane 4). This suggests
that the ORF of NORF1 can be translated in vitro, and in vivo, into a 130-kDa
polypeptide.

It is not known if the anti-NORF1-pep#1 antibodies detect yeast

Upf1 p but it is unlikely that it would do so as the peptide epitope used to
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Figure40. Hydrophobicity plot of NORF1 used to design NORF1 peptides.· The
plot was generated by submitting the polypeptide sequence below the
hydrophobicity plot to the ExPASy molecular biology server at
http://expasy.hcuge.ch/www/ tools.html. The bracket in the plot represents the
region of NORF1 residues used as an immunogen. The exact residues are
shown below the plot and are in bold and underlined.
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Figure 41. In vitro transcription-translation (IVTL) and western blot
analysis of IVTL products and cellular lysates. Western blot analysis of
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detected by fluorography for 4 days. Molecular mass protein standards
are indicated in kilodaltons (kDa) on the left.
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generate the anti-NORF1-pep#1 antibodies is not found within the predicted
UPF1 polypeptide. Based on these data, I conclude that I have cloned a human

cDNA (NORF1) that exhibits a large degree of amino acid identity to that of yeast
Upf1 p, a group 1 RNA helicase required for nonsense codon-mediated mRNA
degradation.

It also suggests that both human and mouse cells express the

NORF1 protein.

Functional Analysis of NORF1

NORF1 Complementation of an upf1 Null Yeast Strain

To determine if NORF1 is capable of reducing nonsense mRNA levels in
a upf1 null (upf1) yeast strain, I transformed the yeast strain PLY154 ura3::1-f/S4
(PLY154) with a plasmid that contains the complete ORF of NORF1 cDNA under
the control of the inducible ga/1-10 promoter. PLY154 cells contain a nonsense
LEU2 allele (leu2-1), which encodes a nonsense leu2-1 mRNA. Because Upf1p

is absent from PLY154 cells, nonsense leu2-1 mRNA becomes more stable and
a low degree of translational readthrough can generate enough Leu2p to support
the growth of PLY154 cells in the absence of leucine. If NORF1 can replace the
function of Upf1 p in yeast, leu2-1 mRNA should rapidly be degraded and the
transformants will not grow in the absence of leucine. Six transformants were
isolated and tested for their inability to grow in the absence and presence of
leucine.

The growth of these transformants was compared to yeast cells

transformed with a control plasmid lacking an insert (pYes 2.0, lnvitrogen).
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Figure 42 shows the results from these experiments. Yeast containing either the
NORF1 cDNA (a-d) or the control plasmid (e-h) were both able to grow in the

absence of uracil (indicating the presence of the transformed plasmid), the
presence of galactose (which induces expression of the NORF1 cDNA), and in
the absence of leucine, indicating that levels of nonsense /eu2-1 mRNA have not
been decreased. Therefore, I conclude that the presence of the NORF1 cDNA
under inducing conditions is not able to replace the function of Upf1 p, that is, to
induce the degradation of nonsense mRNA.
Leeds and co-workers (1992) were able to determine that mutations in the
RNA helicase region of the UPF1 gene led to a dominant-negative effect in yeast
cells containing a wild type copy of the UPF1 gene.

Based on these

observations, it may be possible NORF1 rather blocks Upf1 p leading to a UPF1minus (upf1) phenotype.

To test this idea, yeast cells containing a wild type

UPF1 gene were transformed with the plasmid containing the complete NORF1

ORF or with a control plasmid that does not contain the NORF1 ORF. If NORF1
acts in a dominant-negative fashion, it will interfere with Upf1 p and prevent the
degradation of the nonsense mRNA transcribed from the /eu2-1 gene, which will
change the phenotype of the transformed yeast cell from Leu- to Leu+.
Transformants were generated and grown in the absence of uracil (which selects
for the presence of the transformed plasmid library) and the presence of
galactose (which induces the expression of the NORF1). However, when replica
plated on plates with or without leucine, none of the cells transformed with the
NORF1

(Figure

43

a-d)

or

control

plasmid

(e-h)

grew

on

plates
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Figure 42. Complementation of a UPF1 null (upf1) yeast strain with the NORF1
cDNA. The yeast strain PLY154 ura3::HIS4 was transformed with the galactose
inducible NORF1 cDNA yeast shuttle plasmid (11.2.2) or with the galactose
inducible yeast shuttle plasmid pYes 2.0 with no insert. Transformants were
patched onto plates lacking uracil (Ura-) and replica plated to the indicated
plates. The plasmid used to transform the yeast is shown above the plate and
the composition of the plate medium is shown below the plate. Whether cell
growth was observed is noted in parentheses after the medium.
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Figure 43. Dominant-negative test of a UPF1 null (upf1) yeast strain with the
NORF1 cDNA. The yeast strain SL988-11A was transformed with the galactose
inducible NORF1 cDNA yeast shuttle plasmid (11.2.2) or with the galactose
inducible yeast shuttle plasmid pYes 2.0 with no insert. Transformants were
patched onto plates lacking uracil (Ura-) and replica plated to the indicated
plates. The plasmid used to transform the yeast is shown above the plate and
the composition of the plate medium is shown below the plate. Whether cell
growth was observed is noted in parentheses after the medium.
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supplemented with leucine. From this result I conclude that NORF1 does not
block the function of Upf1 p in yeast cells. But in fact, more control experiments
need to be done to confirm the expression of NORF1 protein in the yeast cells
grown under inducing conditions.
In summary, NORF1 when expressed in yeast cells does not replace nor
block the function of Upf1 p.

However, it is possible that in both the

complementation and dominant-negative approaches NORF1 was expressed at
levels that were not high enough to replace Upf1 p or to act dominant-negative.
Alternatively, NORF1 might not replace the function of Upf1 p in yeast cells,
because it cannot interact with another protein that is required to induce the
degradation of nonsense mRNA.

NORF1 Antisense RNA Expression in Mammalian Cells
To determine if the NORF1 protein controls nonsense mRNA levels in a
mammalian cell, I stably expressed NORF1 antisense transcripts from a
transfected NORF1 cDNA in mouse B cells containing a immunoglobulin µ
mRNA with a nonsense codon (Jack and Wabl, 1989) (Figure 44). If NORF1 is
involved in the regulation of nonsense mRNA, downregulation of NORF1
synthesis by antisense NORF1 transcripts should result in an increase in µ
mRNA levels.

NORF1

bla

p B-actin
5'
3•
Q__ r:-Cap
)
lntron
.
pHBAPr- \J ./'11.3' ,,l/
NORF1 K I t{. - - - - - - - Stable Transfectants

Mouse Hybridoma VXH

Figure 44. Schematic representation of the antisense orientation cloning of NORF1 into the expression
vector pHp-APr-1-neo and subsequent transfection into the mouse B cell hybridoma VXH. The complete
NORF1 ORF was excised on a Xhol/Hindlll fragment and cloned into the vector prepared with Hindlll/BamHI.
The pHp-APr-1-neo contains a p-actin promoter (P), a 5' UTR intron, a SV40 poly(A) addition site, an ampicillin
resistance gene (bla), and a neomycin/G418 resistance gene (neo). Structure of the nonsense µ mRNA in
VXH is shown in the cell. The exons are indicated by boxes (VH variable; C, constant) and the length of
translation products by lines below the mRNA. The position of the nonsense codon at the end of the VH
exon is represented by the X.
N
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216
Construction of a Mammalian Antisense NORF1 Expression Vector
The complete NORF1 ORF was cloned into the mammalian antisense
expression vector pHpApr-1-neo (Gunning et al., 1987). The NORF1 ORF was
excised from plasmid pGem7Z-NORF1(3.6-kb) as a 3.5-kb Hindlll/Xhol fragment
and cloned in a two-step ligation procedure into the expression vector prepared
with Hindi 11/BamH I.

Stable Expression of NORF1 Antisense RNA in Mouse Cells
To determine whether NORF1 is important for controlling levels of
nonsense mRNA in mammalian cells, I introduced the mammalian antisense
NORF1 expression vector into the mouse hybridoma line VXH. VXH transcribes

an endogenous µ gene with a TAG nonsense codon in its variable (VH) gene
exon (Figure 45). The nonsense mutation reduces the level of µ mRNA in VXH
by a factor of -15 when compared to that of functional µ mRNA in the hybridoma
line FH (Jack and Wabl, 1989). FH cells contain the same µ gene as VXH cells
except that the TAG nonsense codon in the V exon is changed to TAC (Jack and
Wabl, 1989). When I analyzed VXH transfectants on western blots, I found that
antisense clone VXH.3 produced less NORF1 protein (Figure 46A, lane 1) than
control vector-transfected VXH (lane 3) and untransfected FH cells (lane 4).
However, transfected and untransfected VXH clones produce about the same
amount of the heavy chain binding protein, BiP (Haas, 1994). This suggests that
human NORF1 antisense transcripts downregulated the expression of mouse
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A
FH

~ VH

µ
VXH

ICµ1 ICµ2 lCµ3

lCµ4 lAAA

t--~~~~~-------4

-1 VHXICµ1

ICµ2 ICµ3 ICµ4 IAAA

VHI~---1

B
VH81X with Leader to the VXH nonsense codon
MDFGLSLVFLVLILKSGVQCEVQLVESGGGLVQPRESLKLSCESNEYEFPSHDMSWVRKTPEKR
LELVAAINSDGGSTYYPDTMERRFIISRDNTKKTLYLQMSSLRSEDTALYYCARHD
Theoretical Mw for the protein sequence
MDFGLSLVFL ... TALYYCARHD: Theoretical Mw: 13691.44

c
VH81X without Leader to the VXH nonsense codon
GVQCEVQLVESGGGLVQPRESLKLSCESNEYEFPSHDMSWVRKTPEKRLELVAAINSDGGSTYY
PDTMERRFIISRDNTKKTLYLQMSSLRSEDTALYYCARHD
Theoretical Mw for the protein sequence
GVQCEVQLVE ... TALYYCARHD: Theoretical Mw: 11914.23

Figure 45. Schematic diagram and sequence of the two predicted polypeptides
that can be translated from the µ immunoglobulin nonsense mRNA in VXH cells.
(A) Structures of functional µ mRNA in FH cells and nonsense µ mRNA in VXH
cells. The exons are indicated by boxes \VH variable; C, constant) and the
length of translation products by lines below the mRNA. The position of the TAG
nonsense codon at the end of the VH exon, is represented by the X. The m gene
in VXH differs from that in the FH cell by the presence of the TAG stop codon.
(B) Sequence of the polypeptide translated from nonsense mRNA in VXH cells
before cleavage of the leader sequence. (C) Sequence of the polypeptide after
cleavage of the leader sequence. The predicted molecular mass of each
polypeptide is shown below each sequence in bold letters. The nucleotide
sequences used to caculate the molecular mass were obtained from GenBank
entries: accession #X01113, and #K02890 and from Wabl et al., (1985).
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Figure 46. Effect of human NORF1 antisense RNA expression on µ mRNA
levels in transfected mouse cells. (A) Western blot analysis of mouse NORF1 in
untransfected FH cells (lane 4) and VXH cells stably transfected with the human
NORF1 antisense expression vector (lanes 1 and 2) and the expression vector
alone (lane 3). The blot was first probed with anti-NORF1-pep1 antibodies (see
Figure X) and then, to control for loading, restained with anti-BiP antibodies. (B)
Northern blot analysis of µ mRNA expression in transfected VXH and
untransfected FH cells. 5 µg total RNA was analyzed as described in Figure 17.
The blot was probed with a mouse Cµ and a rabbit GAPDH cDNA probe. The
positions of m and GAPDH mRNAs are indicated on the right. (C) Western blot
analysis of polypeptides that react with anti-VH peptide antibodies in transfected
VXH and untransfected VXH cells. The blot was probed with a rabbit anti-VH
peptide antiserum that reacts with an epitope encoded by the VH region in FH
and VXH cells (Hartwell & Jack, unpublished observations). The positions of the
VH and full length µ polypeptides are indicated on the right. Bands other than
those indicated by arrows are also detected in cells that do not produce any lg
chains and thus, result from reactions of rabbit antibodies with non-lg
polypeptides. To control for loading, the blot was reprobed with a rabbit anti-BiP
serum and similar signals of a single 70-kDa band (BiP) were observed in all 4
lanes.
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NORF1 protein in antisense clone VXH.3.

The downregulation of NORF1

protein correlated with an increase in nonsenseµ mRNA in VXH.3 transfectants.
On northern blots, I found about 3 times more nonsense µ mRNA in antisense
clone VXH.3 (Figure 468, lane 1) than in a VXH clone transfected with the
expression vector alone (lane 4) (Table 10). One possibility to explain why the
level of nonsense µ mRNA was not restored to that of functional µ mRNA in FH
cells (Figure 468, lane 5) is that I still detected some NORF1 protein in antisense
clone VXH.3 (Figure 46A, lane 1). Because the levels of nonsense µ mRNA are
increased in VXH.3 transfectants, I should also detect a shorter lg chain that is
encoded by the ORF extending from the start codon to the nonsense codon µ
mRNA (Figure 45.B and C and Figure 46.C).

Indeed, I detected a band of

approximately 15 kDa by western with anti-VH antibodies in antisense clone
VXH.3 (Figure 46, lane 1), but not in vector-transfected VXH (lane 3) and wildtype FH cells (lane 4). I conclude that the transfection of an antisense NORF1
gene into VXH cells resulted in increased levels of nonsense µ mRNA and,
therefore, that NORF1 is responsible for controlling nonsense µ mRNA levels.
However, this conclusion is based on the result obtained with this one VXH
transfectant as well as from one western blot and northern blot of the indicated
transfectants.

The accuracy of the data obtained needs to be confirmed by

repeating the western and northern blot analysis on these and possibly other
independent transfectants.

Table 10. -- Quantitation of Northern Blot Analysis in Figure 46
Cell line and
transfectant clone
number

RNA
loaded

µ

pre-µ

GAP DH

[CPM]

[CPM]

[CPM]

3

rel[µ]
[µ/GAP DH]

rel [pre-µ)
[pre-µ/GADPH]

FH

5 µg

289.5

11.1

132.3

17

1

VXH vector

5 µg

7.5

3.9

56.9

1

1

VXH.1

5 µg

22.5

8.0

101.2

1.7

1.1

VXH.2

5 µg

22.6

8.2

109.9

1.6

1

VXH.3

5 µg

35.3

10.7

99.3

2.8

1.5

3

Radioactivity of respective bands in each Northern blot (CPM) was determined by using a betascope blot analyzer.
Relative steady-state level of respective RNA was calculated by dividing CPM ofµ by that of GAPDH in the same lane.
Blots were determined to be free of background by emperical observation so no adjustments of the numbers collected
were made.
% [µ] is the percent of[µ] relative to that of the hybridoma VXH by setting VXH value equal to 100%.
An [*] indicates the absence of data due to either background hybridization or to the absence of this data to perform
caculations.
Note: This data is the result of only one experiment.

N
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Isolation of a Mouse NORF1 Homologue
The current work in our lab involves the analysis of immunoglobulin
mRNA with nonsense codons in murine B cells. To study the function of the
NORF1 gene in mouse cells, the mouse NORF1 cDNA was isolated. Southern
blot analysis of mouse genomic DNA using the complete human NORF1 cDNA
revealed the presence of hybridizing bands under high stringent conditions (data
not shown). I concluded from this result that the mouse genome likely encodes a
gene that has nucleotide identity with the human NORF1 gene. Therefore I used
the human 3.6-kb NORF1 cDNA probe to screen approximately 2 X 105
individual cDNA plaques from a mouse C2 muscle cell line oligo-d(T)-primed /...phage library under low stringency hybridization conditions.

The library was

generated from a mouse muscle cell line and, because NORF1 is likely to be
expressed in all cells, the library should contain NORF1 cDNA clones.

Two

phage clones were identified that hybridized with the human 3.6-kb NORF1
probe.

One of these clones was plaque purified using low stringency

hybridization, the plasmid was excised from the phage, and was found to contain
a 4.5-kb cDNA insert (Appendix Figure 4.A). The plasmid and insert were also
mapped (Appendix Figure 4.8, C, D, E, F, and G). Northern blot analysis using
the 4.5-kb mouse insert revealed a single band of about 4.6-kb, the size
expected for a full-length cDNA clone of NORF1 (Figure 47).
The nucleotide sequence of the insert was partially determined and was
very similar at the nt and aa level to that of the corresponding human sequence.
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Figure 47. Northern blot analysis of total human and mouse RNA using
human and mouse NORF1 probes. 10 µg of total RNA was separated by
formaldahyde gel electrophoresis and blotted. Each blot was probed with
the indicated NORF1 probe onto GeneScreen Plus. Two strips with
identical RNA samples were cut from the membrane. One was hybridized
with the 4.5-kb mouse NORF1 and the other with the 5.5-kb human
NORF1. RNA size markers are indicated in kilobases (kb) on the left and
the right. The position of the two NORF1 transcripts in the center. The
blots were exposed to X-ray film for 36 hours at -70°C using an enhancing
screen.
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(Figure 48). From these sequence data I conclude that I cloned a murine cDNA
that exhibits a high degree of identity to the human 3.6-kb NORF1 gene.
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FIGURE 48. Sequence comparison of 5' sequences of human (h) and mouse
(m) NORF1. The complementary 5' nucleotide and deduced amino acid
sequences of hNORF1 were aligned manually with the 5' nucleotide and
deduced amino acid sequence of the mouse 4.5-kb cDNA fragment. The
numbers at the right indicate nucleotide and amino acid positions. Untranslated
regions are shown in lowercase and translated regions in uppercase letters. The
start codon of NORF1 and the in-frame stop codons upstream of the start codon
are in bold. The deduced amino acid sequences of hNORF1 and mNORF1 (in
single letter IUPC code) are shown above and below their corresponding partial
nucleotide sequences. In the alignments, a period indicates an identical amino
acid residue, a X an unidentified nucleic and amino acid residue, and a forward
slash a gap of one amino acid or nucleotide introduced for optimal alignments.
The cysteine-rich putative zinc finger motifs and the GP-rich motifs are
underlined in bold.
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mNORFl
hNORFl

ctataactantggatcccccgggctgcaggaattcggcacragctacggcggttcctgtc 60
caggggtctgaaacggcggtcggctttgaggcaancancttacggaggggcgcggcggcg 120

mNORFl
hNORFl

gcggcggcggcggcaactcaaaactcaaaaccggcggcccggctc/tgctttcggaggcc 179
gcggcggctcggcactgttacctctcggtccggctggcgccgcgggcggtt 51

mNORFl
hNORFl

gactcggaacccgcccggctctcagggcggcggcagcggctgctccggattacggcctag 239
tggtcctttccgggcgcgcgggggcgacagcggcagcgacccgaggc/ t/gcggcctag 108

mNORFl
hNORFl

gcctanccgaascctcgggctcgattgcggtgaggcgcccgctgaaggcgcggcccgggc 298
gcctcagcgcggcggcgggctcgagtgcagcgcggaaccggcccgagggccctacccgga 168

mNORFp
mNORFl
hNORFl
hNORFp

16
ggcaggATRANTGTGGAGGCGTACGGCCCCAGCTCGCAAACACTCACCTTCTTGGACACT 358
ggcaccATGAGCGTGGAGGCGTACGGGCCCAGCTCGCAGACTCTCACTTTCCTGGACACG 228
M S V E A Y G P S S Q T L T F L D T 18

mNORFp
mNORFl
hNORFl
hNORFp

GAGGAGGCCGAGCTGCTCGGCGCCGACACCCAGGGCTCCGANTTCGAATTCACCGACTTC 418
GAGGAGGCCGAGCTGCTTGGCGCCGACACACAGGGCTCCGAGTTCGAGTTCACCGACTTT 288

mNORFp
mNORFl
hNORFl
hNORFp

A
51
ACCCTTCCCAGCCAAA.CNCAAACCCCCCCCGGCGGCCCCGGCGGCGCGGGXXXXXXXXXX 468
ACTCTTCCTAGCCAGACGCAGACGCCCCCCGGCGGCCCCGGCGGCCCGGGCGGTGGCGGC 348
T L P S Q T Q T P P G G P G G P G G G G 58

mNORFp
mNORFl
hNORFl
hNORFp

X G
X
X
F
66
XXXXXXAGCCCGGGCGGAJl.CGGGCGCANGCGGCGCGGCCGGCCANCTCNACGCACAATTT 522
GCGGGAAGCCCGGGCGGCGCGGGCGCCGGCGCTGCGGCGGGACAGCTCGACGCGCAGGTT 408
A G S P G G A G A G A A A G Q L D A Q V 78

mNORFp
mNORFl
hNORFl
hNORFp

x
85
GGACCAGAAGGCATCTTGCAAAATGGGGCTGTGGATRACAGTGTGGCCAAAACCAGCCAG 582
GGGCCCGAAGGCATCCTGCAGAACGGGGCTGTGGACGACAGTGTAGCCAAGACCAGCCAG 468

mNORFp
mNORFl
hNORFl
hNORFp

x
104
CTGCTAGCTGAGCTGAACTTCAAGGAAGATGAAGAAGACCTNCXTTACCTTAAGGACTCC 641

mNORFp
mNORFl
hNORFl
hNORFp

X X
P
X
X E X
CANXTCCACCCCTGCANTTACNGTGAAXTCCATGATCCTGGCTGCGTNGTTTACTGTAAT
CCCATACACGCCTGCAGTTACTGTGGAATACACGATCCTGCCTGCGTGGTTTACTGTAAT
P I H A C S Y C G I H D P A C V V Y C N

119

mNORFp
mNORFl
hNORFl
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X X
X
H
X R
X
N P
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DISCUSSION
The yeast UPF1 gene plays a defined role in the accelerated degradation
of yeast nonsense mRNAs (Leeds et al., 1992; He et al., 1993).

The

identification of the UPF1 homologue, NORF1, in both human and mouse cells
suggests that mammalian genes reduce levels of nonsense mRNA, at least in
part, by similar mechanisms as yeast. Two results support the hypothesis that
NORF1 is a UPF1 homologue. First, the conservation of key functional elements
of Upf1 p such as the zinc-finger-like domain and RNA helicase region in NORF1
suggest that it may act in a similar manner.

Second, antisense NORf1

expression partially reduces, the levels of nonsense mRNA in mammalian cells.

Putative Functions of Motifs Conserved Between UPF1 and NORF1

The Zinc-finger Motif
NORF1 and Upf1 p contain very similar cysteine-rich regions which are
characteristic of proteins that interact with nucleic acids.
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The cysteine-rich
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domain contains two zinc-finger-like motifs that can be partially aligned with the
zinc finger/knuckle motif, CysX2_5CysX4_12 Cys/HisX2-4Cys/His.

Zinc finger/

knuckle motifs are found in some zinc finger DNA binding proteins as well as in
polypeptides that interact with RNA (Burd and Dreyfuss, 1994).

The RNA Helicase Domain
NORF1 and Upf1 p also contain a very similar RNA helicase domain that is
characteristic of RNA helicases. These enzymes can unwind double stranded
RNA (reviewed in Schmid and Linder, 1992). Purified Upf1 p is able to unwind
dsRNA in in vitro tests in an ATP-dependent fashion (Czaplinski et al., 1995).
Because NORF1 contains a conserved superfamily I ATP-dependent RNA
helicase region, it is possible that NORF1 is also able to unwind dsRNA and
uses ATP as the energy source. How this activity may affect nonsense mRNA is
discussed below.

The Acidic Region
NORF1 and Upf1 p contain a stretch of acidic amino acids without
conserved residues and NORF1 has an additional stretch with the same net
charge as the acidic stretch shared by Upf1 p and NORF1. Some DNA-binding
proteins require these domains to allow transcriptional activation (Umesono and
Evans, 1989). This region, as well as regions discussed below, could bind to
other proteins that are part of the machinery that recognize nonsense mRNA.
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Possible Functions of Other Motifs in NORF1
The predicted NORF1 protein contains at its N- terminal end a prolineglycine rich region motif that is not present in Upf1 p.

When DNA databases

were searched with the praline-glycine rich region of the NORF1 gene, matches
were found with transcription factors that contained praline-glycine rich regions at
their N-terminal ends. When these praline-glycine rich regions are changed, the
activity of a transcription factor can decrease or is completely abolished
(Umesono and Evans, 1989).

It is thought that this region is important for

interactions of transcription factors with DNA.

In NORF1 this region could

interact with double stranded RNA.
NORF1 contains a number of SQ-space (serine and glutamine) and SQPspace (serine, glutamine and praline) di- and tri-residue repeats at the carboxy
end of the protein. Searches of protein and DNA databases with the C-terminal
end of NORF1 containing the SQ and SOP repeats did not reveal any significant
matches.

I speculate that it is possible that a SQ-space-SQ repeat could

produce a highly hydrophillic region of polypeptide responsible for interactions
with proteins that modifiy the activity of NORF1, that is, NORF1 might gain a
function different from that of Upf1 p.
mammalian homologue of Upf2p.

Alternatively, it might interact with a
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Expression of NORF1
Northern blot analysis with the 3.6-kb NORF1 probe revealed a 5.5-kb
and 3.6-kb transcript in all cell lines used in the analysis. Results of restriction
and sequence analysis suggest that both transcripts encode NORF1. Although I
did not quantitate the transcript levels in various cell lines,

the result of the

northern blot analysis in Figure 34 suggests that the ratio of the 3.6-kb and 5.5kb transcripts might be different from cell line to cell line. It is possible that the
3.6-kb transcript represents a constitutively expressed mRNA, whereas levels of
the 5.6-kb are regulated depending on the level of truncated polypeptides. It is
tempting to speculate that sequences in the 3' UTR of the 5.6-kb species, about
2-kb, might be responsible for this regulation. The complete sequence of the 5'
UTR of clone 5.6 and a repeat of northern blot analysis with different cell lines
and tissues might support this idea. It is hard to imagine how a truncated protein
can signal the upregulation of a mRNA.

However, truncated and mis-folded

polypeptides that bind to the ER chaperone protein BiP could trigger an
intracellular signal pathway activating a protein that binds to the 5' UTR of the
5.6-kb NORF1 mRNA.

Alternatively, NORF1 might directly be involved.

We

detected a putative tyrosine phosphorylation site in NORF1.
The finding that an antiserum against human NORF1 detects a 130-kDa
polypeptide in human and mouse cells (Figure 41) suggests some protein
conservation. This is supported by Southern blot analysis of mouse DNA with
the human probe as well as by sequence data of the mouse NORF_1 cDNA.
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Interestingly, western blot analysis of rabbit proteins using the anti-human
NORF1 peptide antiserum revealed a band of 115 kDa (data not shown). This
may indicate that certain regions of the mouse and human NORF1 are
dispensable for nonsense mRNA reduction.

Therefore, the cloning and

sequence of the rabbit NORF1 gene should identify regions that are different
from mouse and human and possibly dispensable for NORF1 function.

Function of NORF1
To test whether NORF1 is able to promote nonsense mRNA reduction, I
generated stable transfectants of a human NORF1 antisense cDNA into a mouse
cell that expresses a nonsense µ mRNA.

We found in one experiment and in

one antisense transfectant that the expression of antisense-NORF1 mRNA
correlated with a decrease of mouse NORF1 protein, an increase in nonsense µ
mRNA, and the detection of a shorter polypeptide encoded by the nonsense µ
mRNA. The reason why the level of nonsense µ mRNA was not restored to that
of functional µ mRNA in FH could be that low levels of NORF1 protein can still be
detected in antisense clone VXH.3. This raises the question of why the human
NORF1 antisense transcripts do not completely decrease the level of mouse
NORF1 protein. One possibility is that differences in the nucleotide sequence
between human and mouse NORF1 result in a sense/antisense RNA hybrid that
is only partially able to inhibit ribosomal translation of the mouse NORF1 protein.
Indeed, partial sequence comparison of the mouse and human NORF1 genes
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reveals that the two cDNAs contain nucleotide differences.

Nevertheless, the

most straightforward interpretation of these functional tests is that NORF1 is
responsible for reducing nonsense µ mRNA levels. These results suggest that
NORF1 is the first mammalian gene product that can affect the steady state level
of a nonsense mRNA. However, this conclusion is based on the result obtained
with this one VXH transfectant as well as from one western blot and northern blot
of the indicated transfectants. The accuracy of the data obtained needs to be
confirmed by repeating the western and northern blot analysis on these and
possibly other independent transfectants.
Another approach involved transforming a yeast upf1 mutant with a
NORF1 expression plasmid to test for its ability to complement the upf1 defect.
The presence of the NORF1 expressing plasmid, and presumed NORF1
expression, did not result in yeast with an upf1 phenotype as determined by no
change in the Leu- phenotype. There may be a number of reasons that NORF1
did not complement the upf1 defect. First, the yeast may not have expressed
NORF1 mRNA and protein.

This is unlikely as the yeast grew readily in the

presence of galactose, indicating the presence of endogenous yeast factors
needed for metabolism as well as induction of the NORF1 cDNA. Additionally,
the NORF1 cDNA was found to be in the correct orientation in the expression
vector (data not shown).

Because experiments confirming the presence of

NORF1 mRNA and protein were not performed, these possibilities cannot be
excluded. Second, NORF1 may not complement upf1 because it may .not have
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the ability to interact with factors also required to rapidly degrade nonsense
mRNA. The alignment of NORF1 with UPF1 (Figure 37) has revealed that not all
regions of UPF1 are conserved in NORF1.

For example, both proteins have

different N- and C-terminal tails. It could be that these are the regions of Upf1 p
that interact with the other UPF factors required to promote nonsense mRNA
reduction.

Because NORF1 lacks this region(s), it may not interact with other

UPF factors.

In another attempt to determine if NORF1 promotes nonsense mRNA
reduction, I transformed yeast containing a wild-type UPF1 gene with a NORF1expression plasmid to determine if NORF1 could act in a dominant-negative
fashion on Upf1p.

The presence of the NORF1-expressing plasmid, and

presumed expression of NORF1 protein, did not result in yeast with an upf1
phenotype. There may be a number of reasons that NORF1 did not act in a
dominant-negative fashion.

First, the yeast may not have expressed NORF1

mRNA and protein as discussed above.

Second, there may be differences

between NORF1 and Upf1 p that do not allow direct interaction. The differences
between Upf1 p and NORF1 at their N- and C-terminal ends may prevent such
interactions.
The final test of NORF1 function should be perfomed in a cell line that
lacks NORF1 expresion. The next experiments to be done are 1) isolating of a
genomic fragment and disrupting the NORF1 gene in a mouse cell line, 2)
finishing the sequence of the mouse NORF1 cDNA to identify conserved and
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possible functional residues, 3) isolating clones that encode proteins interacting
with NORF1 in a yeast two-hybrid system, and 4) generating antibodies against
mouse NORF1 to localize the intracelluar localization of NORF1 by immuno
electron microscopy.

Models to Explain How NORF1 Reduces Nonsense mRNA levels
In yeast, nonsense mRNA seems to be selectively degraded in the
cytoplasm in an UPF-dependent manner (reviewed in Maquat, 1995). However,
cytoplasmic levels of nonsense mRNA in mammalian cells seem to be reduced
by both nuclear and cytoplasmic events (reviewed in Maquat, 1995). NORF1, in
concert with other NORF factors, could be involved in both events. It is tempting
to speculate that the two zinc-finger-like motifs of the NORF1 may facilitate the
recognition of nonsense codons either in mature mRNA in the nucleus and/or the
cytoplasm or in looped-out nuclear pre-mRNA, in which the exons have been
aligned to form a continuous translational reading frame (Dietz and Kendzior,
1994). One way in which the zinc-finger motif of NORF1 could be involved in
nonsense codon recognition is that it could interact with a dsRNA region formed
by the association of ribosomal subunits.

The formation of dsRNA between

ribosomal subunits is supported by experiments that have shown that the RNA
components of mammalian ribosomes become less accessible to chemical
modification after the 408 and 608 subunits have assembled into the BOS
ribosome (Holmberg et al., 1994). From these results the authors believed that
the RNA regions that are not modified are involved in rRNA subunit interactions.
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Alternatively, rRNA could pair with tRNA molecules and form ds-rRNA/tRNA
regions. That rRNA interacts with tRNA is suported by studies in prokaryotes
that have shown that rRNA molecules are involved in tRNA selection and
translational accuracy (reviewed by Noller, 1994). It may be possible that the
zinc-finger motif of NORF1 binds to dsRNA or ds-rRNA/tRNA complexes. When
these double-stranded regions are changed, either because tRNA is absent from
the ribosomal A site, or ribosomal subunits disassociate, the binding of the zincfinger to its double-stranded RNA binding site might be disrupted, which could
result in the activation of the RNA helicase domain. Consequently, the helicase
is activated, which leads to the degradation of nonsense mRNA as described
below. That a zinc-finger motif could bind to dsRNA has been proposed for the
ribosomal elongation factor elF-2p. In elF-2p, the zinc-finger motif is required for
the recognition of the AUG start codon during the ribosome-mediated
translational scanning process (Donahue et al., 1988). It has been suggested
that the zinc-finger motif of elF-2P could participate in start site selection by
either scanning for an AUG or by stabilizing the AUG codon-anticodon
interaction (a dsRNA interaction). Because a stop codon has no tRNA with an
anticodon, NORF1 may only participate in interactions with ribosomal rRNA to
recognize stop codons, similar to the way elF-2P could interact with tRNA to
stabilize AUG codon-anticodon interactions, and when activated by ribosomal
disassociation, promote nonsense mRNA reduction (Figure 49). The importance

3'

5'
ATG

Alterations in rRNA or tRNA/rRNA
interactions due to an empty P site
lead to disruption in Zn finger binding
and activation of RNA Helicase

Figure 49. Model for activation of NORF1 leading to decay of an mRNA with a nonsense codon.
The tRNA and rRNA present in the BOS ribosome are shown as squiggles.
N
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of the zinc-finger motif in Upf1 p has already been shown, because mutations in
the zinc-finger motif of Upf1 p eliminate its ability to recognize a nonsense codon
but does

not influence the

RNA helciase activity of Upf1 p (personal

communication with K. Czaplinski) (see Table 2).

These experiments were

discussed in Chapter 11.
The RNA helicase region of the Upf1 p is critical for its ability to promote
the decay of nonsense mRNAs (Leeds et al., 1992). It has been suggested that
upon activation (discussed above), Upf1 p could melt any secondary structure
downstream of a nonsense codon by using its RNA helicase region, thereby
leaving the mRNA exposed to nucleases (Figure 50.B; Peltz et al., 1993). For
example, the ATP-dependent RNA helicase elF-4A can render RNA susceptible
to nucleases (Ray et al., 1985). NORF1 may also act in this way (Figure 50.B).
Another way in which Upf1 p is thought to influence the degradation of a
nonsense mRNA is to promote the rapid de-capping of the nonsense message
(Muhlrad and Parker, 1994). One way to explain how the RNA helicase activity
of NORF1 could facilitate the rapid de-capping of a nonsense mRNA is that
Upf1 p could unwind a trans-RNA interaction between the RNA portion of a
RNA/protein complex and the capped end of a nonsense mRNA (Figure 50.C).
This complex could somehow be involved in protecting the cap complex.
Alternatively, the RNA helicase activity of NORF1

could

unwind

rRNA

interactions in the ribosome which might result in the activation of other NORF
factors that induce decapping (Figure 50.C). Yet, another way by which the RNA
helicase activity of NORF1 could activate de-capping is to disrupt interactions
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Figure 50. Models to explain NORF1 helicase action induces the rapid decay of a nonsense mRNA. The 5' and 3' end
of a mRNA are indicated. The inactive NORF1 factor (indicated by a diamond) is associated with the translating
ribosomes, becomes active (indicated by hands) after encountering a nonsense codon. (A) Schematic diagram of a
nonsense mRNA with extensive secondary structure downstream of the nonsense codon. (B) Activation of NORF1
leads to removal of secondary structure downstream of the nonsense codon by the RNA helicase region, resulting in
the production of a target for an endonuclease. (C) Activation of NORF1 induces RNA helicase activity. This results
in the removal of a cap-protecting ribonucleo-complex, which results in decapping and degradation of the mRNA.
Alternatively, NORF1 actication can lead to ribosomal disassembly and activation of other NORF factors. (D)
Activation of NORF1 prevents 5' 3' RNA interaction, either directly (as shown) or indirectly by disruption of ribosomes.
The inhibition of 5' 3' interactions leads to decapping and subsquent mRNA degradation.
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between the 5' cap and 3' poly(A)-tail (Figure 50.D). This would expose the cap
to a decapping enzyme and, subsequently, to 5'-3' exonuclease attack.

That

poly(A)/cap interactions might be required to protect mRNA from

rapid

degradation,

comes

from

experiments

that

show

that

translation

and

deadenylation are prerequisites to decapping (Muhlrad et al., 1994) and from
electron micrograph studies that show circular polysomes (Christensen et al.,
1987).
If NORF1 can activate nonsense codon mRNA reduction, it raises the
question of why mRNA with normal stop codons are not affected by the action of
NORF1. It may be that NORF1 is a labile factor and may only be associated
with an elongating ribosome for a limited time.

The further a ribosome

elongates, the greater its chance of loosing NORF1. After a certain distance,
any ribosome encountering a stop codon will not recognize it as a nonsense
codon because it lacks NORF1.
As mentioned above, nonsense mRNA in yeast seems to be selectively
degraded in the cytoplasm in an UPF1-dependent manner (Peltz et al., 1994).
However, cytoplasmic levels of nonsense mRNA in mammalian cells are
apparently reduced by both nuclear and cytoplasmic events (reviewed in
Maquat, 1995). If NORF1 is not found in the nucleus, other factors might be
responsible for reducing nuclear levels of nonsense mRNA either by degrading
mature nuclear mRNA or influencing the splicing of nonsense pre-mRNA
(reviewed in Maquat, 1995).

A mammalian homologue of Upf3p might be a
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candidtate for a second factor.

Upf3p contains a bi-partite nuclear localization

sequence and thus, is thought to be present in the yeast nucleus (Lee and
Culbertson, 1995).
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NORF1: The Big Picture
The conservation of a protein that reduces levels of nonsense mRNA in
lower (S. cerevesiae and C. elegans) and higher eukaryotes, such as mouse and
human, implies an important biological function, presumably because it reduces
nonsense mRNA levels and, thus, high levels of truncated polypeptides. Most
truncated proteins might not be deleterious for a single cell. However, it might
prevent in a dominant-negative fashion the assembly of signal-transducing
receptors and prevent a cell from proceeding along a differentiation pathway or
to fulfill its major physiologic function.

If applied to the immune system, it is

possible that nonsense immunoglobulin or T-cell receptor genes generated by
DNA rearrangements could produce nonsense mRNA that can be translated into
a truncated polypeptide. Such truncated lg or TCR chains could interfere with
the assembly of an lg or TCR molecule, respectively, thereby eliminating the
ability of the cell to respond to foreign antigens. The presence of a truncated
polypeptide encoded by a stable nonsense mRNA correlates with a number of
human diseases. For example, certain cases of Larons syndrome (Hashimoto et
al., 1995), p-thalassemia (Hall and Thein, 1994), cancer associated with altered
p53 expression (Kawasaki et al., 1994), Marfan syndrome (Dietz et al., 1994),
and many others diseases are all thought to be the result of a dominant-negative
protein product being translated from a mRNA containing a nonsense codon
(see Table 1 for additional examples and references). It may be possible that
these patients also have a defect in NORF1 (or another NORF gene) making
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them susceptible to protein products produced from nonsense mRNAs that are
not eliminated. Therefore, NORF1 not only protects a cell from nonsense
mRNAs but also from the deleterious effect of truncated polypeptides encoded
by nonsense mRNA.

APPENDIX
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Additional Figure 1. Determination of insert size and restriction enzyme mapping of 'A YES cDNA clones that
hybridize with EST clone R13609. (A) Determination of insert size in phage excised plasmid DNA. Plasmid DNA
was analyzed by TAE/agarose gel electrophoresis using Xhol digestion. Molecular weight markers are in the
indicated lanes. The band representing the 'AYES vector DNA is indicated by the arrow on the right. (B)
Mapping of inserts in phage excised plasmid DNA by C. Kampershorer (5/16/96). Plasmid DNA was digested
with BstXI and Xhol and analyzed by TAE/agarose gel electrophoresis. The faint 900 bp fragment identified in
certian lanes is indicated by a white circle. (C) Table listing the phage clone picks and their insert sizes in kb.
(D) Schematic representation of results from restriction enzyme mapping in B using diagnostic BstXI (8) and Xhol
(X) mapping. Clone 22.1.1 gave no results and clone 11.1.1 was not tested (CK).
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Additional Figure 4. DNA restriction enzyme analysis of mouse 4.5-kb NORF1 clone (20.1.1.1 ). (A) Initial
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insert but as the results show, apparently only linearized it. Small non-photographable band at -450 bp is
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the indicated enzymes and mapped. (B) 4.5-kb cDNA insert is indicated by the arrow on the right. Molecular
weight markers are shown in the indicated lanes. (G) Schematic representation of the pBluescript SK
plasmid containing the 4.5-kb NORF1 cDNA clone.
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